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Vascular health plays a major role in several human disorders, particularly in 
cardiovascular diseases (CVD) (1,2). The endothelium can be considered an organ that 
regulates vascular homeostasis by maintaining an appropriate vascular tone, platelet activity, 
leukocyte adhesion and angiogenesis. When one or more of these components is compromised 
due to impaired endothelial vascular signalling, endothelial dysfunction (ED) may occur (1). 
One of the main key metabolic manifestations of ED is reduced nitric oxide (NO) 
bioavailability. NO is an important signalling molecule that regulates various vascular 
processes, including through its main role as a vasodilator, acting through relaxation of smooth 
muscle cells (2,3). Impaired bioavailability of NO and up-regulation of various molecules 
involved in vascular function are partly explained by the cooperative and synergistic action of 
inflammation and oxidative stress on ED (4–6). This is particularly evident in older adults, as 
several studies support a new immune-metabolic viewpoint for age-related diseases, termed 
“inflammaging” which is characterized by a chronic low-grade inflammation (7). Thus, 
interventions aiming to regulate the immune response and to prevent the accumulation of 
deleterious reactive species, have been considered to be a relevant therapeutic target to improve 
vascular health (8). 
Nutrition plays a major role in regulating the inflammatory state and enhancing 
endogenous antioxidant defences (9). Many dietary patterns have been associated with the 
prevention of diseases associated with inflammation in epidemiological studies (10), while at 
the same time a large range of dietary interventions have been explored in clinical practice to 
treat pathological conditions such as ED (11). Flavonoids, a class of dietary polyphenols, are 
bioactive compounds that have potential to both prevent and treat conditions related to a pro-
inflammatory and oxidative stress state (12,13). Meta-analysis of controlled trials and cohort 
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studies demonstrate a protective effect of flavonoid intake on CVD (14–18), particularly on 
hypertension (19,20). Anthocyanins, a subclass of flavonoids, are emerging as a potential 
therapeutic option for CVD risk factors (21). Anthocyanins are the largest class of water-
soluble plant pigments, that are responsible for the blue, purple and red colour of many fruits 
and vegetables, such as blueberries, blackberries, red grapes, plums and eggplants (22). The 
beneficial effects of anthocyanins on CVD risk factors are related to their antioxidant and 
immunomodulatory effects, thereby attenuating the synergistic deleterious effects of oxidative 
stress and inflammation in CVD (21,23). In humans, anthocyanin intake has been shown to be 
associated with a lower risk of cardiovascular events (24,25). Intervention studies using 
anthocyanins have demonstrated improvements in vascular function (26) and biomarkers 
related to oxidative stress (27–30),  as well as antioxidant status (28,30–32), lipid profile (33–
35) and inflammatory response (36,37) in both long-term and acute designs. 
Despite these promising findings, there are still several gaps in the literature regarding 
the potential health benefits of flavonoids and anthocyanins. At the epidemiological level, a 
few populations have been investigated in appropriate large-scale studies. Epidemiological 
studies require a specific approach to quantify flavonoid content in foods due to significant 
variation between crops grown in different geographic areas, as well as consideration of the 
variety of diet patterns, both within and between countries. At the clinical level, a number of 
studies have investigated the potential effect of anthocyanins in attenuating and preventing 
pathological conditions. The immediate effect of anthocyanins in the postprandial state has 
been evaluated in several studies using a high-fat high-energy meal challenge. Acute feeding 
studies allow investigation of the ability of these bioactive compounds to attenuate the 
deleterious effects following a stressor meal; however, the findings have not been adequately 
collated to facilitate translation into dietary guidance. Such studies have not included a robust 
investigation of sensitive measures of vascular function in the postprandial state, which along 
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with the immune response are important predictors of CVD. Additionally, there are still several 
gaps to be addressed regarding the effect of anthocyanins on vascular health and inflammation 
in older adults, especially among those with neurodegenerative conditions, such as mild 
cognitive impairment (MCI), which share risk factors with CVD. 
This thesis addresses the following research questions:  
1. Is dietary intake of flavonoids, including anthocyanins, associated with the 
incidence of hypertension in Australian women? 
2. What is the current level of evidence on the postprandial effects of anthocyanins on 
CVD risk factors in high-fat high energy (HFHE) meal challenge studies? 
3. What are the post-prandial effects of anthocyanins on micro- and vascular function, 
and other CVD risk factors in overweight older adults following a HFHE challenge? 
4. What are the chronic effects of anthocyanins on microvascular function, 
inflammatory biomarkers and 24 h ambulatory blood pressure in older adults with 
diagnosis of MCI? 
 
Four studies were conducted to address these research questions. At the 
epidemiological level, nationally representative cohort study data was used to estimate the total 
dietary intake of flavonoids and their subclasses in Australian women. This provided novel 
data that demonstrated an association between flavonoids subclasses with a lower risk of 
hypertension in Australian women. This contributes to the body of evidence that informs 
nutrition messaging and policies for improved cardiovascular health in this population. 
At the clinical level, knowledge synthesis was conducted using a systematic literature 
review approach to collate information on the postprandial effects of anthocyanins on CVD 
risk factors in high-fat meal challenge studies. A total of 13 eligible randomized clinical trials 
reported beneficial effects of anthocyanins, with most the promising results evident for the 
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attenuation of deleterious postprandial effects on oxidative stress and antioxidant status, 
triacylglycerol and total cholesterol concentrations, vascular endothelial function and 
inflammatory biomarkers. Post-prandial changes in blood pressure and lipoproteins were least 
affected by acute anthocyanin consumption.   
A randomised crossover, placebo controlled clinical trial was subsequently designed to 
investigate the postprandial effects of anthocyanins following a HFHE meal challenge, but 
using a novel and robust evaluation of vascular function, namely macro and microvascular 
parameters.  Methodologies combined both classical techniques (flow-mediated dilatation 
(FMD) with the novel imaging technology Laser Speckle Contrast Imaging (LSCI). To our 
knowledge, this is the first study to conduct this type of protocol in studies of nutritional 
interventions. Fruit-based anthocyanins attenuated the postprandial detrimental effects of a 
HFHE challenge on parameters of vascular and microvascular function, and inflammatory 
biomarkers in 16 overweight older adults. 
A second randomised, placebo controlled clinical trial was conducted to investigate the 
longer term effects (8 weeks) of two different doses of anthocyanins provided by Queen Garnet 
plum on inflammatory markers associated with CVD risk factors, along with analysis of 
microvascular function and 24-hour ABP. The innovative aim of this study was to investigate 
such parameters in an older population diagnosed with mild cognitive impairment (MCI), a 
neurodegenerative condition that shares pathological mechanisms with CVD. A daily high dose 
(201 mg/day) of fruit-based anthocyanins consumed for 8 weeks significantly reduced tumour 
necrosis alpha (TNF-α), but did not alter interleulin-6 (IL-6), interleukin-1 beta (IL-1β), high- 
sensitivity C-reactive protein (hs-CRP), microvascular function nor blood pressure parameters. 
No effects were observed in the low dose (45mg/day) group. 
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This body of research contributes novel data on the role of flavonoids, and specifically 
anthocyanins, on vascular function, inflammation and CVD risk across various levels of 
evidence, including: 
• Epidemiological evidence: analytical work conducted in national representative 
cohort of Australian women. 
• Knowledge synthesis: systematic literature review. 
• Experimental evidence: Two randomised controlled clinical trials with 
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CHAPTER 1: Introduction 
1.1 Vascular function and cardiovascular diseases 
 
The health of the vascular system plays a major role in several human disorders, 
particularly in CVD (1,2). CVD is a major cause of mortality globally and is the leading cause 
of death for Australian men and women, responsible for over 43,500 deaths (27%) in the year 
2017 (38). Following a pattern that is also similar worldwide, about 1 in 3 Australians aged 18 
years and over (34%) have high blood pressure, comprised of 23% adults with uncontrolled 
high blood pressure and 11% whose blood pressure was controlled using medication (39).  
A common characteristic among CVDs is the alteration of vascular function and/or 
structure. The endothelium, which is comprised of cells that line the internal surface of the 
lumen of blood vessels, is an organ that regulates vascular homeostasis by maintaining an 
appropriate vascular tone, platelet activity, leukocyte adhesion and angiogenesis through the 
controlled release of mediators such as NO and other regulatory factors (3,40). When one or 
more of these components becomes dysregulated due to impaired endothelial vascular 
signalling, a pathological state named endothelial dysfunction (ED) occurs. In the case of ED, 
there is attenuated vasodilation, augmented vasoconstriction, and remodelling of the vessel 
structure that occurs simultaneously in multiple vascular beds (3,41).  
 Determining the aetiology of ED is complex issue, as this condition shares causes and 
outcomes with several other diseases. For example, classical CVD risk factors such as smoking, 
high blood pressure, obesity, dyslipidaemia and glucose intolerance are associated with the 
occurrence of ED (1,40). Furthermore, because the degeneration of vascular beds occurs over 
time, ageing is an independent risk factor for ED (42). After ED manifests, it worsens the 
clinical status in people who have pre-existing diseases such as diabetes, peripheral vascular 
diseases, stroke and other vascular events, hypertension and atherosclerosis (1,2). In CVD for 
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instance, ED is involved in its pathogenesis by increasing its coexistent risk factors, correlating 
with disease progression and predicting cardiovascular events (43–47). 
One of the main key metabolic manifestations of ED is the partial functional loss of 
endothelial-derived vasodilators, such as NO, in which an aberrant accumulation of reactive 
oxygen species (ROS) is one of the leading causes (3).  The bioavailability of NO depends on 
its proper synthesis, which involves the enzyme nitric oxide synthase (NOS). NOS is a family 
of enzymes that catalyse a complex reaction involving L-arginine, NADPH, H+ and O2 into 
citrullline, H2O, NADP and NO, besides other cofactors. Endothelial production of nitric oxide 
synthase (eNOS) is key to the maintenance of vascular health. In a state of exacerbated 
oxidative stress, several intracellular interactions may occur in the endothelium, resulting in a 
phenomenon called “eNOS uncoupling”. This attenuated and/or altered activity of the enzyme 
leads to a switch from the generation of NO to the generation of superoxide anions and 
hydrogen peroxide, thus creating a vicious cycle in regard to the production of ROS and down-
regulation of eNOS (5,48). The outcome of this process is an endothelial phenotype consisting 
of arterial stiffness, altered vasomotion, increased cytokine synthesis, chemokine secretion, 
leucocyte adherence, LDL oxidation, platelet activation, smooth cell proliferation and 
migration and up-regulation of adhesion molecules. This dysregulation in eNOS signalling and 
remodelling of vasculature are the earliest pathological findings in atherosclerosis, a first step 
to CVD development(49,50). 
 
1.2 Inflammation and oxidative stress: Implications for vascular health 
and cardiovascular diseases 
 
Despite the development of successful treatments for dyslipidaemia and hypertension, 
and knowledge of well-established risk factors, CVD still accounts for one third of all deaths 
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worldwide. The multifactorial background makes it difficult to detect initial pathological 
events, which are usually subclinical during the early phase of disease (51). Oxidative stress 
and inflammation are known to contribute to endothelial dysfunction and vascular damage, and 
their roles in the pathophysiology of hypertension and atherosclerosis are now well accepted 
(52,53). 
Inflammation is a complex series of coordinated events regulated by a diverse number 
of features of the immune system including cytokines, enzymes, lipid mediators and vasoactive 
mediators. In non-diseased conditions, inflammatory responses are resolved when pro-
inflammatory factors are no longer active, resulting in maintenance of a highly active and well-
regulated balanced state. However, in certain conditions, inflammation may not be completely 
resolved, resulting in persistent and low intensity stimulation that produces continuous 
inflammatory responses (54,55). This sustained pro-inflammatory state, also called low-grade 
inflammation, can enhance ED (55). ED is an early marker and one of most predominant risk 
factors in the development of atherosclerosis and can be detected before any structural change 
affects the vessel walls (3,40,56). 
The traditional view is that atherosclerosis represents a consequence of lipid 
accumulation as a degenerative process associated with ageing, where cholesterol is 
indisputably recognized as an environmental and genetic driver of the disease. However, this 
does not explain the entire pathophysiological process. Robust evidence shows that 
inflammation participates centrally in all stages of the disease, from initial lesions to end-stage 
thrombotic complications, and current research is addressing questions about which 
inflammatory mechanisms are involved, as well as identification of therapeutic interventions 
(53,57,58). As the endothelium progresses to a dysfunctional state, anti-thrombotic properties 
and endothelial permeability are impaired, along with upregulation of pro-inflammatory 
cytokines and expression of adhesion molecules, thereby facilitating leukocyte adhesion to the 
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endothelium. Subsequently, leukocytes cross the endothelium and migrate into the intima, 
mediated by chemo-attractants. Upon reaching the intima, monocytes transform into 
macrophages and express receptors that facilitate uptake of lipids, leading to the transformation 
into foam cells, which initiate an atherosclerotic lesion (59,60). 
In addition to the more specific vascular inflammatory process described above, which 
involve several mediators such as vascular adhesion molecules (intercellular adhesion 
molecule 1 and vascular adhesion molecule 1), proteases (plasminogen activator inhibitor-1 
and metalloproteinases), endothelins, chemokines (monocyte chemo-attractant protein-1) and 
others, the role of peripheral inflammatory biomarkers such as C-reactive protein (CRP), 
tumour necrosis alpha (TNF-α), interleukin-6 (IL-6) and interleukin-1 beta (IL-1β) have been 
associated with an increased CVD risk (55,61,62).  This is particularly evident in older adults, 
as several studies support a new immune-metabolic viewpoint for age-related diseases, termed 
“inflammaging”, which is characterized by a chronic, low-grade inflammatory response in the 
absence of a pathogen (7). Additionally, excessive adiposity across all ages is associated with 
an up-regulation of a pro-inflammatory state, as the accumulation of adipose tissue mass 
promotes the secretion and release of inflammatory mediators, including C-reactive protein 
(CRP), interleukin-6 (IL-6), interleukin 1 beta (IL-1β) and tumour necrosis factor alpha (TNF-
α) (63,64). This process also leads to chronic low-grade inflammation that is driven by a 
nutrient excess and/or overnutrition and has the same mechanisms as those underpinning 
“inflammaging” (7).  
CRP has emerged as a major marker of vascular inflammation, playing a direct role in 
promoting ED (65,66) and the development of CVD (67,68). CRP is an acute-phase reactant 
considered to be a reliable biomarker of underlying systemic inflammation due its long half-
life and clinically-available bioassay (53). Although CRP levels may increase up to 1000-fold 
in response to trauma or relevant infections, levels are remarkably stable over long periods of 
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time when measured in asymptomatic individuals, and a high-normal range concentration of 
CRP has been identified as an independent predictor of future vascular events (55). Increasing 
evidence suggests that CRP directly participates in the inflammatory process of atherogenesis, 
with a high expression in the atherosclerotic plaque and an important role in plaque 
vulnerability (69). In a study of 302 autopsies of an atherosclerosis phenotype, it was found 
that the lowest high-sensitivity c-reactive protein (hs-CRP) concentrations were observed in 
those who had died of non-cardiac causes (70). Stable plaques showed a modest elevation, 
while erosive plaques showed a greater elevation, and a marked elevation in hs-CRP was seen 
in ruptured plaques. The highest quartile of hs-CRP concentration was associated with a 1.5 to 
1.7-fold increase in relative risk of symptomatic atherosclerosis. In all cases of sudden cardiac 
death, high concentrations of hs-CRP were identified, regardless of the presence or absence of 
thrombosis, suggesting that hs-CRP identifies lesions rich in lipids and macrophages, and that 
it is associated with a risk of a vascular event, even in patients with clinically stable coronary 
heart disease (70).   
CRP levels may be useful for short-term prognosis and long-term risk assessment after 
a cardiovascular event (69). Therefore, several studies have investigated associations between 
CRP levels and the risk of a wide range of CVD events. A number of studies have investigated 
the predictive role of CRP in myocardial infarction (MI).The Honolulu Heart Study found that 
the odds of MI increased in the first few years of follow-up in participants with high CRP 
concentrations, and that trend was similar after 20 years of follow-up, showing that 
inflammation may play both an early and late role in the atherosclerotic process (71). In another 
study, among 1,086 men followed up for over 8 years, those with the highest quartile of hs-
CRP had a 2.9-fold greater relative risk for MI (p < 0.001) and 1.9-fold greater relative risk for 
stroke (p = 0.02) compared to men in the lowest quartile, that was independent of traditional 
cardiovascular risk factors (72). Another study conducted in 82,544 adults [66,796 men and 
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15,748 women; mean (SD) age 55.1 (9.86) y] without prior cardiovascular diseases or cancer 
at baseline reported 714 incident MI cases over 6 years of follow-up (61). Higher baseline and 
cumulative average concentrations of hs-CRP were consistently associated with increased risk 
of MI (p<0.001 for both).  A longitudinal increase in hs-CRP was also associated with a higher 
future risk of MI, after adjustment for baseline values and other covariates (p<0.001). Each 
1mg/L increment per year in hs-CRP was associated with a 9.3% increase in risk for future MI 
[hazard ratio (HR) = 1.09, 95% CI, 1.03; 1.17]. Participants with high-grade inflammatory 
status (hs-CRP ≥10 mg/L) had a higher risk of MI occurring <3 months versus those compared 
with those that had hs-CRP concentrations <0.5 mg/L (HR = 6.64; 95% CI, 1.49-29.6), and 
with MI occurring ≥4 years (HR = 2.95; 95% CI, 0.90, 9.65) (61). A meta-analysis investigated 
the ability of CRP to predict major cardiovascular events in 5401 individuals with peripheral 
arterial disease (PAD). PAD patients with higher CRP had a significantly higher risk of major 
cardiovascular events compared with those with lower CRP concentrations (HR 2.26, 95% CI 
1.65 to 3.09, p < 0.001). The HR for major cardiovascular events was 1.38 (95% CI 1.16 to1.63, 
p < 0.001) per unit increase in CRP concentration (73). Concerning coronary heart disease 
(CHD), a meta-analysis was conducted presenting a body of evidence of good quality, 
consistency, and applicability. For studies that adjusted for all Framingham risk variables, the 
relative risk for incident CHD was 1.58 (95% CI, 1.37 to 1.83) for CRP levels greater than 3.0 
mg/L compared with levels less than 1.0 mg/L(74).  
TNF-α is a cytokine with a wide range of pro-inflammatory activities and is primarily 
produced by macrophages, endothelial cells, and smooth muscle cells of atherosclerotic arteries 
(75). TNF-α may influence the atherosclerotic process both by causing metabolic perturbations 
and by increasing the expression of surface leukocyte adhesion molecules, chemokines and 
enhancing the production of other cytokines and growth factors. TNF-α also stimulates new 
vessel formation and induces features characteristic of developing atheroma. High 
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concentrations of TNF-α have been associated with premature coronary artery disease, acute 
MI, peripheral arterial disease, and congestive heart failure (75). Concerning the predictive role 
of TNF-α in CVD, a case-cohort study comprising 105 coronary artery disease (CAD) cases 
and 638 individuals randomly selected from a cohort of 5,404 participants aged 35–74 years 
(mean follow-up of 6.1 years) reported that TNF-α was significantly and independently 
associated with CAD (adjusted HRs=1.87;1.31–2.66) (75). Furthermore, there is evidence from 
a large-scale prospective cohort study (2225 participants aged 70-79 years old without baseline 
CVD) that were assessed for incident coronary heart disease, stroke and congestive heart failure 
events during an average follow-up of 3.6 years. TNF-α was significantly associated with CHD 
(per TNF-α SD increase: RR, 1.22; 95% CI, 1.04-1.43) and congestive heart failure (per TNF-
α SD increase: RR, 1.59; 95% CI, 1.30 to 1.95) (76).  
IL-6 is a pleiotropic cytokine with both anti and pro-inflammatory roles that regulates 
a plethora of immune and metabolic responses; however, high concentrations of this cytokine 
have been associated with CVD and mortality (76,77). IL-6 is highly expressed by the vascular 
endothelium and the pharmacological inhibition of IL-6 improves endothelial function (78) 
Such findings are clinically meaningful considering the predictive roles of IL-6 concentrations 
in CVD risk supported by a number of studies. Hazard ratios of 1.80 have been reported 
according to each 1-SD increase in IL-6 for risk of first-ever cerebrovascular events in 
individuals with vascular risk factors but without any pre-existing cardiovascular disease (79). 
Further, in a meta-analysis of 17 prospective studies investigating clinical coronary outcomes 
(i.e., myocardial infarction or coronary death), an odds ratio of 1.61 (95% CI 1.42–1.83) was 
found per 2 SD increase in baseline IL-6 (80). Another meta-analysis of 17 studies comprising 
288,738 healthy individuals reported significantly higher IL-6 concentration in CVD cases 
compared to non-CVD controls [standardized mean difference of 0.14, (95% CI) 0.09- 
0.20]/mean difference of 0.36 [0.28-0.44] pg/mL) (81).  
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IL-1β also plays a central role in CVD development, representing one of the most potent 
inducers of innate immunity and acts as an upstream regulator in the inflammatory cascade 
(82). IL-1β synthesis is significantly upregulated after cardiovascular events such as 
myocardial infarction, as well as in advanced plaque formations in atherosclerotic disease, thus 
it has been investigated as a therapeutic option in secondary and tertiary prevention of CVD 
(83). Intrinsic vascular wall cells and lesional leukocytes alike can produce this cytokine. Local 
stimuli in the plaque induce the generation of active IL-1β through the action of a molecular 
assembly known as the inflammasome (84). The convincing links between IL-1β and pro-
inflammatory diseases, such as atherosclerosis, indicates this cytokine to be a potential 
therapeutic target to improve cardiovascular outcomes (84). In this matter, an anti-IL-1β 
therapy was investigated in a large randomized, double-blind, placebo-controlled trial of 
including 10,061 patients (median follow-up of 3.7y) with a history of myocardial infarction 
and CRP concentrations ≥ 2 mg/L. The treatment with canakinumab (anti-IL-1β monoclonal 
antibody) led to 15% reduction in major adverse cardiovascular events (p=0.007) (85). 
Furthermore, a meta-analysis including 6 cohort studies with 1,855 CVD cases and 18,745 non-
cases with (follow-up times between 5-16y) investigated the effect on incident CVD of  an 
Interleukin-1 receptor antagonist (IL-1RA), which counter-regulates IL-1β as an endogenous 
inhibitor in vivo by blocking the binding site for IL-1β. A pooled standardized hazard ratio 
(95% CI) for incident CVD of 1.11 (1.06–1.17) was found after adjustment for age, sex, 
anthropometric, metabolic, and lifestyle factors (P<0.0001) (82).  
Oxidative metabolism is essential for aerobic life, as nutrients provide energy through 
oxidative phosphorylation, while intermediary metabolism adds direct incorporation of oxygen 
atoms from molecular oxygen (O2) into biomolecules. Any molecules or atoms generated by 
this process containing 1 or more unpaired electrons (free radical) are highly reactive (86). This 
biological process involving generation of oxidative breakdown products can interact and lead 
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to oxidation of DNA, proteins, carbohydrates and lipids. On the other hand, the human 
metabolism has several strategies of defence against oxidative damage, such as enzymatic and 
non-enzymatic antioxidants, besides adaptive responses (87,88).  
The imbalance between oxidants and antioxidants in favour of oxidants, potentially 
leading to tissue damage and/or triggering cell death pathways, is called oxidative stress (50). 
Reactive species or free radicals include reactive oxygen and nitrogen species (RNS), which 
are also important components of intracellular signalling cascades. Thus, the deleterious 
oxidative overload in cells, organs or the entire organism is a condition that can be 
characterized not only by an aberrant quantity, but also by the quality (source) of these 
molecules, as aforementioned in the eNOS uncoupling example (5,88).  
ROS molecules include free oxygen radicals, such as superoxide, hydroxyl and peroxyl, 
as well as non-radicals, such as hydrogen peroxide. The non-radicals are either oxidizing agents 
or are easily converted into radicals. RNS are molecules containing nitrogen such as NO, 
peroxynitrite, and nitrogen dioxide. The source of these molecules may be from by-products 
of endogenous compounds or xenobiotics through mechanisms, such as the electron transport 
chain, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase 
(XO), metabolism of the arachidonic acid and cytochrome P-450 (89,90).  
 In a normal physiological state, a sufficient supply of antioxidants is provided during 
metabolic processes, as well from dietary sources, that neutralizes harmful activity of reactive 
species. However, several factors can increase the concentration of such harmful molecules by 
depleting antioxidant defences leading to oxidative stress. These include smoking, sleep 
deprivation, acute microbial infections, being overweight, high sugar and/or fat intake, and 
exposure to metals and air pollutants (5,87). Oxidative stress can lead to injury of the 
endothelium and impairment of NO bioavailability, as well as reduce other functions, such as 
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regulation of blood clotting, local immune responses, control of the fluid volume and 
transportation of electrolytes and other substances between blood vessels and tissues (1,91).  
The immune response plays a major role in ED pathogenesis and also acts directly in 
oxidative balance. Myeloid cells and T lymphocytes protect the host organism from pathogens 
by attacking with bursts of ROS. While these ROS may help to preserve the vascular tone, an 
aberrant production of ROS triggered by immune cells in the absence of any hemodynamic 
insult can lead to damage to the endothelium. Nonetheless, an oxidative stressed state in 
cardiovascular control organs may likewise potentiate inflammatory responses and augment 
ED. Therefore, inflammation and oxidative stress act as cooperative and synergistic partners 
in the pathogenesis of ED (4,5).  
 
1.3 Assessment of vascular and microvascular function 
 
There is increased interest in methods to assess ED to better understand the 
pathogenesis of CVD and other diseases. With the simultaneous advance of knowledge and 
technology in this field, there are already many non-invasive options available in both clinical 
practice and research. Traditional techniques, such as flow-mediated vasodilation (FMD), 
pulse wave velocity (PWV), and carotid intima media thickness are highly correlated with 
cardiovascular outcomes and are useful to track disease progression and assess the efficacy of 
therapeutic interventions in overall vascular health (11). The CVD risk prediction of FMD was 
addressed in a meta-analysis of 23 studies that included 14,753 subjects finding an overall 8 % 
reduction in CVD risk (RR= 0.92; 95%CI: 0.88; 0.95) for each percentage increase in FMD 
(92). However, these methods evaluate conduit artery function, therefore providing limited 
information with regard to mechanisms of systemic microvascular physiopathology.  
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The microcirculation comprises arteries with low resistance, arterioles, capillaries, and 
venules. While the capillary network acts on nutrient and gas exchanges between blood and 
tissues, arterioles play a major role in blood flow regulation by mechanisms including arteriolar 
myogenic response, flow-induced vasodilation, metabolic and neural mediators (93). These 
mechanisms, as well as pathological processes that might affect them are evident in the 
cutaneous microcirculation and can represent ED features and mechanisms upon other vascular 
beds. Therefore, considering that the skin is readily accessible, several imaging techniques have 
been developed in order to use cutaneous microcirculation to investigate the mechanisms of 
systemic microcirculatory function and dysfunction in various diseases (94,95).  
 The first imaging techniques for this purpose were developed using Laser Doppler 
technology. Laser Doppler flowmetry (LDF) assesses blood flow over a small volume (< 
1mm3) and detects and quantifies relative changes in skin blood flow in response to a given 
stimulus. However, this technique presents a relatively poor reproducibility due to the 
significant spatial variability by a heterogenic capture of skin perfusion. Laser Doppler Imaging 
(LDI), the subsequent developed technology, decreased this spatial variability drawback, but it 
is much slower than LDF, thereby, recording rapid changes in skin blood flow over the larger 
areas becomes particularly challenging (95,96). Laser Speckle Contrast Imaging (LSCI) is a 
recent technique based on speckle contrast analysis that provides an index of blood flow. LSCI 
supports a continuous rate of high frame assessment of skin perfusion over wide areas, 
combining advantages of LDF and LDI, and thereby providing good reproducibility of tests 
such as the post-occlusive reactive hyperaemia (PORH) and local thermal heating (LTH) 
challenges (97,98). 
Microvascular reactivity is assessed by stimulating microvessels with various 
physiological or pharmacological challenges. The most common tests that are used in 
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combination with imaging techniques are iontophoresis of vasoactive drugs, such as 
acetylcholine and sodium nitroprusside, PORH and thermal challenges, such as LTH (93). 
Iontophoresis is a non-invasive method of transdermal delivery of drugs based on the 
transfer of charged molecules using electric currents. Acetylcholine and sodium nitroprusside 
iontophoresis have been widely used to assess endothelial-dependent and -independent 
microvascular vasodilation, respectively (95,99). Exact proportions of mechanisms that are 
predominant in the acetylcholine-induced vasodilation are still not clear; however, C-fiber 
(axon reflexes), COX-dependent pathways and NO contribute to this response. In addition, 
endothelial-derived hyperpolarization also contributes to acetylcholine-mediated vasodilation 
in a dose dependent manner (100). In order to avoid non-specific vasodilatory effects, one 
group of researchers reviewed several protocols of iontophoresis of acetylcholine and sodium 
nitroprusside, showing that the type of diluent used for each vasoactive agent, intensity of 
current and the method of electrical current delivery are important to maintain good 
reproducibility (101).  
 PORH is a microvascular reactivity test commonly conducted in the forearm when a 
transient increase in cutaneous blood flow occurs following release of a brief occlusion in the 
brachial artery. There is still no standardized protocol for this test; however, most studies use 
a method in which a cuff, placed above the antecubital fossa, is inflated 50-60mmHg above 
systolic pressure for 2-5 minutes (93). The mechanisms involved in this induced vasodilation 
are still being elucidated, with some studies showing inconsistent results. Many mediators seem 
to contribute to PORH vasodilation and although most of these responses are endothelial-
dependent, NO and COX pathways appear not to exert significant influence (102,103). The 
major contributors to peak and time course of this microvascular reactivity are sensory nerves 
through an axon reflex response (96). The endothelium-derived hyperpolarizing factors 
(EDHF) are also involved, including activity of large-conductance calcium activated potassium 
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channels (BKCa) by epoxyeicosatrienoic acids (95,104). In addition to the abovementioned 
endothelial challenges that allow the evaluation of specific mechanisms, the postprandial state 
is a condition that presents a particular modulation of endothelial function.  
There is emerging evidence that metabolic imbalances in the postprandial state, 
particularly after a high-energy meal rich in fat, are important contributing factors to 
development of CVD (105,106). Overall, the underlying mechanism involves a sharp increase 
in triacylglycerol along with an aberrant production of pro-oxidant molecules leading to an 
oxidative stress state. This may impair vascular and endothelial functions, and mediate the 
onset of an inflammatory response, which further contributes to the generation of more free 
radicals, thus creating a deleterious vicious cycle (105–107). Dietary fats comprise 
heterogeneous molecules with diverse structures, which affect diverse cell processes such as 
transcription regulation, cellular and organelle membrane structure and function, ion channel 
activity and electrophysiology. Responses vary depending on both the fatty acid composition 
of the food source, as well interactions with accompanying nutrients, the food matrix and 
process (108). Modification of the type of dietary fat in a food or overall meal has been shown 
to result in postprandial effects on appetite (109), lipaemia and markers for inflammation and 
endothelial activity (110). 
The high-fat meal (HFM) challenge is one way to investigate the imbalances that are 
promoted on a daily basis in Western diets (105). Considering that a significant part of the day, 
usually two thirds of day time, is spent in the postprandial state, this is an important focus for 
therapeutic investigations. Further details of this type of study and its implications in CVD are 
provided in Chapter 3 of this thesis. 
Taken together, the assessment of macro and microvascular function, including 
techniques that evaluate structural changes in these vascular beds, such as FMD and PORH 
combined with LSCI technology, along with evaluation of biomarkers related to the immune 
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response and oxidative stress, provide reliable information to investigate prediction, severity 
and responsiveness of treatment of several diseases, in particular CVD. Using these methods, 
a wide range of dietary interventions can be explored as potential therapeutic options. 
 
1.4 Flavonoids and implication on cardiovascular diseases 
Diet is one of the most important factors in modulating metabolic and immune 
responses by its direct effect on bioenergetics, body weight, gut microbiota and many other 
systemic body regulation mechanisms. Among different dietary components, polyphenols are 
bioactive compounds that naturally occur in various fruits, vegetables, cereals and beverages. 
They partly contribute to the bitterness, astringency, colour, flavour, odour and oxidative 
stability of such foods (111). Among the vast number of phenolic compounds, the most 
common and widely distributed class are flavonoids, present virtually present in all plants. In 
foods, flavonoids occur as aglycones, methylated derivatives and mostly as glycosides, also 
providing prevention of fat oxidation and protection of vitamins and enzymes. There are more 
than 9,000 flavonoids present in nature with different physical, chemical and physiological 
properties, characteristics that delineate their biological activities. They are found in subclasses 
such as flavanols, flavonols, flavanones, flavones, isoflavones and anthocyanins(112).  
 Dietary intake of flavonoids have been associated with the prevention and incidence of 
several diseases in epidemiological studies. Dietary flavonoid interventions have been  
explored in clinical trials to treat pathological conditions, such as ED (12,13). In the 
endothelium, dietary flavonoids can exert physiological effects as both antioxidant and as 
signalling molecules.  The antioxidant activity is due to their ability to donate hydrogen, bind 
metal ions, resonance stabilization of phenoxyl radicals, thereby acting as reducing agents, 
metal chelators, ROS scavengers, chain-breaking antioxidants, quenchers of singlet oxygen 
formation and protectors of endogenous ascorbic acid. The signalling properties of flavonoids 
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are attributed to interactions with enzymes, kinases and cellular receptors in regulatory 
pathways mediating physiological responses or altering gene expressions (113,114). For 
instance, certain types of flavonoids can modify protein kinase-mediated signal transduction 
and up-regulate antioxidant and anti-inflammatory gene expression (115,116), as well as down-
regulate inflammatory gene expression and improve blood pressure (117).  
 The association between dietary flavonoid intake and potential health benefits in large 
studies can present methodological challenges. Besides the fact that flavonoid content in foods 
is likely to be influenced by seasonality and geographical areas, there are some relevant 
discrepancies between food composition databases with regard to flavonoid content in foods. 
Additionally, the methods used to assess dietary intake of participants are generally insensitive 
to accurately characterise flavonoid consumption (118). Nonetheless, some large prospective 
studies and pooled analyses of clinical trials show positive results in relation to total dietary 
flavonoid and certain subclasses. In a total of 2,087 fatal coronary heart disease (CHD) events 
among 7 prospective cohorts, subjects in the higher tertile of dietary flavonol intake presented 
a combined risk ratio of 0.80 in comparison to subjects in the lower tertile, after adjustment for 
disease and dietary factors. The main flavonol sources that could be extracted from these 
cohorts were from a small number of fruits and vegetables, tea and red wine (16). A meta-
analysis of ten studies investigated mortality by CVD events. The relative risk (RR) of all-
cause mortality among subjects in the higher category of total flavonoid intake was 0.82 in 
relation to subjects in the lower category intake. A trend was also found for risk of death from 
CVD (RR: 0.85 and P=0.099) and CHD (RR: 0.74 and P=0.069). A dose-response analysis 
showed that the lowest risk of all-cause mortality was lower in subjects consuming >200mg/d 
of total flavonoids (13). The effects of cocoa flavonols was analysed in a meta-analysis of 35 
studies, involving 40 treatment comparisons. This pooled analysis with moderate quality 
evidence showed a modest, but significant lowering of both systolic and diastolic blood 
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pressure of 1.8 mmHg on average (19). Furthermore, another subclass of flavonoids, quercetin, 
has also been found to be effective in lowering blood pressure; however, a meta-analysis of 7 
clinical trials only reached significance with dosages of >500mg/day (28). Another study 
evaluated the dietary intake of total flavonoids and subclasses on incidence of hypertension. In 
a prospective cohort of 40,574 healthy women, 9,350 cases of hypertension were observed 
during a follow-up of approximately 14 years. A 10% lower rate of hypertension was found in 
individuals within the higher quintile of flavonol intake when compared to the lower quintile 
[hazard ratio (HR): 0.90, p=0.031]. Proanthocyanidin and anthocyanins also showed a similar 
effect of lowering the incidence of hypertension by 9% between the highest and lowest quintile 
of consumption (HR: 0.91, P= 0.0075 and HR: 0.91, P= 0.0051, respectively)(119). In this 
matter, anthocyanins are emerging as a potential therapeutic option for CVD due to its effects 
on ED mechanisms, mainly on oxidative stress and immune response. 
 
1.5 Anthocyanins 
Anthocyanins are the largest class of water-soluble plant pigments, which are 
responsible for the blue, purple and red colour of many fruits and vegetables. Anthocyanins are 
formed by the coupling of sugars to anthocyanidins, whilst anthocyanidins are their sugar-free 
analogues. There are more than 300 known anthocyanins, but considering the different 
possibilities for their glycosylated part, this can number more than 8,000 types. The most 
common anthocyanins in foods are from six subclasses, namely cyanindin, (comprising 50% 
of anthocyanins), pelargonidin (12%), peonidin (12%), delphinidin (12%), petunidin (7%) and 
malvidin (7%). Degradation of anthocyanins in foods can occur by several food processing and 
storage factors including pH, temperature, exposure to light and oxygen or interactions with 
foods components, such as ascorbic acid, sugar and metal ions (120,121). 
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In large population studies, the estimated average intake of anthocyanins is even more 
challenging than assessing of total flavonoids due to a lack of valid and reliable data on the 
food composition of dietary sources. Nonetheless, a multi-centre investigation in Europe 
estimated the average daily intake of anthocyanins for men to be 19.83 mg and 64.88 mg in 
Holland and Italy, respectively. Among women, the results showed an average daily intake of 
18.73 mg in Spain and 44.08 mg in Italy (122). Besides the difficulties in obtaining accurate 
information on the anthocyanin content of foods and challenges with the assessment of dietary 
intake, seasonality and geographic variation also complicate such analysis. In Australia, a food 
frequency questionnaire was validated to measure flavonoid intake in older adults, and an 
Australian-specific anthocyanin food composition database for dietary studies is being 
developed (123). 
 Cell culture, animal model, human clinical trials and epidemiological studies have 
shown the potential effect of anthocyanins to improve vascular function, inflammatory 
response and other CVD risk factors (26,121,124–137). The essential feature of these benefits 
refers to the major role of anthocyanins modulating the immune response. A large number of 
in vitro and animal studies (121,127,138–140) explain the mechanisms related to the anti-
inflammatory actions of anthocyanins. These include: (1) modulation of arachidonic acid 
metabolism, in which lipid mediators that regulate inflammation (e.g.  prostaglandins and 
leukotrienes) have their key enzymes cyclooxygenases and lipoxygenases inhibited by 
anthocyanins; (2) decreased activity of the NF-κB pathway, which is a transcription factor 
responsible for triggering and regulating inflammatory processes, leading to the expression of 
pro-inflammatory cytokines and enzymes; and (3) suppression of  acute pro-inflammatory 
genes that regulate inducible nitric oxide synthase (iNOS), which is responsible for preventing 
excessive production of nitric oxide (NO).  
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The beneficial effects of anthocyanins on ED may also be related to their ability to 
mitigate the oxidative stress-related damage to the endothelium and their action in 
endothelium-dependent vasodilation signalling pathways. Antioxidant mechanisms of 
anthocyanins are exerted by direct and indirect pathways. Anthocyanins provide direct free 
radical scavenging activity by electron donation (hydrogen), as well as by improving 
endogenous antioxidant defences, such as restoring or enhancing antioxidant enzyme activity, 
such as superoxide dismutase and glutathione peroxidase, as well as up-regulating gene 
expression of glutathione peroxidase (22,138). This antioxidant activity appears to be superior 
to that of other conventional antioxidants such as α-tocopherol, trolox and catechin 
(138,141,142). The chemical structure of each anthocyanin subclasses also influences its 
potential antioxidant effect, which is related to the number and position of hydroxyl groups, 
conjugation groups, degree of glycosylation and the capacity of the aromatic group of donating 
electrons. Thus, different anthocyanins may show different levels of scavenging activity 
towards ROS and reactive nitrogen species (RNS), or other adverse metabolic products 
(138,143). 
 The increase in bioavailability of NO, through increased expression of eNOS, has been 
investigated in cell culture studies. Edirisinghe et al. (126), pre-treated human umbilical vein 
endothelial cells with different concentrations of blackcurrant juice and for different time 
periods, independent of vitamin C. The results showed an up-regulation of eNOS that was 
activated via the Akt/PI3 kinase pathway, while the effect was not vitamin C-dependent. An 
increased eNOS expression was also demonstrated in bovine artery endothelial cells treated 
with cyanidin-3-glucoside. This increase, exerted via the Src-ERK1/2-Sp1 signalling pathway, 
was in a dose and time-dependent manner. Significant results were observed after an incubation 
time of only 8 hours, while after 24 hours of incubation NO output increased twofold (144).   
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In animal models, studies using anthocyanins as a dietary intervention confirmed many 
of the aforementioned effects observed in cell culture studies, including regulation of the 
immune response and reduced oxidative stress, as well as mediation of lipid transport and 
accumulation, lowering of blood pressure and improved vascular reactivity.  In two acute 
experimental mice models of peritonitis and paw oedema, anthocyanins provided from wild 
mulberry inhibited carrageenan-induced inflammation by suppressing mRNA as well as 
protein levels of COX-2 (145).  In a model of hypercholesterolemia, mice fed with a high-fat 
diet and treated with 2% açai pulp had improved oxidative stress-related biomarkers and better 
lipid profiles, as well as reduced superoxide dismutase activity and increased paraoxonase 
activity (protection of lipoproteins and membranes to oxidative damage) (146). Regarding 
weight loss and adiposity, another study of rodents fed with a high-fat diet for 12 weeks along 
with 40 and 200 mg/kg of cherry anthocyanins attenuated weight gain by 5.2% and 11.2%, 
respectively. This was associated with a lower concentration of plasma leptin, glucose, 
triacylglycerol, total cholesterol and LDL cholesterol, along with a decreased gene expression 
of Il-6 and TNF in this tissue, and a reduction in adipose cell size (147). Cholesterol efflux 
signalling can also be influenced by anthocyanins; however, this effect is attributed to its 
downstream metabolites. For example, protocatechuic acid, a gut microbiota metabolite in 
mice, exerts this cholesterol efflux from macrophages; however, anthocyanins in 
physiologically reachable concentrations did not show this effect (148).   
Parameters related to vascular function such as blood pressure and vascular reactivity 
have also been investigated in animal models. In stroke-prone rats, treatment with a 3% 
blueberry diet for 8 weeks resulted in a significant decrease in systolic blood pressure of 19% 
and 30% in weeks 4 and 6, respectively, along with reduced markers of renal oxidative stress, 
such as proteinuria and kidney nitrite (149). In vascular reactivity parameters, rats fed with 
blueberries for 7 weeks showed diminished vasoconstrictor response to an L-phenylephrine 
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challenge, while inhibition of NOS, but not COX caused a higher vasoconstriction in the 
blueberry group. This was also evidenced as the endothelium-dependent vasorelaxation 
induced by acetylcholine, mediated by the NO pathway, was greater in the anthocyanins group 
compared to the placebo (150). Moreover, another study showed improvements in the aortic 
endothelium-dependent vasorelaxation response, also induced by acetylcholine, in mice fed 
with 2g/kg of cyanidin-3-glucoside for 8 weeks. This result was followed by an increase in 
cGMP concentration and eNOS phosphorylation at Ser 1177 in the aorta (151). 
A few studies have also advanced in nutrigenomic analysis of anthocyanin effects in 
mice models. A mouse model of accelerated atherosclerosis development was fed with 0.02% 
of the diet comprising bilberry anthocyanins extract. The attenuated atherosclerotic lesions in 
the anthocyanins group was followed by a modulation in expression of 1,261 genes, which 
were related mainly to different cellular processes such as oxidative stress, inflammation, 
regulation of adhesion molecules, cell to cell adhesion, paracelullar permeability and 
angiogenesis (152). The same research group previously found altered expression of 2,289 
genes in liver tissue, in the same experimental model provided with the same diet. 
Transcriptional analyses showed that these genes were involved in bile acid synthesis and 
cholesterol uptake into the liver, and downregulation of pro-inflammatory cytokines (153). 
The translation of findings from anthocyanin intervention studies is complex. This is 
because the potential effects of these compounds depends on their complex absorption, 
breakdown to phenolic metabolites and subsequent various actions in cells. Despite promising 
findings to date, many of the mechanistic pathways of their effects are not fully elucidated in 
humans. The method of delivery of anthocyanins also differs between studies and they may be 
provided in whole foods, juices, extracts or as purified anthocyanins. While there is 
homogeneity regarding some outcomes, many other parameters are not consistent between 
studies. Table 1 summarizes several clinical trials using different forms of anthocyanins, and 
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for several conditions related to ED. Studies evaluating parameters related to oxidative stress, 
inflammation, lipid profile, glucose homeostasis, blood pressure, hemodynamic and vascular 
outcomes were included. However, conditions such as inflammatory and infectious diseases, 
cancers, as well as studies evaluating specific groups of individuals such as professional 
athletes, smokers, children, and pregnant or breastfeeding women were not included.  
 Overall, chronic supplementation of anthocyanins showed a relevant role in oxidative 
stress, lipid peroxidation, antioxidant status and vascular outcomes with the majority of studies 
reporting improvements in related parameters. A moderate beneficial effect, with some 
heterogeneity among studies, was evidenced for lipid profile, glucose homeostasis, vascular 
inflammatory markers and hemodynamic factors. Although some studies showed 
improvements in outcomes such as blood pressure, peripheral inflammatory markers and 
anthropometry, these were the parameters with the highest inconsistency between studies using 
anthocyanins in medium or long-term dietary interventions. On the other hand, postprandial 
studies show the most promising results in the attenuation of deleterious postprandial effects 
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Table 1-1. List of clinical trials with chronic and acute supplementation of anthocyanins 









– anthocyanins content 
Duratio
n (days) 
Results (intervention vs control) 
Traustadó






12 Double blind, 
placebo controlled, 
crossover 
Tart cherry juice 
(480mL) - 59.5 mg of 
total anthocyanins  
14 ↓forearm ischemia-reperfusion  F2-
isoprostane response 
↓ urinary 8-hydroxy-2 
9-deoxyguanosine; 8-hydroxyguanosine 
↔ urinary isoprostanes 









63 Double blind, 
placebo controlled, 
RCT 
Extract of black soybean 
- 31.45 mg of total 
anthocyanins 














Extract of maqui berry - 
468 mg of total 
anthocyanins 
28 ↓ plasma OxLDL; urinary F2-isoprostanes 
↔ anthropometry; blood pressure; lipid 
profile 













anthocyanins – 160mg  
of total anthocyanins 
168 ↓LDL-c; TG;  apolipoprotein B-48;  
apolipoprotein C-III; glucose; HOMA-IR 
↑ HDL-c 
↓F2-isoprostanes; 13-
hydroxyoctadecadienoic acid;  carbonylated 
proteins 













65g of frozen bilberries 
– 194mg of total 
anthocyanins 
42 ↓ TC; TG; LDL-c; glucose;  
↑ HDL-c 














(equivalent to 250 g 
rehydrated berries) – 
total anthocyanins value 
not provided 
42 ↓ AIx; aortic systolic pressure 
↔ anthropometry; overall blood pressure 
↓ diastolic blood pressure (sub-analyses) 
↑ absolute NK cells 













Juice – 277.5mg of total 
anthocyanins; smoothie 
- 324.7mg of total 
anthocyanins 
14 ↑plasma superoxide dismutase; catalase 
activity; TEAC 
↔ plasma glutathione peroxidase and 
erythrocyte superoxide dismutase 
↓ plasma and urinary MDA 
↔IL-2, -6, -8 and -10; CRP; sCD40;TNF-









– anthocyanins content 
Duratio
n (days) 
Results (intervention vs control) 
Kardum 







Chokeberry juice - 
25mg of total 
anthocyanins 
84 ↓ TBARS; PAB; TOS 
↑ PON1; TAC 
↔ anthropometry; blood pressure; 
biochemical parameters 









Tart cherry juice 
concentrate - 273.5mg 
total anthocyanins 













Dried purple carrot- 
118.5 mg of total 
anthocyanins 



















xyloside (4.2%), and 3-
O-cyanidinglucoside 
(2.4%) – mg? 
60 ↓ systolic and diastolic blood pressure; 
endothelin-1; TBARS; antioxidant enzymes 
catalase 
↓TC; LDL-c; TG;  
↑ superoxide dismutase;  glutathione 
peroxidase; fibrinogen 
↔ CRP 









Cranberry juice - 12.4 
mg of total anthocyanins 
;  119mg of total 
Proanthocyanidins 
56 ↔blood pressure; lipid profile; glucose; 
CRP; IL-6 
↓ serum MDA and 4-hydroxynonenal; 
plasma OxLDL 
↑ plasma antioxidant capacity 
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Blueberry beverage – 
742mg of  total 
anthocyanins 
56 ↓ diastolic and systolic blood pressure;  
↓ plasma MDA; 4-hydroxynonenal; 
OxLDL 
↔  lipid profile; glucose;  HbA1C; CRP; 
CAMs; IL-6;  myeloperoxidase 
Dohadwal









44 Double blind, 
placebo controlled, 
crossover, RCT 
Cranberry juice – 94mg 
of total anthocyanins 
28 ↔ blood pressure; FMD; carotid-radial 
PWV 
↓ carotid-femoral PWV 
↔ lipid profile; glucose; insulin; CRP, 
ICAM-1 









Cherry juice – 138 mg 
of total anthocyanins 84 
↓ Systolic and diastolic blood pressure 















































crossover,  RCT 
Blackberry and billberry 
extracts - 320mg of total 
anthocyanins 
28 
↓ monocyte-platelet aggregate formation;  
platelet endothelial cell adhesion molecule-
1; procaspase activating compound-; P-
selectin; ADP-induced whole blood platelet 
aggregation 
↔ blood pressure; fibrinogen; lipid profile, 
CRP 











crossover,  RCT 
Purified anthocyanins - 
320mg of total 
anthocyanins 
84 
↑ FMD;  serum cGMP 
↔ blood pressure; TG; TC; glucose; insulin 













31 Double blind, 
placebo controlled, 
crossover, RCT 
Purified anthocyanins – 
640mg of total 
anthocyanins 
28 ↔ blood pressure 
↑ HDL-c; von Willebrand factor, 
↔ TC; TG; LDL-c; glucose; CRP; MCP-1; 
P-selectin; CAMs; IL-6 (trend); TNF-α; IL-
4; L-arg/ADMA; FRAP 
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Results (intervention vs control) 














High fat and carbohydrate 
meal with freeze-dried whole 
strawberry powder (0, 10, 20, 
30 and 40g) 
0, 0.5, 1, 
1.5,  2, 3, 
4, 5 and 6 













Organic red grape juice – 
159.2  mg  of total 
anthocyanins / conventional  
red grape juice – 42  mg of 
total anthocyanins  











Hibiscus sabdariffa L. 
aqueous extract - 130.25mg 
of total anthocyanins 
0, 0.5, 1, 
1.5, 2, 
2.5, 3, 4, 
6, 8 and 
10h 
↑ plasma FRAP AUC; plasma 
ascorbic acid  
↓ plasma uric acid 
↓ urinary MDA  
↑ urinary ascorbic acid 
Edirisingh
















fat meal + strawberry 
beverage - 120.69mg of total 
anthocyanins   
0, 0.5, 1, 
1.5,  2, 3, 
4, 5 and 6 
↓ CRP; IL-6;  insulin 














Results (intervention vs control) 
Alqurashi 











Açai-based smoothie – 
493mg of total anthocyanins 
0, 1, 2, 3, 
4, 5, 6 
and 7h 
↑ FMD 
↓ total peroxide oxidative status 
AUC 
↔ blood pressure; glucose 
Dohadwal








15 Open label Cranberry juice – 94mg of 
total anthocyanins 
0, 2 and 
4h 
↔ blood pressure;  




Symbols: ↑ Higher than control treatment ↓ Lower than control treatment ↔ No significant effect. Abbreviations: RCT, random clinical trial; LDL-c, low-density lipoprotein 
cholesterol; OxLDL, oxidized low-density lipoprotein; TBARS, thiobarbituric acid reactive substances; ORAC, oxygen radical absorbance capacity; FRAP, ferric ion reducing 
antioxidant power; TEAC, trolox equivalent antioxidant capacity; MDA, malondialdehyde;  TNF-α, Tumour necrosis factor alpha; MCP-1, monocyte chemoattractant protein-
1; CAMs, cell adhesion molecules; TAC, total  antioxidative  capacity; TOS, total   oxidative   status; PON1, paroxonase-1 activity; PAB, pro-oxidant-antioxidant balance; 
AUC, area under the curve; CAT, antioxidant enzymes catalase; FMD, flow-mediated dilation; HbA1C , glycated haemoglobin; PWV, pulse wave velocity; ICAM-1, intercellular 
adhesion molecule-1; VCAM-1, vascular adhesion molecule-1; DVP-RI, digital volume pulse reflection index; DVP-SI, digital volume pulse stiffness index; AIx, augmentation 







Hg, DBP >80 









Montmorency tart cherry 
juice – 73.5 mg of total 
anthocyanins 
0, 1, 2, 3, 
5 and 8h 
↓ systolic blood pressure; DVP-RI; 
PWV; peripheral blood pressure; 
mean arterial pressure 
↔ microvascular reactivity 
[endothelium (trend) and non-
endothelium dependent] ; heart rate;  
DVP-SI(trend); AIx 











Blackcurrant juice – 50.5mg 
of total anthocyanins 








↑ plasma ascorbic acid; uric acid; 
insulin 
↔ microvascular reactivity 
↔ plasma FRAP; ORAC; TG; 
ICAM-1; VCAM-1; glucose;  









13 Pilot cross-over 
study 
High-flavonoid cherry juice 
(300mLx1 and 100mLx3) -  
0, 2 and 
6h 
↓ systolic and diastolic blood 













Five blueberry beverages – 
129, 258, 310, 517 and 
724mg of total anthocyanins 
0, 2, 4 
and 6h 
↑ FMD 
↓NADPH oxidase activity 
↔ Aix; PWV; DVP-SI; DVP-RI; 
↔ peripheral and central blood 
pressures  












Purified anthocyanins - 
320mg of total anthocyanins 
0, 1, 2 
and 4h 
↑ FMD;  serum cGMP 
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on oxidative stress and antioxidant status, triacylglycerol and total cholesterol concentrations, 
vascular endothelial function and inflammatory biomarkers. Post-prandial changes in blood 
pressure and lipoproteins were least affected by anthocyanins (more details are provided in 
Chapter 3: The postprandial effect of anthocyanins on cardiovascular disease risk factors: a 
systematic literature review of high-fat meal challenge). 
 In addition to the findings reported in Table 1, other studies investigated the effect of 
anthocyanins in a large numbers of subjects, both in large prospective cohorts and systematic 
reviews with or without meta-analysis. Cassidy et al (183–185), conducted three different 
analyses in the Nurses’ Health Study II evaluating the anthocyanin intake and incidence of 
certain conditions and events related to ED. The flavonoid and anthocyanin intakes were 
calculated using validated food-frequency questionnaires. In one cohort analysis of 93,600 
healthy women aged between 25 and 42 years, an inverse association between intake of 
anthocyanins (highest versus lowest quintiles) and risk of myocardial infarction was observed 
(HR: 0.68; 95% CI, 0.49-0.96; P=0.03) after multivariate adjustment. The combined intake of 
blueberries and strawberries, in individuals consuming more than three serving per week versus 
a lower intake, tended to be associated with a decreased risk of myocardial infarction (HR: 
0.66; 95% CI, 0.40-1.08; P=0.03). Anthocyanins were the only flavonoid class to show  
positive benefits in relation to the incidence of these CVD events (184). Furthermore, while 
following 43,880 healthy men with no prior diagnosis of CVD for 24 years, a total of 4046 
myocardial infarction and 1572 stroke cases occurred, in which all of these events were 
confirmed by medical records. After multivariate adjustment, a higher anthocyanin intake was 
inverse associated with non-fatal myocardial infarction (HR: 0.81; 95% CI: 0.69-0.96; P= 0.03) 
in normotensive individuals, whilst a borderline significant trend was observed in all 
individuals (HR: 0.87; 95% CI: 0.75-1.00; P = 0.04; P= 0.098). Fatal myocardial infarction and 
stroke was not associated with anthocyanin intake in that analysis (183). In another 
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investigation, Cassidy et al.(185) examined the association between flavonoid intake and 
incidence of hypertension by grouping results from three different cohorts. A total of 133,914 
women from the Nurses' Health Study I and II, as well as 23,043 men from the Health 
Professionals Follow-Up Study were followed-up for 14 years, resulting in 29,018 cases of 
hypertension in women and 5629 cases of hypertension in men. A reduction of 8% in risk of 
hypertension (RR: 0.92; 95% CI: 0.86, 0.98; P < 0.03) was found comparing individuals from 
the highest quintile versus lowest quintile of anthocyanins intake. This effect was even higher 
among individuals under 60 years of age (RR: 0.88; 95% CI: 0.84, 0.93; P < 0.001).  
Regarding the pooled analyses of anthocyanin interventions in clinical trials, systematic 
reviews and meta-analysis have been conducted for outcomes related to ED such as blood 
pressure, CVD risk factors and vascular function, with inconsistent results. A meta-analysis 
evaluating the effect of berries on CVD risk factors among healthy individuals or patients with 
CVD (n = 1,251 subjects from 21 randomized clinical trials) reported that berry consumption 
lowered LDL-c, systolic blood pressure, fasting glucose, body mass index, haemoglobin A1c 
and TNF-α, whilst no significant effects were demonstrated for HDL-c, triglycerides, total 
cholesterol and diastolic blood pressure. It is important to note that not all berries have 
anthocyanins as their primary source of polyphenols; however, the majority of dietary 
interventions from the included studies were rich in anthocyanins (186). Another systematic 
review of randomized controlled trials evaluated the effect of purified anthocyanins and 
anthocyanin-rich extracts on markers of CVD. A total of twelve clinical trials with both healthy 
and individuals with CVD were included in this review, but the large heterogeneity prevented 
the conduct of a meta-analysis. Considering LDL-c, HDL-c, total cholesterol, triglycerides and 
blood pressure, an improvement was only evident for LDL-c among diseased individuals or 
those with elevated concentrations of this biomarkers (131).  
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 Parameters such as vascular reactivity and stiffness have also been evaluated in a 
systematic review and meta-analysis of 24 studies, including both acute and chronic dietary 
interventions of anthocyanin-rich foods or extracts(26). Among the acute studies, FMD was 
reported in 4 studies, while reactive hyperaemia index by peripheral arterial tonometry was 
evaluated only in 2 studies. The pooled analysis showed a significant improvement for FMD, 
mainly observed 1-8 hours after consumption of anthocyanin doses, which ranged from 7 to 
724mg. There was no improvement in reactive hyperaemia index; however, when the 
microvascular reactivity outcome was analysed collectively along with FMD, there was a 
significant improvement after anthocyanin provision. Arterial stiffness, which was evaluated 
through pulse wave velocity, was also improved by acute anthocyanins intake, whilst no 
changes were observed for augmentation index. Once again, considering both outcomes for a 
pooled analysis of vascular stiffness, there was a trend towards an improvement of this 
parameter following anthocyanins intake. Among longer term studies ranging from one week 
to six months, with anthocyanin daily doses of 12 to 320mg, an improvement in FMD was 
found. The increase in reactive hyperaemia index did not reach significance; however, taken 
together along with FMD for a vascular reactivity measure, the pooled analysis showed an 
improvement in this parameter. In relation to arterial stiffness, the results from both pulse wave 
velocity and augmentation index showed no improvements when analysed individually; 
however, there was a trend toward an improvement in vascular stiffness when these two 
parameters were analysed collectively (26). 
 Taken together, this body of pre-clinical, clinical and epidemiological evidence support 
the potential beneficial effects of anthocyanins on vascular function and other CVD risk 
factors, and warrant the conduction of clinical trials with innovative methodologies for a robust 




1.6 Problem statement 
 
Several gaps in the literature remain regarding the association of flavonoids and their 
potential health benefits. At the epidemiological level, only a few populations have been 
investigated in appropriate large-scale studies. This type of evidence requires consideration of 
specific differences in the flavonoid content of foods that exist between different geographical 
areas and crops, as well as the variety of dietary patterns and cuisines between populations will 
affect the amount and type of consumption of flavonoid-rich food items, while differing 
lifestyle factors and life expectancies will also influence the contribution of flavonoids to the 
incidence of hypertension and other chronic diseases. These methodological challenges limit 
extrapolation of findings from epidemiological studies of flavonoid intake and incidence of 
disease outcomes from one population to another. Still, previous analysis of dietary patterns, 
conducted in the Australian population identified differences in the level of consumption of 
individual food groups by age (187). Therefore, considering the limited evidence from 
longitudinal studies that assess the association between the incidence of hypertension and 
consumption of flavonoids in the Australian population, a life course approach is necessary.  
At the clinical level, a number of studies have investigated the effect of specific 
flavonoids across a wide range of conditions. Among the different groups of flavonoids, 
anthocyanins are particularly promising in terms of their potential benefits in attenuating and 
preventing pathological conditions, mainly through their potential anti-inflammatory, anti-
oxidant and signalling effects. The effect of anthocyanins in the postprandial state have been 
evaluated by several studies using the HFHE meal challenge. This method allows investigation 
of whether these bioactive compounds are capable of attenuating the deleterious effects 
following a HFHE meal; however, such findings have not been adequately collated and 
synthesized regarding the scope of the impact of acute anthocyanin dietary intake on CVD risk 
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factors. Within this range of studies, another gap that was identified is the lack of robust 
investigation of the vascular function in the postprandial state, which along with the immune 
response is an important predictor of CVD. This is particularly evident in older adults, as 
several studies support a gradual loss of vascular health, and a new immune-metabolic 
viewpoint for age-related diseases, termed ‘inflammaging’, characterized as a chronic low-
grade inflammation. Additionally, there are still several gaps to be addressed regarding the 
effect of anthocyanins in this vascular-inflammatory axis in older adults, especially among 




Following the problem statement, this thesis has three main hypotheses, namely: 
1) A higher dietary intake of flavonoids is associated with a lower incidence of 
hypertension in Australian women; 
2) An acute dietary intervention with food anthocyanins is capable of attenuating 
potential postprandial deleterious effects of a high-fat high energy-meal on 
vascular function, immune response and other CVD risk factors; 
3) A chronic dietary intervention with food anthocyanins will improve 
microvascular health, and reduce inflammation and blood pressure in older 
adults with a diagnosis of MCI. 
 
 
1.8 Research Objectives and Conceptual Framework 




1) To determine if there is an association between higher dietary intake of flavonoids and 
subclasses and the incidence of hypertension in two cohorts of Australian women; 
2) To collate and synthesize the current evidence of the postprandial effects of 
anthocyanins on CVD risk factors in high-fat meal challenge studies; 
3) To determine if consumption of food anthocyanins has postprandial effects on the 
macro and microvascular function, inflammatory and oxidative stress biomarkers, and 
lipid profile following a high-fat high-energy meal in overweight or obese older adults; 
4) To determine if chronic consumption of food anthocyanins has beneficial effects on the 
microvascular function, inflammatory biomarkers and 24 h ambulatory BP in older 
adults with a diagnosis of MCI. 
 
In order to test the above hypothesis and address the research objectives, four studies 
were developed across three levels of evidence, including: 
• Epidemiological evidence: Secondary analysis of data from a nationally representative 
cohort of Australian women. 
• Knowledge synthesis: Systematic Literature Review. 
• Experimental evidence: Two randomised placebo-controlled Clinical Trials (RCTs) 
with an innovative design that allowed interpretation of both acute and chronic effects of 
anthocyanin intake. 
 
The Conceptual Framework for the thesis, demonstrating the four studies across the three levels 




 Figure 1-1. Thesis Conceptual Framework 




1.9 Significance of the Research 
Flavonoids are emerging as potential dietary bioactive components that exert beneficial 
effects on certain pathological conditions, as well as having a preventive role in several chronic 
and degenerative diseases. This thesis aims to explore gaps in the literature in both cases. 
Regarding the epidemiological aspect, this thesis addresses the association between daily 
consumption of flavonoids and the incidence of hypertension. A population-based study was 
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conducted to estimate the total intake of flavonoids and their subclasses in the Australian 
female population by exploring data collected in a nationally representative cohort study.  This 
analysis found an association between flavonoids and the occurrence of hypertension, which is 
a novel finding. This provides evidence that is useful for nutrition messaging and policies 
targeting improved cardiovascular health in this population. 
A robust review of pre-clinical literature showed that anthocyanins are capable of 
improving vascular endothelial function, and have relevant anti-inflammatory and anti-oxidant 
effects; however, clinical evidence of these effects in humans is still lacking in many aspects. 
This thesis aims to advance this field, by conducting a systematic literature review to synthesize 
and summarise the published literature relating to the acute effect of anthocyanins on 
postprandial responses to a high energy, high fat stressor meal, as well as by undertaking two 
randomised, placebo- controlled clinical trials to add to knowledge inquiry.   
The two innovative clinical trials were conducted in older adults. The first investigated 
the postprandial effects of anthocyanins following a HFHE meal challenge using a more robust 
evaluation of vascular function than has been conducted in previous similar studies. Vascular 
function was measured by exploring macro and microvascular parameters through a 
combination of classical and novel techniques using the latest imaging technologies, including 
FMD and LSCI. To our knowledge, this was the first study of its kind to conduct this protocol 
using an anthocyanin dietary intervention. As well as the assessment of vascular function, 
classical CVD biomarkers were included, such as lipid profile, blood pressure, and 
inflammatory biomarkers. Another clinical trial was conducted to investigate the longer term 
effects (8 weeks) of anthocyanin supplementation provided through the Australian-grown 
Queen Garnet plum on inflammatory markers associated with CVD risk factors, along with 
analysis of microvascular function and 24-hour ABP. The aim of this study was to investigate 
such parameters in an older population with a diagnosis of mild cognitive impairment, which 
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is a neurodegenerative condition that shares pathological mechanisms with CVD. Considering 
the major role of the inflammatory response and vascular function in CVD and cognitive 






















Chapter 2: Association between flavonoid intake and risk of 
hypertension in two cohorts of Australian women: a longitudinal 
study 
 
Large prospective studies and pooled analyses of clinical trials have shown health 
benefits of flavonoids on CVD risk factors and incidence. However, only a few populations 
were investigated by appropriate large-scale studies, including a comprehensive assessment of 
flavonoid subclasses and food sources. This type of evidence requires a specific approach as 
flavonoid content in foods can vary significantly among different geographic areas and crops, 
as well as considering the cultural diversity in cuisine and dietary patterns within a country and 
worldwide. Therefore, epidemiological studies associating flavonoid intake and incidence of 
diseases can hardly be extrapolated from one population to another. In this matter, the present 
population-based study estimated the association between intake of total flavonoids and its 
subclasses and incidence of hypertension in two population-based cohorts of Australian 
women, including reproductive-aged and middle-aged individuals. Flavonoid intake was 
associated with a lower incidence of hypertension in both cohorts. Higher intakes of flavones, 
isoflavones and flavanones, attributed mainly to orange, orange juice, apples and soy milk, 
were associated with a reduced risk of hypertension among middle-aged women followed-up 
over 15 years. Higher intakes of flavanols, attributed mainly to red wine and apples, were 
associated with a reduced risk of hypertension among reproductive-aged women followed-up 
for 12 years. These findings can be used in nutritional messages and policies aimed at 
improving the cardiovascular health of women of different life stages 





Cardiovascular disease (CVD) is a major cause of mortality globally and is the leading 
cause of death for Australian men and women. In 2018, CVD was responsible for over 41,800 
deaths in Australia (26% of all deaths)(188). Following a similar pattern to that observed 
worldwide, the prevalence of hypertension among adults was 33.7% (36.0% among men and 
31.4% among women in 2017-2018[1]. This prevalence increased with age, from less than 10% 
in the 18-34 year age group to almost 50% in people aged over 85 years(188).  
Hypertension is an independent risk factor for CVD and does not have a defined 
aetiology. Several factors play a role in increased blood pressure including modifiable factors, 
such as smoking, body weight, physical activity, alcohol, high sodium intake and other dietary 
imbalances(189). Among the various pathophysiological mechanisms involved in 
hypertension, the co-operative and synergistic action of inflammation and oxidative stress play 
an important role(190–192).  
Nutrition plays a major role in enhancing endogenous antioxidant defences and 
regulating the inflammatory state(193). Epidemiological studies have identified many dietary 
patterns that are associated with the prevention of diseases associated with inflammation(194). 
Among the various protective dietary components are polyphenols, which are bioactive, plant-
based compounds that naturally occur in fruits, vegetables, cereals and beverages(195). Of the 
large number of polyphenolic compounds found in foods, the most common and widely 
distributed class are flavonoids, present in virtually all plants. Flavonoids are classified into six 
subclasses, namely flavanols (including proanthocyanidins), flavonols, flavanones, flavones, 
isoflavones and anthocyanins(196). In the endothelium, dietary flavonoids can exert 
physiological effects as both antioxidants and as signalling molecules(196,197). 
Several large prospective studies and pooled analyses of clinical trials show health 
benefits for total dietary flavonoid intake and some of its subclasses. A meta-analysis of five 
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prospective cohort studies, comprising 200,256 individuals and 45,732 cases of hypertension, 
showed a non-significant lower risk of hypertension for higher total flavonoid intake, while 
dietary anthocyanin intake was associated with an 8% reduction in risk of hypertension when 
comparing highest vs. lowest intake(198). The effects of cocoa flavonols were analysed in a 
meta-analysis of 35 randomized clinical trials studies, showing significant lowering of both 
systolic and diastolic blood pressure by 1.8 mm Hg(199). Furthermore, a meta-analysis of 7 
trials involving 587 participants found that intake of quercetin, a flavanol subclass, resulted in 
a significant reduction in blood pressure(200). However, differing dietary patterns and cuisines 
between populations will affect the amount and type of consumption of flavonoid-rich food 
items, while differing lifestyle factors and life expectancies will also influence the contribution 
of flavonoids to the incidence of hypertension and other chronic diseases. Previous analysis of 
dietary patterns in the ALSWH identified differences in the level of consumption of individual 
food groups in the middle-aged and reproductive-aged cohorts (187). Therefore, considering 
the limited evidence from longitudinal studies that assess the association between the incidence 
of hypertension and consumption of flavonoids in the Australian population, a life course 
approach is necessary. 
This study aims to evaluate the association between intake of total flavonoids and its 
subclasses and incidence of hypertension in two population-based cohorts of Australian women 
that included reproductive-aged and middle-aged individuals. 
2.2 Methods 
Study population 
 The Australian Longitudinal Study on Women’s Health (ALSWH) includes a 
representative sample of more than 40,000 women that were recruited in 1996. Women were 
randomly sampled from the National Health Insurance scheme (Medicare) that includes all 
Australian citizens and permanent residents(201). The reproductive-aged and middle-aged 
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cohorts (including women born in 1973–78 and 1946–51, respectively) were used for the 
purpose of this study, as these cohorts included validated assessment of dietary intake. Further 
details of the recruitment methods, response rates, retention and attrition have been described 
elsewhere (202). 
These cohorts have been surveyed seven and eight times at approximately three-year 
intervals, respectively, since 1996. The initial sample response rate from the middle-aged 
cohort was n = 13,714 for Survey 1, with subsequent Surveys 2 to 8 yielding samples of n = 
12,338 (90%), n = 11,221 (81.8%), n = 10,905 (79.5%), n = 100 10,638 (77.6%), n = 10,011 
(73.0%), n = 9,151 (66.7%) and n = 8,622 (62.9%), respectively. In the reproductive-aged 
cohort, the initial sample comprised n = 14,247, while response rates for Surveys 2 to 7 were 
n = 9,688 (68%), n = 9,081 (63.7%), n = 9,145 (64.2%), n = 8,200 (27.6%), n = 8,126 (57%) 
and n = 7,186 (50%), respectively. Dietary intake was assessed at Surveys 3 and 5 in the 
reproductive-aged cohort, and at Surveys 3 and 7 in the middle-aged cohort. Survey 3 was 
therefore used as baseline for both cohorts. The Human Research Ethics Committees of the 
University of Newcastle and the University of Queensland approved the study methods. All 
participants signed a consent form before joining the study. 
 
Dietary intake 
Dietary intake over the past 12 months was assessed through a validated FFQ, The 
Dietary Questionnaire for Epidemiological Studies, version 2 (DQES v2)(203,204), which has 
been validated against seven days of weighed food records with correlation coefficients ranging 
from 0.28 for vitamin A to 0.78 for carbohydrates(204). Participants reported their usual daily 
frequency of intake and portion size for 101 individual food items according to a 10-point scale 
ranging from ‘Never’ to ‘Three or more times per day’. The Australian Food Composition 
Database (NUTTAB95) was used to calculate energy, macro and micronutrient intakes(205). 
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In order to determine flavonoid intake, each food item was assigned a total flavonoid 
and subclasses content value using the ‘PhenolExplorer’ polyphenol food composition 
database. The PhenolExplorer is a comprehensive and freely available database that contains 
more than 35,000 content values for 500 different polyphenols in over 400 foods(206). Each 
selected food item from the FFQ was manually cross‐referenced with this database. Foods 
listed in the FFQ that were not in PhenolExplorer were assumed to contain no flavonoids. Of 
the foods in the FFQ, 42 foods were assigned a flavonoid content. Flavonoid and subclass 
intakes from each food were measured by multiplying the consumption (g/day) for each food 
by its flavonoid content (per gram edible weight). Individual flavonoids from the six subclasses 
were summed to provide a total value for each subclass, and data for total flavonoids were 
calculated as the sum of these subclasses. A daily dietary intake of each flavonoid subclass and 
total flavonoid intake was calculated for each individual. The food item ‘tea’, which is an 
important source of flavonoids in this population, was not included in this version of the FFQ, 
but a relevant question was present in another part of the survey. However, the rate of responses 
and missing values differed from the FFQ data, thus the inclusion of “tea” and “herbal tea” 
flavonoids was addressed in a sub-analysis.  
Dietary intake was not assessed at every survey. Based on previous research showing 
that diet quality is stable in these age cohorts(207,208), dietary intake data from Survey 3 were 
applied to survey 4 in the reproductive-aged cohort and to Surveys 4 to 6 in the middle-aged 
cohort. Survey 5 dietary data were applied to subsequent surveys in the reproductive-aged 
cohort to account for any changes in intake. 
 
Incidence of hypertension 
The occurrence of hypertension was determined from self‐reported data on doctor-
diagnosed hypertension available in each survey from the following question: “In the past three 
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years, have you been diagnosed or treated for: High blood pressure (hypertension)”. For 
incidence estimation, hypertension was defined as new onset reported at Survey 4 onwards, 
while participants that reported hypertension in the first three surveys were excluded from our 
analysis. A previous study showed an agreement of 89% between self-reported hypertension 




Data on a wide range of demographic, socio-economic factors and hypertension risk 
factors were collected in each survey for both cohorts. The following variables were included 
as covariates: education (low – no formal qualifications or school or intermediate certificate or 
equivalent; intermediate – high school or leaving certificate, trade/apprenticeships, or 
certificate or diploma; or high – university degree); income management (impossible/difficult 
all the time; difficult some of the time; or easy); body mass index (BMI)[underweight and 
normal weight (BMI up to 25 kg/m2); overweight (BMI 25-30 kg/m2); or obese (BMI >30 
kg/m2)]; smoking status (never been a smoker; former smoker; or current smoker); alcohol 
consumption [rarely & non-drinker (<1 drink per week); low risk (up to 14 drinks per week); 
or risky (15 to 28 drinks per week) & high risk (more than 28 drinks per week)]; doctor-
diagnosed diabetes type I & II combined (no or yes). Physical activity scores were derived 
from validated questions on frequency and duration of walking, and on moderate- and 
vigorous-intensity activity, and were categorised as: sedentary/low (<500 total metabolic 
equivalent (MET) minutes/week); moderate (500 - <1000 MET minutes/week); or high (>1000 
MET minutes/week)(210). In the middle-aged cohort, menopause status was determined using 
questions regarding the occurrence of hysterectomy, oophorectomy, hormone replacement 
therapy (HRT) and menstrual pattern, and categorised as ‘surgical menopause’, ‘not defined 
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due to HRT or oral contraceptive pill, ‘pre-menopausal’, ‘peri-menopausal’ or ‘post-
menopausal’. Four dietary intake variables derived from the FFQ, (fibre, cholesterol, vitamin 
C and sodium) were also included as covariates. 
 
Data analysis 
Generalised Estimating Equation (GEE) analyses investigated associations of quintiles 
of total flavonoid and subclass intake with incident hypertension, adjusting for demographic 
and dietary variables, and hypertension risk factors. GEE was the chosen statistical approach 
to enable accounting for repeated exposure and outcome measures in the same individual. 
Survival analysis could not be performed due to lack of data on date of hypertension diagnosis. 
An exchangeable correlation matrix, a binomial distribution of dependent variables and a log 
link function were selected to conduct the GEE. Potential confounders were defined a priori 
based on literature and on the available data. Four models were used to adjust for potential 
confounders: (1) adjusted for energy intake and age; (2) additionally adjusted for hypertension 
risk factors (diabetes, smoking, physical activity, alcohol intake and menopause status) and 
demographics (education and income management); (3) additionally adjusted for dietary intake 
variables related to flavonoid intake and hypertension risk (fibre, vitamin C, sodium and 
cholesterol); and (4) additionally adjusted for BMI (potential mediator).  
Sub-analyses were conducted by adding the total flavonoids, flavanols and flavonols 
related to tea consumption for each individual. Another sub-analysis was conducted to 
determine the influence on the results of additionally adjusting for gestational diabetes and 
hypertension among women who reported a live birth during the study period. All analyses 





In the middle-aged cohort, 11,221 women completed Survey 3 and after exclusion for 
hypertension reported prior to Survey 4 (n=3,334), missing data on dietary intake (n=407), 
hypertension (n=339) and covariates (n=463), as well as implausible energy intake (<500kcal 
or >5000 kcal/day) (n=48), 6,630 women were included for data analyses (Figure 2-1). In the 
reproductive-aged cohort, 9,081 women completed Survey 3 and after exclusion for 
hypertension reported prior to Survey 4 (n=693), missing data on dietary intake (n=140), 
hypertension (n=1,367) and covariates (n=737), and implausible energy intake (n=45), 6,099 
women were included for data analyses (Figure 2-2). No differences were found in baseline 
characteristics between women in- and excluded for analyses in the middle-aged and 


















Figure 2.1. Flow diagram of the sample for analyses of the association between flavonoids 
intake and incidenct hypertension in middle-aged women in the Australian Longitudinal Study 
on Women’s Health, n=6,630 
 
All baseline characteristics are presented according to quintiles of total flavonoid intake (Table 
2-1 and 2-2 for middle-aged and reproductive-aged cohorts, respectively). There was a higher 
level of education and physical activity, and a lower BMI, according to higher quintiles of total 
flavonoid intake, in both cohorts. In the middle-aged cohort, there was a decreasing number of 
current smokers across the quintiles of total flavonoids consumption, which was not observed 
in the reproductive-aged cohort. Comparing the 5th quintile of intake between cohorts, there 
was more than double the number of current smokers in the younger cohort compared to the 




Figure 2-2. Flow diagram of the sample for analyses of the association between flavonoids 
intake and incidenct hypertension in reproductive-aged women in the Australian Longitudinal 
Study on Women’s Health, n=6,099 
 
across quintiles in both cohorts for the ‘risky & high risk” alcohol intake category, however 
individuals in the 5th quintile had higher values in both cohorts, which could be attributed to 
the high flavonoid content of red wine. Concerning income management, the category “easy” 
presented an increase across quintiles of flavonoid intake, while a decrease was observed in 
the category “impossible/difficult all the time”, showing that higher income is associated with 





Table 2-1. Baseline characteristics of middle-aged women in the Australian Longitudinal 
Study on Women’s Health according to quintiles of total flavonoids intake, n=6,630 


































low 74.31   66.08   62.48   54.93   53.72   
< 
0.0001 
intermediate 15.55   19.93   22.06   24.09   23.70   





lt all the time 
12.80   11.03   8.05   7.16   6.67   
< 
0.0001 
difficult some of 
the time 
26.67   26.97   23.33   26.20   22.41   
not too bad 43.11   44.49   48.10   44.14   47.39   
easy 17.42 17.52  20.52  22.49  23.52  
BMIc (%) 
normal weight 46.26  49.58   51.18   51.47   54.92   
< 
0.0001 
overweight  32.68   30.21   32.28   32.60   31.14   
obese 21.06 20.20  16.55  15.92  13.94  
Smoking status 
(%) 
never smoker 52.46   58.29   65.82   65.63   61.76   
< 
0.0001 
former smoker 25.10   25.30   21.88   24.09   28.31   
current smoker 22.44 16.40  12.30  10.28  9.92  
      
Physical 
activityd (%) 
sedentary or low  57.09   51.81   45.84   44.23    39.78   
< 
0.0001 
moderate  21.16   18.91   23.69   23.67   25.41   






46.46   39.94   37.88   30.83   23.78   
< 
0.0001 low risk 47.64   53.01   58.32   64.70   65.53   





29.23   29.19   25.77   27.13   22.67   
0.039 
not defined due to 
HRT/OCP 
18.60   19.46   19.98   18.96   18.99   
pre-menopausal 9.55   9.36   10.49   8.85   10.44   
peri-menopausal  19.39   17.33   17.99   19.55   22.67   
post-menopausal 23.23  24.65  25.77  25.53  25.24  
Diabetes type I 
& II (%) 
no 97.24 97.50 97.02 96.38 98.03 
0.167 
yes  2.76 2.50  2.98  3.62  1.97  
BMI, body mass index; HRT, hormone replacement therapy; OCP, oral contraceptive pill. aP-value of 
chi-square test. bEducation: low, none or school certificate; intermediate, high school certificate, 
trade/apprenticeship, certificate/diploma; high: university or higher university degree. cBMI: normal 
weight, 16-25 kg/m2; overweight, 25-30 kg/m2, obese, >30 kg/m2. dPhysical activity: sedentary & low, 
<500 metabolic equivalents (MET) per week; moderate, 500-1000 MET per week; high, >1000 MET 





Table 2-2. Baseline characteristics of reproductive-aged women in the Australian Longitudinal 
Study on Women’s Health according to quintiles of total flavonoids intake, n=6,099 


































low 13.42   9.72   7.03   5.24   6.02   
< 
0.0001 
intermediate 51.60   47.11   43.06   37.69   34.81   





lt all the time 
12.07   10.99   9.92   7.81   9.47   
< 
0.0001 
difficult some of 
the time 
33.64   30.62   24.86   27.79   25.44   
not too bad 37.77   39.94   39.79   41.54   39.74   
easy 16.51  18.45  25.43  22.85  25.35  
BMIc (%) 
normal weight 58.93   63.98   65.61   67.36   68.74   
< 
0.0001 
overweight  22.60   22.47   20.42   21.66   20.51   
obese 18.47  13.54  13.97  10.98  10.75  
Smoking status 
(%) 
never smoker 57.38   63.98    62.04   62.12   60.36   
< 
0.0001 
former smoker 16.82   15.41   17.15   17.51   18.84   
current smoker 25.80  20.61  20.81  20.38  20.81  
Physical 
activityd (%) 
sedentary or low  51.39   44.16   39.11   33.04   30.37   
< 
0.0001 
moderate  22.08   24.83   25.53   24.33   23.87   






46.54   38.96   32.18   24.83   20.71   
< 
0.0001 low risk 50.77   58.98   65.41   72.50   73.27   
risky & high risk 2.68  2.06  2.41  2.67  6.02  
Diabetes type I 
& II (%) 
no 98.86   98.92   98.65   98.81   99.01   
0.956 
yes  1.14  1.08  1.35  1.19  0.99  
BMI, body mass index. aP-value of chi-square test. bEducation: low, none or school certificate; 
intermediate, high school certificate, trade/apprenticeship, certificate/diploma; high: university or 
higher university degree. cBMI: normal weight, 16-25 kg/m2; overweight, 25-30 kg/m2, obese, >30 
kg/m2. dPhysical activity: sedentary & low, <500 metabolic equivalents (MET) per week; moderate, 
500-1000 MET per week; high, >1000 MET per week. 
 
Baseline nutrient and food group intake, according to quintiles of total flavonoid intake, 
are presented in the Supplementary material (Table 2-S3 and 2-S4 for middle-aged and 
reproductive-aged cohorts, respectively). There was an increasing consumption of the majority 
of dietary variables (energy, PUFA, protein, carbohydrates, vitamin C, fibre, calcium, iron, low 
fat dairy, vegetables, legumes, fruits and fruit juice) across quintiles in both cohorts, while 
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‘high fat dairy’ was the only variable which decreased across quintiles. The consumption of 
tea increased with the increasing consumption of total flavonoids in the middle-aged cohort, 
but not in the reproductive-aged cohort. 
The baseline proportional intake of flavonoid subclasses that contributed to total 
flavonoids for both cohorts are presented in the Supplementary material (Figure 2-S1). The 
addition of tea substantially increased total flavonoid intake (89.8 to 244.7 mg and 71.5 to 
167.2 mg in the middle-aged and reproductive-aged cohorts, respectively) as well as the 
relative contribution of flavonols to total flavonoid intake (47 to 79%, and 32 to 70%, in the 
middle-aged and reproductive-aged cohorts, respectively). Baseline food sources of flavonoid 
subclass intakes are presented in the Supplementary material (Figure 2-S2 and 2-S3 for middle-
aged and reproductive-aged cohorts, respectively). The top two contributors to flavonols, 
flavanols and isoflavones, along with the three top contributors to sources of anthocyanins, 
flavones and flavanones, were identical in both cohorts. Red wine and apples were the main 
source of flavanols, while strawberries and red wines were the main source of anthocyanins. 
Orange and orange juice were the main sources of flavanones, while orange juice and 
watermelon were the major source of flavones. Red wine, onion and spinach were the main 
sources of flavonols, while soymilk was the major source of isoflavones.  
In the middle-aged cohort, there were 1,645 cases (24.9%) of hypertension during a 
maximum of 15 years follow-up. Higher intakes of flavones [adjusted relative risk (ARR) for 
intake quintile 5 vs 1: 0.82, 95% CI: 0.70-0.97], isoflavones (0.86, 0.75-0.99) and flavanones 
(0.83, 0.69-1.00) were associated with a lower risk of hypertension (Table 2-3). Intakes of total 
flavonoids, anthocyanins, flavanols and flavonols were not associated with incidence of 
hypertension. In the reproductive-aged cohort, there were 336 cases (5.5%) of hypertension 
during a maximum of 12 years follow-up. In this cohort, the relative risks for total flavonoids, 
flavanols and flavonols were lower when comparing quintile 4 versus quintile 1. A higher 
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intake of flavanols (ARR for intake quintile 4 vs 1: 0.70, 95% CI: 0.49-0.99) was associated 
with a 30% lower risk of hypertension (Table 2-4). In both cohorts when including tea in the 
analysis, intake of total flavonoids and flavanols, were not associated with incidence of 
hypertension (Table 2-S5 and 2-S6). A sub-analysis was conducted in the reproductive-aged 
cohort among women that gave birth to children. In addition to the fully adjusted model from 
previous analyses, a model additionally adjusted for gestational diabetes and gestational 
hypertension did not change the results (Table 2-S7).  
 
Table 2-3. Relative risks for associations of total flavonoids and subclasses intake with incident 
hypertension in middle-aged women in the Australian Longitudinal Study on Women’s Health, 
n=6,630  
 Total Flavonoids  
 Quintile 1 
n =1289 
Quintile 2  
n =1304 
Quintile 3  
n =1315 
Quintile 4  
n =1367 





27.9 (10.0) 52.4 (5.8) 74.0 (7.1) 102.9 (10.4) 169.6 (48.5) 
N (%) 
cases 
312 (24.2) 351 (26.9) 328 (24.9) 342 (25.0) 301 (22.2) 
Model 1 1.00 1.02 (0.89 – 1.16) 0.90 (0.78 – 1.03) 0.88 (0.77 – 1.01) 0.76 (0.66 – 0.87) 
Model 2 1.00 1.07 (0.93 – 1.22) 0.99 (0.86 – 1.13) 0.99 (0.86 – 1.14) 0.86 (0.74 – 0.99) 
Model 3 1.00 1.07 (0.93- 1.22) 0.98 (0.86 – 1.13) 0.99 (0.85 – 1.14) 0.84 (0.71 – 1.00) 
Model 4 1.00 1.08 (0.95 – 1.24) 1.02 (0.88 – 1.17) 1.03 (0.89 – 1.19) 0.90 (0.76 -1.06) 




9.7 (4.4) 23.9 (3.8) 36.0 (2.7) 47.6 (4.3) 86.6 (34.8) 
N (%) 
cases 
303 (23.5) 341 (26.1) 319 (24.2) 359 (26.2) 312 (23.1) 
Model 1 1.00 0.97 (0.85 – 1.11) 0.94 (0.82 – 1.08) 0.97 (0.85 – 1.11) 0.81 (0.70 – 0.93) 
Model 2 1.00 1.02 (0.89 – 1.16) 0.97 (0.85 – 1.11) 1.05 (0.92 – 1.20) 0.88 (0.77 – 1.02) 
Model 3 1.00 1.04 (0.91 – 1.19) 0.99 (0.86 – 1.13) 1.10 (0.96 – 1.26) 0.94 (0.81 – 1.09) 
Model 4 1.00 1.03 (0.90 – 1.18) 1.01 (0.88 – 1.15) 1.10 (0.96 – 1.26) 0.97 (0.83 – 1.12) 




3.4 (1.5) 5.5 (2.6) 6.3 (3.9) 6.4 (3.9) 15.0 (8.3) 
N (%) 
cases 
318 (24.7) 304 (23.3) 348 (26.5) 341 (24.9) 323 (23.9) 
Model 1 1.00 0.90 (0.78 – 1.03) 0.95 (0.83 – 1.08) 0.96 (0.84 – 1.09) 0.86 (0.76 – 0.99) 
Model 2 1.00 0.94 (0.82 – 1.08) 1.00 (0.88 – 1.15) 1.00 (0.88 – 1.14) 0.93 (0.81 – 1.07) 
Model 3 1.00 0.96 (0.83 – 1.10) 1.03 (0.90 – 1.17) 1.02 (0.90 – 1.17) 0.98 (0.85 – 1.13) 
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Model 4 1.00 0.97 (0.84 – 1.11) 1.04 (0.91 – 1.19) 1.04 (0.91 – 1.18) 1.02 (0.89 – 1.18) 




0.61 (0.3) 1.6 (0.3) 2.9 (0.5) 5.3 (0.99) 12.4 (5.8) 
N (%) 
cases 
308 (23.9) 341 (26.1) 354 (26.9) 311 (22.7) 320 (23.6) 
Model 1 1.00 0.99 (0.86 – 1.13) 1.02 (0.90 – 1.17) 0.85 (0.74 -0.98) 0.92 (0.80 – 1.05) 
Model 2 1.00 1.03 (0.90 – 1.18) 1.08 (0.95 – 1.24) 0.95 (0.82 – 1.09) 0.99 (0.86 – 1.14) 
Model 3 1.00 1.04 (0.91 – 1.19) 1.10 (0.96 – 1.26) 0.97 (0.84 – 1.11) 1.03 (0.89 – 1.19) 
Model 4 1.00 1.02 (0.90 – 1.17) 1.08 (0.94 – 1.23) 0.94 (0.81 – 1.08) 0.99 (0.86 – 1.15) 




1.54 (0.7) 3.9 (0.7) 6.8 (0.9) 10.7 (1.4) 21.0 (8.5) 
N (%) 
cases 
347 (26.9) 305 (23.4) 335 (25.5) 357 (26.1) 290 (21.4) 
Model 1 1.00 0.83 (0.73 – 0.95) 0.86 (0.76 – 0.98) 0.88 (0.77 – 1.00) 0.72 (0.63 – 0.83) 
Model 2 1.00 0.88 (0.77 – 1.00) 0.94 (0.82 -1.07) 0.98 (0.86 – 1.11) 0.81 (0.70 – 0.93) 
Model 3 1.00 0.87 (0.76 – 1.00) 0.93 (0.81 – 1.07) 0.97 (0.84 – 1.12) 0.82 (0.69 – 0.97) 
Model 4 1.00 0.88 (0.77 – 1.00) 0.94 (0.82 – 1.08) 0.96 (0.84 – 1.11 0.81 (0.69 – 0.96) 




0.22 (2.5) 0.31 (3.4) 0.30 (2.8) 0.61 (4.0) 13.8 (16.6) 
N (%) 
cases 
361 (28.0) 340 (26.1) 318 (24.2) 325 (23.8) 290 (21.4) 
Model 1 1.00 0.92 (0.81 -1.05) 0.85 (0.74 – 0.97) 0.84 (0.74 – 0.97) 0.70 (0.61 – 0.80) 
Model 2 1.00 0.92 (0.81 – 1.04) 0.86 (0.76 -0.98) 0.89 (0.78 – 1.01) 0.77 (0.68 – 0.89) 
Model 3 1.00 0.92 (0.81 – 1.05) 0.87 (0.76 – 0.99) 0.90 (0.80 – 1.04) 0.81 (0.71 -0.94) 
Model 4 1.00 0.91 (0.80 – 1.04) 0.87 (0.76 - 0.99) 0.95 (0.84 – 1.09) 0.87 (0.76 – 1.00) 




6.1 (9.2) 13.9 (10.2) 22.6 (9.8) 35.4 (11.3) 64.7 (27.9) 
N (%) 
cases 
343 (26.6) 322 (24.7) 339 (25.8) 322 (23.5) 308 (22.8) 
Model 1 1.00 0.85 (0.74 – 0.97) 0.88 (0.77 – 0.99) 0.82 (0.72 – 0.94) 0.77 (0.67 – 0.88) 
Model 2 1.00 0.90 (0.79 – 1.03)  0.96 (0.84 – 1.10) 0.92 (0.80 – 1.05) 0.87 (0.76 – 1.00) 
Model 3 1.00 0.90 (0.79 – 1.03) 0.94 (0.82 – 1.08) 0.88 (0.75 – 1.03) 0.79 (0.65 – 0.96) 
Model 4 1.00 0.91 (0.80 – 1.04) 0.95 (0.83 -1.09) 0.90 (0.77 – 1.04) 0.83 (0.69 – 1.00) 
Model 1: adjusted for total energy intake and age; Model 2: model 1 + additionally adjusted for 
hypertension risk factors (smoking status, diabetes, physical activity, alcohol intake, menopause status) 
and demographics variables (education, income management); Model 3: model 2 + additionally 
adjusted for dietary intake variables (fibre, cholesterol, vitamin C, sodium); Model 4: model 3 + 






Table 2-4. Relative risks for associations of total flavonoids and subclasses intake with incident 
hypertension in reproductive-aged women in the Australian Longitudinal Study on Women’s Health, 
n=6,099 
 Total Flavonoids  













32.6 (27.9) 49.2 (29.3) 63.2 (30.6) 83.8 (34.2) 126.0 (54.4) 
N (%) 
cases 
74 (6.3) 79 (6.1) 70 (5.3) 51 (4.1) 62 (4.6) 
Model 1 1.00 0.97 (0.71 – 1.32) 0.85 (0.62 – 1.17) 0.60 (0.42 – 0.86) 0.74 (0.53 – 1.05) 
Model 2 1.00 1.02 (0.75 – 1.39) 0.92 (0.66 – 1.27) 0.66 (0.46 – 0.95) 0.79 (0.55 – 1.12) 
Model 3 1.00 0.99 (0.72 – 1.36) 0.87 (0.62 – 1.23) 0.61 (0.42 – 0.91) 0.68 (0.44 – 1.06) 
Model 4 1.00 1.05 (076. 1.43) 0.93 (0.66 – 1.30) 0.68 (0.46 – 1.01) 0.77 (0.50 – 1.20) 




7.6 (11.8) 12.5 (14.2) 17.1 (13.8) 23.9 (15.0) 48.3 (31.8) 
N (%) 
cases 
82 (7.0) 77 (6.4) 69 (5.5) 53 (3.9) 55 (4.1) 
Model 1 1.00 0.89 (0.66 – 1.21) 0.76 (0.56 – 1.04) 0.58 (0.41 – 0.81) 0.61 (0.43 – 0.85) 
Model 2 1.00 0.93 (0.69 – 1.27) 0.81 (0.59 – 1.12) 0.63 (0.44 – 0.89) 0.61 (0.43 – 0.88) 
Model 3 1.00 0.94 (0.69 – 1.28) 0.82 (0.59 – 1.14) 0.64 (0.45 – 0.92) 0.64 (0.44 – 0.93) 
Model 4 1.00 0.98 (0.72 – 133) 0.90 (0.65 – 1.24) 0.70 (0.49 – 0.99) 0.72 (0.49 – 1.04) 




3.4 (1.5) 5.5 (2.6) 6.3 (3.9) 6.4 (3.9) 15.0 (8.3) 
N (%) 
cases 
71 (5.5) 82 (6.3) 57 (4.3) 50 (3.7) 55 (4.1) 
Model 1 1.00 1.06 (0.78 – 1.45) 0.75 (0.54 – 1.06) 0.65 (0.45 – 0.92) 0.72 (0.51 – 1.01) 
Model 2 1.00 1.10 (0.81 – 1.51) 0.81 (0.57 – 1.14) 0.69 (0.48 – 0.99) 0.74 (0.52 – 1.06) 
Model 3 1.00 1.10 (0.80 – 1.50) 0.80 (0.56 – 1.15) 0.69 (0.48 – 1.00) 0.74 (0.51 – 1.08) 
Model 4 1.00 1.12 (0.82 – 1.54) 0.88 (0.61 – 1.25) 0.79 (0.54 – 1.14) 0.86 (0.59 – 1.26) 




1.8 (2.9) 2.9 (2.8) 4.1 (2.9) 5.8 (3.4) 10.5 (7.5) 
N (%) 
cases 
70 (5.4) 69 (5.3) 68 (5.2) 68 (5.0) 61 (4.5) 
Model 1 1.00 0.92 (0.66 – 1.28) 0.89 (0.64 – 1.24) 0.92 (0.66 – 1.27) 0.86 (0.61 – 1.20) 
Model 2 1.00 0.97 (0.70 – 1.34) 0.95 (0.68 – 1.32) 0.98 (0.70 – 1.37) 0.89 (0.63 – 1.26) 
Model 3 1.00 0.98 (0.70 – 1.36) 0.96 (0.69 – 1.33) 0.99 (0.71 – 1.40) 0.93 (0.65 -1.33) 
Model 4 1.00 0.97 (0.70 – 1.35) 0.93 (0.67 – 1.30) 0.99 (0.71 – 1.39) 0.88 (0.62 – 1.26) 




1.5 (0.7) 3.9 (0.7) 6.8 (0.9) 10.7 (1.4) 21.0 (8.5) 
N (%) 
cases 
75 (6.4) 58 (4.8) 78 (6.3) 57 (4.6) 68 (5.5) 
Model 1 1.00 0.76 (0.55 – 1.07) 0.99 (0.73 – 1.37) 0.69 (0.49 – 0.97) 0.83 (0.59 – 1.17) 
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Model 2 1.00 0.80 (0.57 – 1.11) 1.04 (0.77 – 1.43) 0.75 (0.53 – 1.05) 0.89 (0.64 – 1.26) 
Model 3 1.00 0.80 (0.57 – 1.12) 1.03 (0.75 – 1.43) 0.73 (0.50 – 1.05) 0.84 (0.54 – 1.32) 
Model 4 1.00 0.79 (0.57 – 1.12) 1.06 (0.77 – 1.46) 0.73 (0.51 – 1.05) 0.84 (0.54 – 1.30) 




0.3 (3.1) 0.3 (2.9) 0.5 (3.9) 1.0 (4.8) 9.5 (14.1) 
N (%) 
cases 
71 (6.0) 62 (5.1) 82 (6.6) 68 (5.5) 53 (4.3) 
Model 1 1.00 0.86 (0.61 – 1.20) 1.16 (0.84 – 1.58) 0.91 (0.65 – 1.26) 0.68 (0.48 – 0.96) 
Model 2 1.00 0.90 (0.64 – 1.25) 1.20 (0.88 – 1.64) 0.99 (0.71 – 1.37) 0.76 (0.53 – 1.08) 
Model 3 1.00 0.90 (0.64 – 1.25) 1.22 (0.89 – 1.66) 1.01 (0.72 – 1.41) 0.83 (0.57 – 1.20) 
Model 4 1.00 0.92 (0.66 – 1.28) 1.30 (0.95 -1.77) 1.12 (0.80 – 1.57) 1.03 (0.71 – 1.49) 




11.2 (15.9) 17.1 (15.0) 24.8 (16.5) 33.7 (18.4) 57.1 (31.2) 
N (%) 
cases 
69 (5.9) 70 (5.8) 51 (4.1) 71 (5.7) 68 (5.5) 
Model 1 1.00 1.01 (0.73 – 1.40) 0.81 (0.58 – 1.15) 0.98 (0.70 – 1.35) 0.95 (0.68 – 1.33) 
Model 2 1.00 1.06 (0.76 – 1.46) 0.86 (0.61 – 1.21) 1.06 (0.76 – 1.48) 1.03 (0.73 – 1.45) 
Model 3 1.00 1.07 (0.77 – 1.49) 0.87 (0.61 – 1.24) 1.09 (0.76 – 1.56) 1.03 (0.64 – 1.66) 
Model 4 1.00 1.13 (0.82 – 1.57) 0.90 (0.63 – 1.28) 1.13 (0.79 – 1.63) 1.08 (0.67 – 1.73) 
Model 1: adjusted for total energy intake and age; Model 2: model 1 + additionally adjusted for 
hypertension risk factors (smoking status, diabetes, physical activity, alcohol intake) and demographics 
variables (education, income management); Model 3: model 2 + additionally adjusted for dietary intake 
variables (fibre, cholesterol, vitamin C, sodium); Model 4: model 3 + additionally adjusted for body 
mass index.  
 
2.4 Discussion 
Findings from this population-based prospective study of Australian women showed an 
association between a higher dietary intake of flavonoid subclasses and lower incidence of 
hypertension. In the middle-aged cohort, a higher intake of flavone, flavanone and isoflavone 
subclasses of flavonoids were associated with a lower incidence of hypertension. In the 
reproductive-aged cohort, higher intakes of flavanols were associated with lower incidence of 
hypertension. Inconsistencies in the present findings between cohorts may be explained by 
generational differences in food intake, as previously demonstrated by differences in the level 
of consumption of individual food items in the ALSWH middle-aged and reproductive-aged 
cohorts(187). Our analyses have also shown differences in the contribution of foods to 
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flavonoid intake, both in the diversity and in the percentage of food items for each subclass, 
which may further contribute to explaining the differences in associations between the cohorts. 
Additionally, the generational differences on hypertension risk factors(211) may also partly 
explain the inconsistencies found for associations between subclasses of flavonoids and 
incidence of hypertension in the two different age-range cohorts in our study. Similar analyses 
have been conducted in other populations. Cassidy et al.(212) examined the association 
between flavonoid intake and incidence of hypertension in a combined grouping of three 
different cohorts that included 133,914 women from the Nurses' Health Study I and II, and 
23,043 men from the Health Professionals Follow-Up Study. Across 14 years of follow-up, 
there were 29,018 cases of hypertension in women and 5629 cases of hypertension in men. A 
reduction of 8% in the risk of hypertension (RR: 0.92; 95% CI: 0.86-0.98) was found, 
comparing individuals from the highest quintile versus lowest quintile of anthocyanin intake. 
This association was stronger among individuals younger than 60 years (RR: 0.88; 95% CI: 
0.84-0.93). Other subclasses were not associated with hypertension; however, a pooled analysis 
for individual compounds suggested a 5% (95% CI: 0.91-0.99) lower risk for the highest 
compared with the lowest quintiles of intake of the flavone apigenin. In participants ≤60 y, a 
6% (95% CI: 0.88-0.97) lower risk was observed for the flavanol catechin(212). Another study 
conducted in women found that the highest quintile of flavonol intake was associated with a 
10% lower rate of hypertension compared to the lowest quintile (HR: 0.90; 95% CI: 0.84-0.97) 
after a follow-up of 14 years(213). Proanthocyanidin (polymerised flavanols) and anthocyanin 
subclasses also showed a similarly lowered risk of 9% in incidence of hypertension between 
highest and lowest quintiles of consumption (HR: 0.91; 95% CI: 0.84-0.97; and HR: 0.91, 95% 
CI: 0.85-0.97, respectively)(213).  
In the present study, there were slight differences between the two age cohorts with regard 
to contribution of subclasses to total flavonoid intake, but few relevant differences compared 
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to the aforementioned studies conducted in other countries. In both the middle-aged and 
reproductive-aged cohorts, the four subclasses that were main sources of flavonoids were the 
same (in descending order: flavanols, flavanones, flavonols and anthocyanins) as those 
reported in USA cohorts(212,214). In a cohort of French women, anthocyanins were the 
subclass that provided the second highest amount of flavonoids(213). There were, however, 
pronounced differences between our study and other cohort studies in total amount of flavonoid 
intake. A limitation is that the FFQ in the ALSWH did not include tea, but this could be 
ascertained from questions in another part of the survey. The daily total flavonoid intake, 
including tea flavonoids, in the middle-aged and reproductive-aged cohorts was 245 and 167 
mg/day, respectively. Comparing to cohort studies from other countries, our results were 
similar to the value of 190 mg/day reported in NHANES 1999–2002(214), but lower than the 
358 to 415 mg/day reported in the analysis of the three Health Professionals cohort studies by 
Cassidy et al.(212) and the amount of 575 ±302 mg/day reported in a French cohort(213). 
Comparisons between such studies need to be interpreted with caution due to the use of 
different databases for flavonoid calculation, as well as considering that such databases are 
constantly being updated to reflect changes in the food supply. However, a previous study 
conducted in a cohort of women aged over 75 years (n=1063) observed that the application of 
the United States Department of Agriculture (USDA) and phenol-explorer source data yielded 
a high correlation of intake estimates for total-flavonoids, flavanols, flavanones and 
anthocyanidins, while a poorer correlation for flavonols and flavones was found(215). Both 
studies conducted in USA(212,214) used the United States Department of Agriculture (USDA) 
database, while the study conducted in France(213) used the European Phenol-Explorer 
database. 
In both the middle-aged and reproductive-aged cohorts, total flavonoid intake increased 
with higher education, income and physical activity and lower BMI, with the same pattern 
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found for education(213,214), income(214), physical activity(212,214) and BMI(212,213) 
among other studies. A higher intake of total flavonoids found in our middle-aged, compared 
to reproductive-aged, cohort (245 vs 167 mg/day, respectively) is consistent with an increased 
flavonoid density of diets with age that is reported in other cohorts(213,214).  
Three subclasses of flavonoids, flavones, isoflavones and flavanones, were associated 
with a lower risk incident hypertension in the middle-aged cohort. The primary contributor for 
flavones and flavanones was orange juice (66% and 45% respectively), while for isoflavones 
was soy milk (93%). Flavones have been shown to exert an anti-hypertensive effect, mainly 
through their vasorelaxation properties(216). Flavone derivatives possess an endothelium-
dependent vasorelaxant effect, associated with an increased production of NO and prostacyclin 
PGI2 in a concentration-dependent manner(216). For example, luteolin, a flavone found in high 
concentrations in food items evaluated in the present study (including watermelon, celery and 
pumpkin) has been shown to exert a direct effect on vasorelaxation by improving acetylcholine-
induced NO generation(217).  
The BP lowering potential of isoflavones is linked to their signalling properties in the 
endothelium. The soy isoflavones, genistein, daidzein and glycitein, activate endothelial nitric 
oxide synthase and increase the capacity of serum to stimulate prostacyclin release in human 
endothelial cells(218). However, their effects on blood pressure remain equivocal, mainly due 
to inter-individual differences in equol (a gut microbiota-derived isoflavone metabolite) 
production as well as different dietary sources of isoflavones(218,219).  
The main flavanones, naringin, hesperidin, and eriodictoyl, present a wide range of 
beneficial properties, such antioxidant, anti-inflammatory, hypolipidemic, and anti-atherogenic 
activities(217). The main source of flavanones worldwide are citrus fruits(217), as was found 
in both cohorts in the present study. A few studies support our findings of the association 
between flavanone intake and reduced incident hypertension. Experimental studies indicate 
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that the antihypertensive activity of flavones are mediated by endothelium-dependent and 
endothelium-independent mechanisms. Not only can flavones increase NO generation, but can 
also reduce [Ca2+]i and the consequent contraction of endothelial muscle cells(220).  
 The inclusion of tea flavonoids in our analyses resulted in the association of flavanols 
with lower incidence of hypertension not remaining longer significant in the reproductive-aged 
cohort. Some factors may explain this finding. The missing values and response rate of the 
FFQ did not match the questions about tea within the survey. Thus, the sub-analysis had a 
lower sample size and less statistical power. The percentage of total flavonoids and flavanols 
from tea is also much higher in the present study compared to other similar studies in the 
USA(212,214) and France(213), in which the annual per capita consumption of tea is 0.23 and 
0.20 kg, compared to 0.75 kg in the Australian population. Lastly, the consumption of black 
tea alone was not associated with a lower incidence of hypertension in the present study (ARR 
for intake quintile 4 vs 1: 0.96, 95% CI: 0.74-1.59).  
Limitations of this study include the use of self-reported data for hypertension. This may 
have caused misclassification of cases; however, a previous study(209) showed a high 
correlation (89%) between self-reported doctor-diagnosed hypertension and use of 
antihypertensive medication. Moreover, flavonoid content in foods is likely to be influenced 
by seasonality and geographic areas, and there may be discrepancies between food composition 
databases and flavonoid content in foods between different countries. Potential measurement 
error and selection bias based on the factors of seasonality and geographic areas were 
attenuated by the fact that the FFQ reflected 12 months of dietary intake and that recruitment 
of participants was proportional in all Australian states. In general, FFQs may lack detail about 
some flavonoid-rich food sources(221). The FFQ included in ALSWH was developed over two 
decades ago(204), and it may not have included relevant high-flavonoid food items that have 
increased in popularity over this period, such as blackberries, cherries, blueberries and 
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raspberries(222). This could have led to an underestimation of anthocyanin intake, as the mean 
intake in the present study was 4.7 mg/day in the middle-aged and 5.0 mg/day in the 
reproductive-aged cohort, compared to 24.2 mg/day reported in 2019 in the overall Australian 
population from a nationally representative sample that used two 24-hr recalls as the method 
of dietary assessment(222). The mean anthocyanin intakes in other cohort studies that have 
found a reduction in incident hypertension were 12.5 mg/day(212) and 71.0 mg/day(213), 
while another cohort from NHANES 1999–2002(214) reported a dietary intake of only 3.03 
mg/day. Strengths of this study include the representative sample of Australian women across 
two age cohorts, the prospective design, and repeated measures.  
Residual confounding is a known problem in all observational studies; however, 
adjustments were made for key confounding factors, in-line with previous studies. Potential 
confounders were extensively explored in our models, with access to a wide range of 
demographic, hypertension risk factor and dietary intake variables. The large sample size 
allowed for a stepwise regression with bidirectional elimination in order to create the models 
for such adjustments, therefore avoiding major multicollinearity and overfitting issues of the 
model. Results were not adjusted for multiple testing. A common limitation is the inability to 
adjust for all dietary intake variables that are highly related (collinearity). The main predictor 
variable in this study, flavonoids, represents bioactive compounds that are present in virtually 
all plants; therefore, adjusting for all dietary components such as fibre, potassium and inorganic 
nitrates, that are also present in plants and/or other high-flavonoid food items is not viable in 
the modelling. We included fibre in our model because of its high significance in the model, 
and the well-established contribution of fibre in overall diet quality that is associated with blood 
pressure, as well as its high linearity with potassium and inorganic nitrates. Lastly, there was a 
relevant number of missing survey data on both cohorts; however, there is only a small 
probability that such loss over time was selective, as it is unlikely that a person would be unable 
81 
 
or unwilling to complete the next survey as a result of being diagnosed with hypertension. 
Hypertension is a ‘silent’ condition that per se has no major cognitive or physical implications, 
and has a non-invasive and non-onerous treatment(189). Potential attrition bias could be due 
to hypertension being a risk factor for major adverse cardiovascular events (MACE), which 
can lead to debilitating complications(223); however, this would only have been a cause for 
selective drop-out if a MACE occurred without the diagnosis of hypertension, or after the 
diagnosis of hypertension and before the following survey (period of approximately 3 years). 
Still, there was a higher response rate for surveys conducted in the middle-aged cohort (62.9%) 
compared to the reproductive-aged cohort (50.0%), despite a 5-fold higher number of cases of 
hypertension in the former. Concerning the exclusion of women due to missing data, there was 
no significant change in any variable included in the models in both cohorts. Recruitment of 
participants was proportional to population size in all Australian states, thereby enabling 
generalizability of the study findings to Australian women. 
 
2.5 Conclusion 
 Flavonoid intake was associated with a lower incidence of hypertension in two 
population-based cohorts of Australian women who were either of reproductive-age or middle-
aged. Higher intakes of flavones, isoflavones and flavanones, attributed mainly to orange, 
orange juice, apples and soy milk, were associated with a reduced risk of hypertension among 
middle-aged women followed-up over 15 years. Higher intakes of flavanols, attributed mainly 
to red wine and apples, were associated with a reduced risk of hypertension among 
reproductive-aged women followed-up for 12 years. These findings can be used in nutritional 





2.6 Supplementary Material 
 
Table 2-S1. Baseline characteristics of the study population comparing the sample with exclusions 
(n=6,630) with the sample with no exclusions (n=7,887) for missing data of middle-aged women in the 
Australian Longitudinal Study on Women’s Health 
Variables Categories n=6,630 n=7,887 P-valuea 
Mean age (years)  - 58.4 ±1.4 58.4 ±1.4 0.99 
Total energy (kcal) - 1583.3 ±539.8 1579.0 ±549.0 0.64 
Total flavonoid 
intake  
- 89.8 ±54.1 88.1 ±54.5 0.06 
Total flavonoid 
intake (including tea) 
- 244.7 ±143.1 243.3 ±144.1 0.54 
Fibre - 20.3 ±8.1 20.0 ±8.0 0.06 
Cholesterol - 240.3 ±107.5 241.3 ±110.1 0.58 
Vitamin C - 117.1 ±64.0 116.5 ±65.5 0.58 
Sodium - 2105.0 ±782.1 2098.3 ±790.3 0.61 
Educationb (%) 
low 61.2 63.2 0.97 
intermediate 21.4 20.7  
high 17.4 16.1  
Income management 
(%) 
impossible/difficult all the 
time 
9.7 10.6 0.99 
difficult some of the time 21.9 22.2  
not too bad 45.5 45.4  
easy 22.9 21.9  
BMIc (%) 
normal weight 45.9 45.3 0.98 
overweight 33.8 33.9  
obese 20.4 20.8  
Smoking status (%) 
never smoker 60.8 60.3 0.97 
former smoker 29.0 28.8  
current smoker 10.2 10.8  
    
Physical activityd (%) 
sedentary or low 35.11 36.2 0.98 
moderate 23.7 23.5  
high 41.1 40.3  
Alcohol consumption 
(%) 
rarely & non-drinker 32.8 33.8  
low risk 61.0 60.1  
risky & high risk 6.2 6.1  
Menopause status 
(%) 
surgical menopause 30.0 30.5 1.0 
not defined due to 
HRT/OCP 
7.1 7.0  
pre-menopausal 0.1 0.1  
peri-menopausal 2.0 2.0  
post-menopausal 60.7 60.3  
Diabetes type I & II 
(%) 
no 94.8 94.8 1.0 
yes 5.2 5.2  
Values are mean and SD (±) or percentages (%). BMI, body mass index; HRT, hormone replacement 
therapy; OCP, oral contraceptive pill. aP-value of independent t-test or chi-square test. bEducation: low, 
none or school certificate; intermediate, high school certificate, trade/apprenticeship, 
83 
 
certificate/diploma; high: university or higher university degree. cBMI: normal weight, 16-25 kg/m2; 
overweight, 25-30 kg/m2, obese, >30 kg/m2. dPhysical activity: sedentary & low, <500 metabolic 





































Table 2-S2. Baseline characteristics of the study population comparing the sample with exclusions 
(n=6,099) versus the sample with no exclusions (n=8,388) for missing data of reproductive-aged women 
in the Australian Longitudinal Study on Women’s Health 
 
Variables Categories n=6,099 n=8,388 P-valuea 
Total energy (kcal) - 1638.7 ±586.5 1638.9 ±604.7  
Total flavonoid 
intake  
- 71.5 ±49.0 70.3 ±48.8 0.14 
Total flavonoid 
intake (including tea) 
- 167.2 ±123.5 165.5 ±123.4 0.41 
Fibre - 19.4 ±7.3 19.3 ±7.4 0.42 
Cholesterol - 266.9 ±115.0 269.3 ±122.1 0.23 
Vitamin C - 105.9 ±59.0 104.9 ±59.0 0.31 
Sodium - 2256.8 ±889.2 2267.4 ±925.3 0.49 
Mean age (years) 
(SD) 
- 
33.7 ±1.4 33.7 ±1.5 0.21 
     
Educationb (%) 
low 5.9 7.0 0.84 
intermediate 37.6 40.0  
high 56.7 53.1  
Income management 
(%) 
impossible/difficult all the 
time 
10.1 11.2 0.98 
difficult some of the time 26.5 28.2  
not too bad 41.2 39.7  
easy 22.2 20.9  
BMIc (%) 
normal weight 56.0 55.8 0.99 
overweight 25.5 25.5  
obese 18.5 18.7  
Smoking status (%) 
never smoker 65.2 62.2 0.85 
former smoker 23.3 24.6  
current smoker 11.5 13.4  
Physical activityd (%) 
sedentary or low 49.4 49.6 0.99 
moderate 22.1 22.5  
high 28.4 27.8  
Alcohol consumption 
(%) 
rarely & non-drinker 35.6 36.3 0.99 
low risk 60.3 59.6  
risky & high risk 4.1 4.2  
Diabetes type I & II 
(%) 
no 97.8 97.6 0.99 
yes 2.2 2.4  
Values are mean and SD (±) or percentages (%). BMI, body mass index. aP-value of independent t-
test or chi-square test. bEducation: low, none or school certificate; intermediate, high school 
certificate, trade/apprenticeship, certificate/diploma; high: university or higher university degree. 
cBMI: normal weight, 16-25 kg/m2; overweight, 25-30 kg/m2, obese, >30 kg/m2. dPhysical activity: 
sedentary & low, <500 metabolic equivalents (MET) per week; moderate, 500-1000 MET per week; 





Table 2-S3. Baseline nutrient and food group intake according to quintiles of total flavonoids intake 
in middle-aged women in the Australian Longitudinal Study on Women’s Health, n=6,630 
 Total flavonoid intake  




Quintile 2  
n =1304 
Quintile 3  
n =1315 
Quintile 4  
n =1367 


























20.2 ±7.2 35.5 ±4.0 47.4 ±4.6 62.1 ±6.3 95.1 ±27.2 <0.0001 
Total fat (g) 58.3 ±24.2 60.4 ±24.1 60.9 ±24.8 63.3 ±25.8 66.9 ±27.1 < 0.0001 
Energy from 
diet (%) 
38.0 36.8 35.1 34.4 33.7  
Saturated fat 
(g) 
24.0 ±10.9 24.7 ±11.1 24.4 ±11.2 24.9 ±11.6 25.9 ±11.9 < 0.0001 
PUFA (g) 8.8 ±4.5 9.0 ±4.3 9.5 ±4.8 10.2 ±4.8 11.0 ±5.5 < 0.0001 




Protein (g) 71.4 ±28.1 76.4 ±28.1 79.4 ±26.5 84.7 ±29.9 89.8 ±34.0 < 0.0001 
Energy from 
diet (%) 
















41.7 42.8 44.9 45.4 46.3  
Vitamin C 
(mg) 


































Iron (mg) 9.5 ±4.2 10.5 ±4.2 11.5 ±4.3 12.4 ±4.8 13.6 ±5.9 < 0.0001 





























































Values presented in mean and standard deviation (±). 1p-value based on one-way ANOVA.  PUFA, 
polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; CHO, carbohydrates; High fat dairy: 
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full cream milk, hard cheese, firm cheese, soft cheese, cream cheese, flavoured milk; Low fat dairy: 
ricotta, cottage cheese, low fat cheese, reduced fat milk, skim milk, soy milk, Vegetables: beetroot, 
broccoli, cabbage, capsicum, carrots, cauliflower, celery, garlic, lettuce, mushrooms, onion, pumpkin, 
spinach, tomatoes, zucchini; Legumes: baked beans, bean sprouts, green beans, other beans, chickpeas; 
Fruit: apples, pineapples, apricots, bananas, mango, watermelon, rockmelon, honeydew, oranges, 

































Table 2-S4. Baseline nutrient and food group intake according to quintiles of total flavonoids intake 





































14.1 ±4.6 25.2 ±3.3 35.6 ±3.8 50.4 ± 5.8 77.8 ±22.7 <0.0001 
Tota fat (g) 61.8 ±27.3 64.0 ±28.5 66.9 ±29.2 66.5 ±29.5 73.1 ±32.2 <0.0001 
Energy from 
diet (%) 
38.7 37.2 36.5 35.6 34.7  
Saturated 
fat (g) 
26.6 ±12.6 27.1 ±13.2 27.9 ±13.0 27.2 ±13.5 29.3 ±14.7 <0.0001 
PUFA (g) 8.3 ±4.3 8.8 ±4.4 9.4 ±5.0 9.7 ±4.7 11.0 ±5.4 <0.0001 
MUFA (g) 21.6 ±9.8 22.4 ±10.3 23.6 ± 10.9 23.5 ±10.8 25.9 ±11.8 <0.0001 
Protein (g) 71.8 ±27.0 77.6 ±29.1 81.9 ±30.9 83.1 ±31.9 91.6 ±36.6 <0.0001 
Energy from 
diet (%) 
20.0 19.4 19.9 19.8 19.3  
Carbohydra
tes (g) 
150.0 ±54.5 167.3 ±56.9 180.9 ±59.5 189.0 ±63.6 219.6 ±49.6 <0.0001 
Energy from 
diet (%) 
41.8 43.2 43.0 45.0 46.3.  
Vitamin c 
(mg) 

























































72.9 ±42.4 87.8 ±46.1 91.9 ±45.3 98.7 ±46.8 109.4 ±54.8 <0.0001 
Legumes (g) 23.6 ±20.7 25.7 ±21.1 26.5 ±21.3 27.7 ±22.0 30.6 ±25.8 <0.0001 
































Values presented in mean and standard deviation (±). 1p-value based on one-way ANOVA.  PUFA, 
polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; CHO, carbohydrates; High fat dairy: 
full cream milk, hard cheese, firm cheese, soft cheese, cream cheese, flavoured milk; Low fat dairy: 
ricotta, cottage cheese, low fat cheese, reduced fat milk, skim milk, soy milk, Vegetables: beetroot, 
broccoli, cabbage, capsicum, carrots, cauliflower, celery, garlic, lettuce, mushrooms, onion, pumpkin, 
spinach, tomatoes, zucchini; Legumes: baked beans, bean sprouts, green beans, other beans, chickpeas; 
Fruit: apples, pineapples, apricots, bananas, mango, watermelon, rockmelon, honeydew, oranges, 
































Table 2-S5. Relative risks for associations of total flavonoids and flavanols intake (including tea) 
with incident hypertension in middle-aged women in the Australian Longitudinal Study on Women’s 
Health, n=6,630  
 Total Flavonoids  
 Quintile 1 
n =1289 
Quintile 2  
n =1304 
Quintile 3  
n =1315 
Quintile 4  
n =1367 





44.8 ±21.6 132.1 ±27.0 241.6 ±28.4 354.3 ±24.6 434.8 ±46.1 
N (%) 
cases 
315 (24.4) 312 (24.2) 343 (26.1) 335 (24.5) 329 (24.3) 
Model 1 1.00 0.87 (0.76 – 1.00) 0.93 (0.81 – 1.06) 0.98 (0.86 – 1.12) 0.89 (0.78 – 1.02) 
Model 2 1.00 0.93 (0.81 – 1.06) 0.99 (0.86 – 1.12) 1.01 (0.88 – 1.15) 0.96 (0.84 – 1.10) 
Model 3 1.00 0.94 (0.87 – 1.14) 1.00 (0.89 – 1.16) 1.02 (0.89 – 1.16) 0.98 (0.85 – 1.13) 
Model 4 1.00 0.95 (0.83 – 1.09) 1.02 (0.90 – 1.17) 1.05 (0.92 – 1.19) 1.02 (0.89 – 1.18) 




13.7 ±8.4 77.0 ±25.7 177.8 ±30.5 288.2 ±38.1 342.0 ±29.8 
N (%) 
cases 
314 (24.3) 309 (23.7) 343 (26.1) 325 (23.8) 343 (25.4) 
Model 1 1.00 0.90 (0.79 – 1.03) 0.97 (0.85 -1.10) 0.96 (0.84 – 1.10) 0.96 (0.84 – 1.09) 
Model 2 1.00 0.95 (0.83 – 1.09) 1.02 (0.89 – 1.16) 0.98 (0.86 – 1.12) 1.03 (0.90 – 1.18) 
Model 3 1.00 0.98 (0.85 – 1.12) 1.04 (0.91 – 1.19) 0.99 (0.86 – 1.13) 1.08 (0.94 – 1.23) 
Model 4 1.00 0.99 (0.86 – 1.13) 1.06 (0.92 -1.20) 1.03 (0.90 – 1.17) 1.11 (0.97 – 1.27) 
Model 1: adjusted for total energy intake and age; Model 2: model 1 + additionally adjusted for 
hypertension risk factors (smoking status, diabetes, physical activity, alcohol intake, menopause status) 
and demographics variables (education, income management); Model 3: model 2 + additionally 
adjusted for dietary intake variables (fibre, cholesterol, vitamin C, sodium); Model 4: model 3 + 
















Table 2-S6. Relative risks for associations of total flavonoids and flavanols intake (including tea) 
with incident hypertension in reproductive-aged women in the Australian Longitudinal Study on 
Women’s Health, n=5,340 
 
 Total Flavonoids  













34.6 ±13.5 77.8 ±13.3 131.6 ±15.7 212.0 ±32.9 370.3 ±72.7 
N (%) 
cases 
68 (6.6) 80 (7.6) 58 (5.3) 50 (4.6) 59 (5.4) 
Model 1 1.00 1.12 (0.82 – 1.54) 0.80 (0.57 – 1.13) 0.69 (0.48 – 0.99) 0.80 (0.57 – 1.12) 
Model 2 1.00 1.19 (0.87 – 1.64) 0.85 (0.61 -1.21) 0.75 (0.52 – 1.08) 0.85 (0.60 – 1.21) 
Model 3 1.00 1.18 (0.85 – 1.63) 0.85 (0.60 -1.22) 0.75 (0.51 – 1.09) 0.86 (0.60 – 1.23) 
Model 4 1.00 1.26 (0.91 – 1.74) 0.94 (0.66 – 1.34) 0.89 (0.61 – 1.30) 1.04 (0.72 – 1.48) 




8.0 ±4.3 30.1 ±9.1  75.9 ±18.5  146.4 ±38.4 300.1 ±67.0 
N (%) 
cases 
79 (7.7) 66 (6.3) 56 (5.1) 52 (5.7) 62 (5.7) 
Model 1 1.00 0.80 (0.58 – 1.10) 0.69 (0.49 – 0.96) 0.63 (0.45 – 0.88) 0.73 (0.53 – 1.01) 
Model 2 1.00 0.84 (0.61 – 1.16) 0.73 (0.52 – 1.02) 0.66 (0.47 -0.94) 0.78 (0.56 – 1.08) 
Model 3 1.00 0.85 (0.62 – 1.18) 0.75 (0.53 – 1.05) 0.68 (0.48 – 0.97) 0.81 (0.58 – 1.13) 
Model 4 1.00 0.88 (0.64 – 1.22) 0.82 (0.58 – 1.15) 0.79 (0.56 – 1.12) 0.95 (0.68 – 1.33) 
Model 1: adjusted for total energy intake and age; Model 2: model 1 + additionally adjusted for 
hypertension risk factors (smoking status, diabetes, physical activity, alcohol intake) and demographics 
variables (education, income management); Model 3: model 2 + additionally adjusted for dietary intake 
variables (fibre, cholesterol, vitamin C, sodium); Model 4: model 3 + additionally adjusted for body 













Table 2-S7. Relative risks for associations of total flavonoids and subclasses intake with incident 
hypertension in reproductive-aged women that gave birth to children in the Australian Longitudinal 
Study on Women’s Health, n=3,345 
 Total Flavonoids  













28.5 ±21.9 45.5 ±24.4 62.1 ±25.1 84.1 ±29.6 132.4 ±51.1 
N (%) 
cases 
31 41 35 19 26 
Model 1 1.00 1.40 (0.87 – 2.24) 1.20 (0.72 – 2.00) 0.65 (0.35 – 1.22) 0.97 (0.49 – 1.91) 
Model 2 1.00 1.43 (0.89 – 2.28) 1.23 (0.74 – 2.04) 0.66 (0.35 -1.24) 0.99 (0.50 – 1.94) 




6.4 ±8.0 11.1 ±11.1 16.4 ±11.3 24.2 ±13.0 50.8 ±29.3 
N (%) 
cases 
30 38 35 25 24 
Model 1 1.00 1.24 (0.77 -1.99) 1.19 (0.73 – 1.97) 0.91 (0.52 – 1.60) 0.87 (0.49 – 1.57) 
Model 2 1.00 1.25 (0.78 – 2.01) 1.23 (0.75 – 2.04) 0.94 (0.54 – 1.64) 0.90 (0.50 – 1.61) 




3.7 ±2.3 5.4 ±2.6 7.2 ±3.4 8.4 ±4.4 12.6 ±7.1 
N (%) 
cases 
33 45 22 25 20 
Model 1 1.00 1.40 (0.89 – 2.18) 0.81 (0.47 -1.40) 0.89 (0.52 – 1.52) 0.75 (0.41 – 1.35) 
Model 2 1.00 1.42 (0.91 – 2.21) 0.84 (0.49 – 1.46) 0.90 (0.52 – 1.54) 0.76 (0.42 – 1.37) 




1.5 ±2.3 2.7 ±2.4 3.9 ±2.6 5.8 ±2.8 10.8 ±6.3 
N (%) 
cases 
37 35 31 31 18 
Model 1 1.00 0.87 (0.55 – 1.37) 0.77 (0.78 – 1.23) 0.82 (0.51 – 1.34) 0.50 (0.28 – 0.90) 
Model 2 1.00 0.87 (0.55 – 1.37) 0.78 (0.49 – 1.25) 0.84 (0.52 – 1.38) 0.52 (0.29 – 0.92) 




1.2 ±1.8 1.9 ±2.0 2.8 ±1.9 4.2 ±2.1 7.6 ±4.4 
N (%) 
cases 
32 30 38 25 27 
Model 1 1.00 1.03 (0.63 – 1.69) 1.27 (0.78 – 2.07) 0.82 (0.46 – 1.46) 0.91 (0.45 – 1.87) 
Model 2 1.00 1.03 (0.63 – 1.69) 1.29 (0.79 – 2.09) 0.85 (0.48 – 1.50) 0.93 (0.45 – 1.89) 




0.27 ±2.8 0.20 ±2.3 0.29 ±2.6 0.61 ±3.3 9.9 ±14.5 
N (%) 
cases 
39 29 39 24 21 
Model 1 1.00 0.73 (0.46 – 1.17) 1.12 (0.72 – 1.74) 0.75 (0.44 – 1.25) 0.87 (0.50 – 1.51) 
Model 2 1.00 0.73 (0.45 – 1.17) 1.12 (0.73 – 1.74) 0.75 (0.45 – 1.25) 0.88 (0.50 – 1.52) 
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9.2 ±13.7 16.0 ±13.1 24.0 ±14.0 33.9 ±15.6 61.1 ±30.8 
N (%) 
cases 
32 34 28 32 26 
Model 1 1.00 1.25 (0.77 – 2.02) 0.98 (0.58 – 1.66) 1.17 (0.67 – 2.04) 1.08 (0.51 – 2.31) 
Model 2 1.00 1.27 (0.79 – 2.06) 1.01 (0.60 – 1.70) 1.19 (0.68 – 2.08) 1.10 (0.52 – 2.36) 




41.2 ±25.0 80.2 ±28.0 130.4 ±31.5 209.4 ±46.4 367.2 ±79.0 
N (%) 
cases 
36 36 26 23 24 
Model 1 1.00 1.10 (0.69 – 1.76) 0.84 (0.50 – 1.40) 0.82 (0.47 – 1.41) 0.79 (0.46 – 1.36) 
Model 2 1.00 1.10 (0.69 – 1.75) 0.85 (0.51 – 1.42) 0.84 (0.48 – 1.44) 0.79 (0.46 – 1.35) 




10.3 ±9.8 30.5 ±13.4 76.2 ±23.8 146.7 ±42.1 297.2 ±68.4 
N (%) 
cases 
37 34 21 24 29 
Model 1 1.00 1.24 (0.77 – 1.99) 1.19 (0.73 – 1.97) 0.91 (0.52 – 1.60) 0.87 (0.49 – 1.57) 
Model 2 1.00 1.25 (0.78 – 2.01) 1.23 (0.75 – 2.04) 0.94 (054 – 1.64) 0.90 (0.50 – 1.61) 
Model 1: adjusted for total energy intake, age, hypertension risk factors (smoking status, diabetes, 
physical activity, alcohol intake, demographics variables (education, income management), dietary 
intake variables (fibre, cholesterol, vitamin C, sodium) and body mass index; Model 2: Model 1 + 













Figure 2-S1. Flavonoids subclasses intake among total flavonoids in reproductive-aged (n=6,099) 
and middle-aged (n=6,630) women in the Australian Longitudinal Study on Women’s Health.
        
 
        
A, middle-aged cohort; B, reproductive-aged cohort; C, middle-aged cohort including tea flavonoids; 

















































Figure 2-S2. Food source of flavonoids subclasses intake in middle-aged women in the Australian 
Longitudinal Study on Women’s Health, n=6,630 
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Figure 2-S3. Food source of flavonoids subclasses intake in reproductive-aged women in the 
Australian Longitudinal Study on Women’s Health, n=6,099 
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CHAPTER 3: The postprandial effect of anthocyanins on 
cardiovascular disease risk factors: a systematic literature review 
of high-fat meal challenge studies 
 
The effect of anthocyanins in the postprandial state have been evaluated by several 
clinical trials using a HFHE meal challenge. This method allows to assess if these bioactive 
compounds are capable of attenuating the deleterious effects following a HFHE meal; however, 
such findings were not yet collated and synthetized with the scope of the impact of 
anthocyanins on CVD risk factors. Therefore, systematic research literature was conducted in 
this purpose. A total of 13 eligible studies were included and beneficial effects of anthocyanins 
were reported with most promising results indicating the attenuation of deleterious postprandial 
effects on oxidative stress and antioxidant status, triacylglycerol and total cholesterol 
concentrations, vascular endothelial function and inflammatory biomarkers. Post-prandial 
changes in blood pressure and lipoproteins were least affected by anthocyanins.   





Cardiovascular diseases (CVD) are still the number one cause of death globally, 
representing 31% of deaths in 2016. Most CVDs can be prevented by addressing and managing 
behavioural risk factors such as diet (224). Several CVD risk factors are associated to the 
atherosclerotic process and other vascular dysfunctions closely linked to nutrition (225).  
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There is an emerging evidence that metabolic imbalances at the postprandial state, 
particularly after a high-energy meal rich in fat, are important contributing factors to 
development of CVD (105,106). Overall, the underlying mechanism involves a sharp increase 
in triacylglycerol along with an aberrant production of pro-oxidant molecules leading to an 
oxidative stress state, which may impair vascular and endothelial functions, as well as mediate 
the onset of an inflammatory response, which further contributes to the generation of more free 
radicals, thus creating a deleterious vicious cycle (105–107). Dietary fats comprise 
heterogeneous molecules with diverse structures, which affect diverse cell processes such as 
transcription regulation, cellular and organelle membrane structure and function, ion channel 
activity and electrophysiology. Responses vary depending on both the fatty acid composition 
of the food source, as well interactions with accompanying nutrients, the food matrix, and how 
it has been processed(108). Modification of the type of dietary fat in a food or overall meal has 
been shown to result in postprandial effects on appetite (109), lipaemia and markers for 
inflammation and endothelial activity (110). 
The high-fat meal (HFM) challenge is one way to investigate these imbalances 
promoted in a daily basis in Western diets (105). Thus, this type of studies allows dietetic 
therapeutic opportunities to attenuate the harmful effects of aberrant production of pro-oxidant 
molecules. Nutrition plays a major role in enhancing endogenous antioxidant defences and 
regulating the inflammatory state (9) and dietary components consumed alongside a high fat 
meal may be beneficial in blunting a harmful postprandial response (226). 
Anthocyanins, a subclass of flavonoids, are emerging as a potential therapeutic option 
for CVD risk factors(21). Anthocyanins are the largest class of water-soluble plant pigments, 
that are responsible for the blue, purple and red colour of many fruits and vegetables, such as 
blueberries, blackberries, red grapes, plums and eggplants (22). The positive results of 
anthocyanins on CVD risk factors are related to its antioxidant and immunomodulatory effects, 
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thereby attenuating the cooperative and synergistic deleterious effects of oxidative stress and 
inflammation in this condition (21,23). In humans, anthocyanins intake has been associated 
with a lower risk of cardiovascular events (24,25), as well as studies using anthocyanins as a 
diet intervention have shown improvements in vascular function (26) and in biomarkers related 
to oxidative stress (27–30), antioxidant status (28,30–32), lipid profile (33–35) and 
inflammatory response (36,37) in both long-term and acute designs. 
  To date, there has been no review of the effect of such compounds in studies using a 
HFM challenge. In order to address this question, a systematic literature review was undertaken 
using the procedures outlined in the PRISMA statement (227) aiming to evaluate if 
concomitant consumption of anthocyanins with a HFM attenuates the deleterious postprandial 
response of parameters known to be CVD risk factors, including blood pressure, vascular 
endothelial function, lipid profile and biomarkers related to oxidative stress, antioxidant status 





A systematic literature review was undertaken using the procedures outlined in the 
PRISMA statement (227). Five electronic databases were searched up to the period of 1st 
February 2020; Medline, Scopus, CINAHL, Web of Science and PubMed. Two researchers 
were responsible for studies selection, data extraction, quality assessment and synthesis. The 
search strategy was carried out in accordance with the database orientations using Boolean 
operators (OR and AND), parenthesis, quotation marks and asterisk. Quotation marks were 
used to search for exact terms or expressions; parenthesis were used to indicate a group of 
search terms or combine two groups of search terms enabling all possible combinations of 
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sentences; asterisks were used to search all words derived of the precedent inflected part. The 
groups of search terms used were: "endothelium function" or "endothelium dysfunction" or 
"laser speckle" or "laser doppler" or "flow-mediated dilatation" or FMD or LSCI or "arterial 
stiffness" or "pulse wave velocity" or PWV or "lipid profile" or LDL or VLDL or ox-LDL or 
"oxidative stress" or "lipid peroxidation" or "blood pressure" or cytokines or inflammation or 
immune or inflammatory or chemokine or adhesion or malondialdehyde or isoprostanes or 
nitrite or nitrate or ENO* "nitric oxide") AND ("postprandial" or "postprandial" or "post 
prandial" or "meal challenge" or "challenge meal" or "test meal") AND anthocyanins. The 
study selection, quality assessment, data extraction and synthesis were conducted by two 




Selection criteria were formed using the Population Intervention Comparison Outcome 
Study design (PICOS) format (227). The criteria used to screen the titles and abstracts of 
literature returned through database searching (Table 3-1).  
 
Table 3-1. PICOS (participants, interventions, comparisons, outcomes, and study 
design) criteria to define the research question 
Parameter Inclusion criteria 
Participants Young adults (18-59 years of age) 
Interventions 
Dietary intervention with anthocyanins in whole food or purified 
extract 
Comparators A comparison group receiving a control intervention 
Outcomes 
CVD risk factors including blood pressure, lipid profile, vascular and 
endothelial function, biomarkers related to inflammation, oxidative 




Randomised or cross-over clinical trials with high fat meal challenge 
for all groups. 
 
Only articles published in English were included. Exclusion criteria: mean age of 
participants <18 or >59 years; no nutritional information of the HFM, placebo or dietary 
intervention; other conditions besides the HFM challenge. Reference lists of included articles 
were screened for further studies that may have been missed in initial database search.  
 
 Data extraction 
Two independent reviewers extracted data and cross checked results to ensure 
consistency. The following data were extracted from each study and reported in a summary 
table; year of publication, author(s), participant demographics, sample size, anthocyanin source 
and dose, control used, test meal and study outcomes (Table 3-2). Authors were contacted if 
further information was required. 
 
Risk of bias assessment 
Studies included in this review were assessed for potential bias using the revised 
Cochrane risk-of-bias tool for randomised trials (228). Two researchers independently 
reviewed each study, performing evaluation across five risk-of-bias domains, with each domain 
rated either low risk, high risk or some concern of bias. The prescribed algorithm was used to 







A total of 9135 articles returned through database searching. 1464 duplicates were 
removed and 7671 articles were excluded during title and abstract screening (Figure 3-1). The 
full-text of the remaining 29 articles were accessed and evaluated according the study selection 
criteria. Sixteen articles were excluded as they did not meet all criteria and the remaining 13 
studies were eligible for the review.  
 
    
Figure 3-1: Flow diagram of the search and selection strategy. 
 
Characteristics of studies included in review 
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The characteristics of the 13 studies reviewed are summarised in Table 3-2. All studies 
included had a cross-over design with a wash-out period ranging from 4 to 28 days, of which 
four were double-blinded (229–232), seven were single-blinded (37,233–238) and two did not 
present blind strategies (239,240). The mean age of subjects involved in included studies 
ranged from 20.2 to 50.9 years and five studies were conducted only in male subjects 
(229,232,233,237,240), while all other recruited men and women. The majority of studies were 
conducted on healthy individuals, except for one study on subjects with an atherosclerosis-
prone phenotype (233), one on subjects with obesity and insulin resistance phenotype (235) 
and another one with participants with at least one CVD risk factor (239). In relation to the 
dose of anthocyanins used in the intervention, six studies used a dose <100mg 
(37,230,231,233,236,239) and four studies used doses >100mg (229,232,237,238), while two 
studies used three different doses (235,240) and one study used two different doses (234) within 
both ranges. Overall, the dose ranged from 11.2 to 1530mg of anthocyanins. The fat content 
within meal challenges were <40g in four studies (37,230,234,235) and >40g in nine studies 
(229,231–233,236–240). Concerning fat content as % of energy, the meal challenges in six 
studies provided >50% of energy from fats(229,230,232,233,239,240), while seven studies 
provided <50% energy from fats(37,231,234–238). The main type of fats within the challenge 
meals were derived from animal products with high content of saturated fats such as cream, 
sausages, cheese, fried potatoes, bacon, eggs and butter. There were no relevant source of 
omega-3 fatty acids included in any of the challenge meals. All studies used a macronutrient 
matched placebo in the control arm. In eleven studies(126,129,186,229–234,241), either a 
beverage, yoghurt or smoothie was used, while two studies(238,240) provided meals without 
incorporating the freeze-dried source of anthocyanins. One study used water as an additional 




Table 3-2. High-fat meal challenge studies analysing cardiovascular risk factors 
Reference Population sample 
size 




Healthy male adults 
(n=23), mean age 46yr 
± 1.9, BMI 27.6kg/m2 
± 0.4 
Açai smoothie: 150g 
frozen açai pulp, 50g 
banana, 155.1Kcal, 
8.5g fat, 2.4g PTN, 









(60.6% from fat), 
58.5g fat, 74.4g 
CHO, 11.4g PTN  
Blood pressure: ↔ 
FMD: ↑ 1.4%, p=0.001 at 2h and ↑ 0.8%, 
p<0.001 at 4h. 
Plasma total oxidant capacity (peroxide 
concentrations): ↓ area under the curve over 
7h, p=0.02 
Cerletti et al. 
2014, 
Italy(239) 
Adults (n=18: 9 
females, 9 males), 
36.9 ± 10.5yr, BMI 
26.8 ±4.0. At least one 
CVD risk factor 
(overweight, 
hypertension, 
smoking, high serum 
cholesterol or TG 
levels 
Red orange juice: 
53.1mg anthocyanins 
a) Blonde orange 
juice; b) water 
890 Kcal (52.6% 
from fat), 52g fat, 
25g PTN, 81g 
CHO 
Augmentation index (vascular stiffness): ↓ 
2.18 ± 19.26 to -6.11 ± 11.90, p=0.0030 
Reactive hyperaemia index (vascular 
reactivity): ↔ 
Blood pressure: ↔ (diastolic blood pressure 
within group:↓ p=0.0045) 






Healthy adults (n=24, 
14 females, 10males) 
BMI 29.2 ±2.3,  
50.9yrs ± 15 








(28.1% from fat), 
30g fat, 36g PTN, 
135g CHO 
 
hsCRP: ↓ 3.1 (SEM 0.1) vs 2.7 (SEM 0.5) 
mg/L, P=0.02 at 6h 
IL-6: ↓ 3.4 (SEM 0.5) vs 4.5 (SEM 0.5) 




Miglio et al. 
2012, 
Italy(230) 
Healhy adults (n=14), 
45yr ± 9, BMI 
26.8kg/m2 ± 2.2 
a) Fruit juice (86% 




b) Fruit juice (63% 
Energy and sugar 
matched placebo, 
66g CHO 
1344 Kcal (54.2% 
from fat), 81g fat, 
104g CHO, 52g 
PTN, 3.1g fibre 
Urinary FRAP: ↑ 35%, p<0.01 
Plasma TRAP: ↑ p<0.05 at 1h, ↑ 8%, 
p<0.001 at 2h, ↑ p<0.01 at 4h. 
Plasma FRAP: ↔ 
Plasma uric acid: ↓ p<0.05 at 8h 
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mix of  pineapple, 




Plasma Thiols: ↓ p<0.05 at 0.5, 1, 4 and 8h, 
↓ p<0.01 




Healthy adults (n=23, 
18 females, 5 males), 
30yr ± 3yr, BMI 
21.9kg/m2 ± 0.4 
Yoghurt + freeze dried 








Kcal, 0.6g fat, 
45.1g CHO, 1.2g 
PTN, 10g fibre 
 
653 Kcal (40.0% 
from fat), 29g fat, 








Park et al. 
2016, 
USA(235) 
Adults with obesity 
and insulin resistance 
phenotype (n=21, 16 
females, 5 males), 
39.8yr ± 13.8, BMI 
40.2 ± 7.2 
Freeze dried whole 
strawberry powder: a) 
42.2mg 
anthocyanins; b) 
87.9mg; c) 154.5mg 
Milk based colour 
and macronutrient 
matched beverage 
967 Kcal (23.6% 
from fat), 25.4g 
fat, 146.2g CHO, 





OxLDL-c: ↓ –3.0 ± 0.8 U/L, p<0.05 
 
Richter et al. 
2017, 
USA(238) 
Healthy adults (n=30, 
13 females, 17 males), 
BMI 31 kg/m2 ± 0.5, 
28yr ± 2.0 
Freeze dried 







(added to meal) 
1004Kcal (44.8% 
from fat), 50g fat, 
105g CHO, 32g 
PTN, 7g fibre 
 




Augmentation index: ↔ 





Healthy adult males 
(n=9), 20.2yr (18.7-
27.3), BMI 24.6 kg/m2 
(20.7-29.4) 
Berry concentrate: a) 
added on beverage, 
90mg anthocyanins; 
b) added on burger 
and on beverage, 
174.3mg 
anthocyanins 
Plain burger and 
water 
527 Kcal (58.9% 
from fat), 48.7g 
PTN, 34.33g fat, 
4.6g CHO 
TAG: ↔ 
MDA: ↓ p<0.05 at all time points for 
intervention “b” and ↓ p<0.05 at 5 and 6h for 
intervention “a” 
PTNcarbonyls: ↓ p<0.05 at 2, 3, 4, 5 and 6h 
for intervention “b” and ↓ p<0.05 at 4 and 6h 
for intervention “a” 
Plasma FRAP: ↔ 






Healthy adults (n= 14, 
9 males and 5 
females), 25yrs ± 4, 
BMI 26kg/m2 ± 2 
Freeze dried 






0.8g PTN, 0.1g 
fat, 9.1g CHO 
 
841 Kcal (43.9% 




IL-6: ↓ p=0.048 (intervention consumed 
before the meal) over 10h; ↔ (intervention 
consumed within and after the meal, trend 
p<0.1) over 10h 




mean age 46.9 ±1.9), 









matched in CHO 
and energy  
853 Kcal (49.3% 
from fat), 46.7 g 
fat, 75.2g CHO, 
32.4g PTN, 4.5g 
fibre  
 
ORAC: ↑ p<0.05 






Peluso et al. 
2011, 
Italy(231) 
Healthy adults, (n=14, 
12 males and 2 
females),  45.1yrs ± 











1344 Kcal (30.0% 
from fat), 184g 
CHO, 44.8g fat, 
49g PTN 
TAG: ↔ 
TC: ↔ [prevented a significant increase 
(p<0.001) observed only at the control group 
over 8h] 
IL-17: ↓ p<0.05 at 4 and p<0.01 at 8h 
IL-6: ↓ 0.5h (p<0.01), 1h (P<0.05) and 2h 
(p<0.001) 
TNF-a: ↓ at multiple time points (p<0.01 at 
1h, p<0.05 at 2 and 6h, p<0.001 at 4 and 8h) 
 











9% raspberry puree, 
7% cherry puree, 39% 















(added cream and 
sugar): 1029 Kcal 
(55.8% from fat), 
63.8g fat, 6.0g 
PTN, 107.6g 
CHO, 1.8g fibre 







ORAC: ↑ p<0.040 at 90min and p<0.02 at 
120 min  







Polley et al. 
2019, 
USA(232) 
Healthy adults (22 yrs 







+11mg of vitamin 
C: 166.5Kcal,  
CHO 39.4g; PTN 
2.24g 
Biscuit, sausage 
patty and butter: 
920 Kcal (58.7% 
from fat), 60.0g 






      
Abbreviations and symbols: CHO, carbohydrate; PTN, protein; FMD, flow-mediated dilatation; Kcal, kilocalories; TAG, triacylglycerol; TC, total cholesterol; 
HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; OxLDL-c, oxidized low-density lipoprotein cholesterol; hsCRP, high 
sensitivity C-reactive protein; FRAP, ferric reducing ability of plasma; TRAP, total radical-trapping antioxidant parameter; ORAC: oxygen radical absorbance 










Risk of bias 
The overall risk of bias was judged as “low risk” for ten studies (37,229,230,232,234–
236,238–240), while three studies (231,233,237) were judged as having “some concern” due 
to ranking as such in one or more risk domains (Table 3-3). Among the studies that were 
identified as having “some concern” regarding risk of bias, two studies (233,237) had missing 
information on domain 1 (risk of bias arising from the randomization process) and one study 
(231) had missing information on domain 3 (risk of bias due to missing outcome data) (228).
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Domain 1: Risk of bias arising 
from the randomisation process              
Domain 2: Risk of bias due to 
deviations from the intended 
interventions (effect of assignment 
to intervention) 
             
Domain 3: Risk of bias due to 
missing outcome data              
Domain 4: Risk of bias in 
measurement of the outcome              
Domain 5: Risk of bias in selection 
of the reported result              
Overall risk of bias 
             




The outcomes analysed in the included studies were blood pressure, lipid profile, 
vascular and endothelial function, as well as biomarkers related to inflammation, oxidative 
stress and antioxidant status (Table 3-2). The postprandial response of such outcomes were 
analysed after the intake of the high-fat meal challenge, which means that a significant decrease 
may actually mean an attenuation of an increase pattern. Three studies measured blood pressure 
(229,238,239) before and after the HFMC, none of which found significant changes in systolic 
blood pressure. One study found a reduction in diastolic blood pressure in the anthocyanins 
intervention group (p=0.0045), while an absence of effect was observed in the other two arms 
administering water or a matched anthocyanins-free placebo (239). Vascular and endothelial 
function were evaluated by three studies (229,238,239). Alqurashi et al. (229) assessed 
endothelial function in the brachial artery by flow-mediated dilatation (FMD) with a 
postprandial increase of 1.4% versus 0.4% at 2h (p=0.001) and an increase of 0.8% versus a 
decrease of -0.3% at 6h (p<0.001), comparing the intervention with the placebo group, 
respectively. Cerletti et al. (239) assessed vascular stiffness through the augmentation index 
(AI) and vascular reactivity through the reactive hyperaemia index (RHI). The latter did not 
present significant changes, but there was a significant decrease (2.18 ± 19.26 to -6.11 ± 11.90, 
p=0.0030) in the AI 3h after the meal only in the anthocyanins intervention arm (239). Richter 
et al. (238) investigated AI and augmentation pressure through pulse wave analysis and the 
aortic stiffness assessed by carotid-femoral pulse wave velocity (PWV). None of the 
parameters were significantly different between intervention and control arms (238). 
Regarding the lipid profile, ten studies evaluated triacylglycerol (TAG) (231–240), of which 
one study found a higher decrease (p=0.0131)  in the intervention group (239) and other study 
found a trend(p=0.059) of a decrease 60 minutes after ingestion of the HFMC (233). Total 
cholesterol (TC) was evaluated by five studies (231,233,234,237,239) and two studies found 
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significant changes. Cerltetti et al. (239) found a reduction (p=0.0339) only in the anthocyanin 
intervention arm (239), while Peluso et al. (231) found that the anthocyanins prevented an 
increase in the intervention group, therefore a significant increase was only observed in the 
control group over 8h (p<0.001) (231). The studies that measured HDL-c (233,234,237) and 
LDL-c (233,234,237) did not find any significant changes.  
Among inflammatory markers, six studies evaluated IL-6 (37,231,233–236) 
concentrations, of which three (37,231,236) reported significant changes. In one study (37) the 
anthocyanin intervention was able to attenuate an increase in IL-6 response six hours after the 
HFMC compared to the placebo group [3.4 (SEM 0.5) versus 4.5 (SEM 0.5) pg/ml, P<0.05]. 
Similarly, Peluso et al. (231) found a significant attenuation in postprandial IL-6 concentration 
at 0.5 (p<0.01), 1 (P<0.05) and 2h (p<0.001) time points (231). Another study (236) found a 
trend to attenuate such response in two groups (consuming the anthocyanins intervention 
within or after the HFMC) and a significant decrease in the group consuming the anthocyanins 
intervention before the meal (p=0.048). The cytokine TNF-α was evaluated by four studies 
(37,231,233,234) and with one study (231) finding a significant result preventing a postprandial 
rise of TNF-α concentrations at multiple time points (p<0.01 at 1h, p<0.05 at 2 and 6h, p<0.001 
at 4 and 8h). 
There were no significant changes in IL-1β concentrations between treatments cross 
the three studies evaluated this cytokine (37,233,234). Only one study (37) evaluated hsCRP 
concentrations before and after the HFMC presenting a significant lower concentration 
compared to placebo [3.1 (SEM 0.1) versus 2.7 (SEM 0.5) mg/L, P=0.02]. Still, there was one 
study that measured IL-8 concentration finding not significant results (234) and one study that 
evaluate Il-17 which found a significant postprandial reduction at 4(p<0.05) and 8h(p<0.001) 
time points (231). 
113 
 
A large variety of oxidative stress and antioxidant status biomarkers were measured by 
nine studies (229,230,232,233,235–238,240) included in this review. Four studies 
(233,235,236,238) evaluated OxLDL-c concentrations; however, only one study (235) found a 
significant reduction (–3.0 ± 0.8 U/L, p<0.05) in the intervention arm compared to placebo. 
Plasma malondialdehyde (MDA) concentration was measured in two studies (238,240) in 
which one found that the anthocyanins interventions arms were able to prevent postprandial 
MDA accumulation (p<0.05 at multiple time points), and the mean value of the area under the 
curve of was reduced compared to placebo (240). This same study also found a reduction 
(p<0.05 at multiple time points for both anthocyanins interventions) in plasma protein 
carbonyls and an increase in the DPPH (2,2-diphenyl-1-picrylhydrazyl) plasma antioxidant 
capacity (240). The ferric reducing ability of plasma (FRAP) assay was used to examine 
antioxidant capacity in was evaluated by three studies (230,232,240), but no significant effects 
of anthocyanin intervention were detected. However, Miglio et al. (230) found a 35% increase 
in the urinary excretion of antioxidants as indicated by raised urinary FRAP (P<0.01). This 
same study found an increase (p<0.05 at 1h, p<0.001 at 2h and p<0.01 at 4h) in plasma total 
radical-trapping antioxidant parameter (TRAP), as well as a significant attenuation in the 
increase of endogenous antioxidants thiols and uric acid (UA) (p<0.05 at 8h). Plasma ascorbic 
acid (vitamin C) was measured in four studies (230,233,237,240), of which one study (233) 
found an increase in the anthocyanin intervention arm (+14 mmol/l, p<0.004) compared to the 
placebo. The oxygen radical absorbance capacity (ORAC) of plasma/serum was evaluated, 
before and after the HFMC, in five studies (232,233,235,237,240), of which two found 
significant changes. In one study (233), the intervention was able to prevent the postprandial 
decrease in the ORAC of plasma at 90 and 120 min following the HFM challenge (p<0.040 
and p<0.02, respectively), while another study (237) found a significant increase in serum 
ORAC 1h after the HFMC in intervention group when compared to the control (p<0.05). 
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Furthermore, this same study found a significant increase in the total antioxidant status (TAS) 
assay (+4.5%, p=0.05). Lastly, one study (229) measured the total oxidant capacity in plasma 
by assessing the total peroxide concentrations, and found a significantly lower incremental area 
under the curve in the intervention group(p = 0.02). 
 
3.4 Discussion 
The results of studies included in this systematic literature review indicate that the 
postprandial state, after exposure to a high fat meal, may provide a useful context to investigate 
acute metabolic changes, from well-known lipid responses to complex phenolic compound 
signalling pathways that contribute to the development of CVD. A wide range of risk factors 
such as blood pressure, lipid profile, vascular and endothelial function, as well as biomarkers 
related to inflammation, oxidative stress and antioxidant status were included as outcomes in 
the acute studies in the review.  
 Despite the lack of positive results in blood pressure, of which only study found a 
significant decrease in diastolic blood pressure (239), vascular and endothelial parameters 
showed more positive results. It is more likely that such parameters will respond in a higher 
magnitude than blood pressure in acute studies, due to the excess postprandial production of 
pro-oxidant molecules following the HFMC. This may in turn inactivate endothelial dependent 
factors, in particular nitric oxide, leading to impaired vasodilation and the onset of an 
inflammatory response, which further leads to the generation of more free radicals (226,242). 
In this matter, açai consumption was associated with improvements in endothelial vascular 
function, measured by FMD, in healthy overweight man, which was also followed by an 
increase in total oxidant capacity in plasma, assessed as a measure of total peroxide 
concentrations (229). The significant improvement in FMD found in this study(229) was 1% 
higher than in controls, a magnitude of effect that has been shown in a meta-analysis to be 
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associated with an overall 8 % reduction in CVD risk (RR= 0.92; 95%CI: 0.88; 0.95) for each  
percentage increase (92) . Flow-mediated dilatation is a non-invasive measurement of 
endothelium function that has been associated with CVD risk prediction(92,243). Another 
study found a decrease in arterial stiffness, measured by AI, after consumption of blood orange 
juice anthocyanins in individual with at least one CVD risk factor (overweight, hypertension, 
smoking, high serum cholesterol or triacylglycerol levels) (239). 
A recent systematic review evaluated the postprandial inflammatory response to HFM 
challenge, in which IL-6 was stated as the inflammatory marker with the stronger response to 
this stress (244). IL-6 has a pleiotropic nature showing both anti and pro-inflammatory roles 
and regulating a plethora of immune and metabolic responses, however a high concentration 
of this cytokine has been associated with CVD and mortality (77,245). Still, IL-6 has a high 
expression on vascular endothelium and the pharmacological inhibition of IL-6 improves 
endothelial function (78). The inhibitory effect on postprandial IL-6 concentrations found 
within the studies added in this review demonstrates a potential therapeutic effect of 
anthocyanins for CVD (37,231,236). One possible mechanism that anthocyanins may exert this 
effect is through decreasing the activity of the NF-κB pathway, which is a transcription factor 
responsible for triggering and regulating inflammatory processes, leading to the expression of 
pro-inflammatory cytokines and enzymes (21,121). Concerning the clinical significance of the 
magnitude of effects reported in the studies that observed benefits associated with anthocyanin 
intake, the significant changes of between 0.34 and 0.90 pg/mL represent changes from 
baseline of >2 SD(37,236) and >3 SD(231). These results are clinically meaningful considering 
the predictive roles of IL-6 concentration in CVD risk. Hazard ratios of 1.80 are reported 
according to each 1-SD increase in IL-6 for risk of first-ever cerebrovascular events in 
individuals with vascular risk factors without any pre-existing cardiovascular disease(79). 
Further, a positive predictive value of 100% is reported for coronary artery disease when IL-6 
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concentrations exceed 1.0 pg/mL in patients who have an intermediate cardiovascular risk 
profile and chest pain(246). In a meta-analysis of 17 prospective studies investigating clinical 
coronary outcomes (i.e., myocardial infarction or coronary death), an odds ratio of 1.61 (95% 
CI 1.42–1.83) was found per 2 SD increase in baseline IL-6 (247). Another meta-analysis of 
17 studies comprising 288,738 healthy individuals reported a significantly higher IL-6 
concentration in CVD cases compared to non-CVD controls (standardized mean difference 
[95% CI]) of 0.14 [0.09, 0.20]/mean difference of 0.36 [0.28, 0.44] pg/mL) [52]. These 
significant changes in IL-6 concentration were found only in studies which the mean BMI of 
participants were >25kg/m2. Overweight and obesity are an independent risk factor for CVD, 
as well as are associated with a low-grade continuous inflammation with high implications in 
the atherosclerotic process. The possibility of regulating this persistent not resolved 
inflammatory state can be crucial in attenuating the progress of the atherosclerosis disease, 
especially in the early stages. This is the same scenario, in which the only study (37) that 
evaluated CRP found a significant reduction of 0.4 (SD 0.1) mg/L in a study population with a 
mean BMI >29kg/m2. This effect reduced the hsCRP concentration in the intervention arm to 
values <3.0 mg/L, which is considered a clinical threshold for many cardiovascular conditions, 
including a reduced hospitalisation rate for heart failure in subjects with stable coronary heart 
disease[53]. CRP is also associated with CVD and mortality (67,68), and has been implicated 
in endothelial dysfunction in in vitro and in vivo studies (65,66). On the other hand, the 
cytokines IL-1β and TNF-α not appear to transiently and/or robustly change in the postprandial 
period after a HFMC, thus a decrease in concentration of these molecules is not likely to occur 
with acute diet interventions (244). In the present review, the three studies that evaluate IL-1β 
were conducted in healthy normal weight (234), healthy overweight (37) and overweight/obese 
adults with atherosclerosis prone phenotype (233), however none of them found significant 
changes. TNF-α also plays a pleiotropic and major role in CVD, but high concentrations have 
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been associated with deleterious effects mainly through vascular dysfunction and atherogenesis 
by many mechanisms such as regulation of the vascular permeability, disruption of the 
endothelial barrier, degradation of glycocalyx, increased production of ROS and decreasing 
NO bioavailability and increase its removal (250,251). In line with the review by Emerson et 
al. (2017) (244), the studies included in our review found inconsistent changes of TNF-α 
concentrations after the HFMC, i.e. two studies found a decrease (233,234), one an increase 
(231) and other study reported no changes (37). The study that had a postprandial increase in 
TNF-α concentration was the only one that found a significant lowering effect with the diet 
intervention with anthocyanins (231). Another relevant finding in this same study was the 
inhibitory effect of on postprandial increase of IL-17, a cytokine with highly pro-inflammatory 
properties that are also associated with CVD, especially with cardiovascular events such as 
stroke and myocardial infarction (252). There is accumulating evidence that IL-17 it is involved 
in the pathogenesis of cardiovascular diseases by amplifying the inflammation induced by other 
cytokines in synergistic interactions (253). This cytokine is also positively correlated with 
OxLDL-c, a molecule with a crucial role in the oxidative stress mediated atherosclerosis 
development.  
OxLDL-c is a key factor in the initiation and progression of atherosclerosis and 
contributes to endothelial dysfunction and plaque destabilization through various mechanisms 
(254). Among the four studies that measured postprandial concentration of Ox-LDL-c, the only 
study that found a significant reduction was conducted in participants with an obese and insulin 
resistant phenotype [35]. Several other oxidative stress and antioxidant status biomarkers were 
investigated within the added studies in this review, showing the most promising results in 
relation to the effects of anthocyanin intervention on parameters following the HFM challenge. 
MDA is an end product of lipid peroxidation, the radical-initiated oxidative decomposition of 
poly-unsaturated fatty acids (255). Urquiaga et al. (240) found a reduction in postprandial 
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concentration of MDA at multiple time points following two different anthocyanin 
interventions (i.e. added to food or beverage) using a berry concentrate. This same study also 
found a reduction in plasma protein carbonyls and an increase in the DPPH (2,2-diphenyl-1-
picrylhydrazyl) plasma antioxidant capacity (240). Protein carbonylation is one of the most 
harmful irreversible oxidative protein modifications, and is considered a major hallmark of 
oxidative stress‐related disorders (256). The DPPH assay is a method that is widely used to test 
the ability of compounds to act as free radical scavengers or hydrogen donors, and therefore 
can be used to evaluate antioxidant activity. Another anti-oxidant assay, the FRAP, (based on 
single electron transfer reaction to evaluate the antioxidant effect of nonenzymatic defense in 
biological fluids) was measured in three studies that reported no significant effect of the 
anthocyanin intervention in plasma (230,232,240). However, one of these studies found a 35% 
increase in the urinary excretion of antioxidants (P<0.01), which was followed by an increase 
TRAP and an attenuation in the increase of endogenous antioxidants thiols and UA. TRAP 
differs from FRAP as an assay that measures the ability of antioxidants to buffer a reaction 
probe against peroxidation, and it’s determined by measuring the length of time that oxygen 
uptake is inhibited (257). Results from both FRAP and TRAP methods have to be carefully 
interpreted considering that FRAP has low specificity in measuring the antioxidant activity of 
many important antioxidants such as ascorbic acid, glutathione and albumin, and that TRAP 
does not necessarily provide a reliable or sensitive measure of the ability of plasma to interfere 
with lipid peroxidation[66].  UA levels are related to oxidative status, especially antioxidant 
capacity and it is well known that high plasma UA levels are strongly associated CVD (258). 
Taken together, the positive results of these three different oxidative stress biomarkers show a 
relevant anti-oxidant signalling effect of anthocyanins in these studies conducted in healthy 
adults (230,240). Another relevant biomarker of antioxidant status is vitamin C, which is a 
readily water-soluble and not storable in tissues. Therefore, vitamin C is a good biomarker for 
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short-term studies (259). One study added in this review found an increase in plasma vitamin 
C (233); however, even though the placebo was matched in macronutrients and energy, only 
the diet intervention had a relevant content of vitamin C (122.3 vs 0.3mg). Thus, it is unlikely 
that the plasma concentration of vitamin C was increased due to the anthocyanins. The ORAC 
of plasma/serum, which was evaluated in five studies in this review, appears to be a 
controversial method in regard to its application for in vivo studies, especially after the 
withdraw of the ORAC food database by the USDA in 2010. There is still debate regarding the 
absorbance and breakdown of polyphenols, such as flavonoids and subclasses, into smaller 
phenolics compounds with signalling, anti-inflammatory and anti-oxidant properties (242). 
Nevertheless, two studies found an increase in plasma ORAC following 60 (233), 90 and 120 
(237) minutes after the HFMC, and one study also found a significant increase in  TAS (237), 
another non-specific assay that assess the overall antioxidant status of a sample.  
The post-prandial response in the lipid profile, when compared to fasting lipids, can 
represent a different and even independent risk factor for CVD (34,106). The transient lipid 
and lipoprotein accumulation that occurs in the circulation after a high-fat meal represents the 
individual capacity to metabolize an acute fat input (260) and has been associated as an 
important risk factor in atherosclerosis development (107). The most relevant postprandial lipid 
marker it is triacylglycerol. It is the lipid with the greatest post-prandial difference from fasting 
lipid markers (34), and has been associated as an independent risk factor for cardiovascular 
events (35). The results found in our review support these statements, as significant changes 
were only found in triacylglycerol (233,239) concentrations and total cholesterol (231,239), 
which has a composition of 20% triacylglycerol in its formula. 
The choice of placebo in this type of acute study design is important in order to identify 
whether it is indeed the anthocyanin effect that is observed in the results, or whether there are 
other nutrients or food constituents that may be affecting the study outcomes. All studies 
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included in this review included a placebo that was matched in macronutrient and fibre content, 
however other nutrients such as vitamin C and other flavonoids that may also play a role in 
postprandial oxidative stress and inflammation are not commonly considered. It is complex, 
and often  impossible, to provide a perfectly matched placebo in food studies of this type, 
therefore results from studies that use different placebos should be carefully scrutinized. 
The most notable challenge and limitation of this study was to address a wide range of 
CVDs biomarkers assessed in this type of acute clinical trial. Overall, the comparison among 
studies had a relevant clinical importance of these metabolic, immune and physiological factors 
that has a synergistic impact on CVDs, however there was a variety of parameters addressed 
with different methods within each of such factors. This made the possibility of meta-analysis 
or other pooled analyses unfeasible, however it not impeded results to be compared narratively. 
Another source of heterogeneity in these studies may have resulted from variability in the HMF 
challenges regarding their macronutrient and energy content, particularly the types of fat, as 
well as the format in which the meals were delivered. Accumulating evidence suggests that the 
health effects of dietary fats vary(108). Substitution of  saturated fatty acids from butterfat with 
omega-6 PUFA resulted in a decreased postprandial lipaemia, as well as reduced 
concentrations of IL-6, TNF-α, soluble TNF-α receptors, and soluble vascular cell adhesion 
molecule-1 in overweight men(110). However, all studies included in this review used animal 
products as the main source of fat, and there were two main types of meals: 1) beverages that 
were enriched with cream and/or milk; or 2) mixed meals including animal products with a 
high content of saturated fat such as sausages, cheese, butter, eggs and bacon. A standardized 
meal for these type of studies would be preferred but may be difficult to implement because of 
cultural diversity in cuisine and dietary patterns. Despite that all included studies were 
conducted in young and middle-aged adults (mean age ranging from 20.2 to 46.9y), there were 
slightly differences in mean BMI with two studies having participants with BMI<25kg/m2 
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(234,240) six with BMI from 25-30kg/m2 (37,229–231,236,239) and three with BMI>30kg/m2 
(233,235,238) .Only three studies were not conducted in healthy adults, of which participants 
were not considered healthy due to lipidaemia (233), insulin-resistance phenotype (235) or with 
at least one CVD risk factor (239). However, studies conducted in participants with major 
chronic diseases with implication on CVDs, such as diabetes and hypertension, were not 
included in this review. Another feature in the design of this type of study is that tests are 
conducted over multiple time following the HFM challenge, thereby raising a concern that the 
number of false positive findings may be inflated. For this reason, the interpretation of results 
found in only one or a few time points, and that are not sustained, has to be interpreted with 
caution. Still, parameters that have been used in the studies to investigate oxidative stress and 
antioxidant status represent a wide range of analytical methods, and there is no formal 





Despite some positive findings, there was heterogeneity for changes in some CVD risk 
factors between studies. The most promising results were for the attenuation of deleterious 
postprandial effects on oxidative stress and antioxidant status, triacylglycerol and total 
cholesterol concentrations, as well as for vascular endothelial function and inflammatory 
biomarkers. The post-prandial changes in blood pressure and lipoproteins were the parameters 
least affected by anthocyanin treatment. Further studies are required in order to advance in the 
knowledge of how post-prandial changes are associated with CVD incidence and progress, and 




CHAPTER 4: Anthocyanins attenuate vascular and inflammatory 
responses to a high fat high energy meal challenge in overweight 
older adults: a cross-over, randomized, double-blind clinical trial. 
 
 The findings from the previous study ‘The postprandial effect of anthocyanins on 
cardiovascular disease risk factors: a systematic literature review of high-fat meal challenge’ 
guided the original design and conduct of this clinical trial. Within this range of studies, another 
gap that was identified is the possibility of a more robust investigation of the vascular function 
in the postprandial state, which along with the immune response are important predictors of 
CVD. Therefore, we created a protocol to explore macro and microvascular parameters by 
combining classical and novel techniques with the latest imaging technologies, such as the 
flow-mediated dilatation (FMD) and the Laser Speckle Contrast Imaging (LSCI). To our 
knowledge, this was the first study to conduct this type of protocol in studies with nutritional 
interventions. Additionally, the present clinical trial also aim to determine if consumption of 
food anthocyanins has postprandial effects on inflammatory and oxidative stress biomarkers, 
and lipid profile following a high-fat high-energy meal in older adults with overweight or 
obesity 
The results supported that fruit-based anthocyanins attenuated the potential 
postprandial detrimental effects of a HFHE challenge on parameters of vascular and 
microvascular function, and inflammatory biomarkers in overweight older adults. 







Metabolic imbalances in the postprandial state, particularly following a high fat high 
energy (HFHE) meal, are associated with long term development of CVD(106,107). The 
underlying mechanisms involve a sharp increase in circulating triacylglycerol concentrations, 
along with a pro-inflammatory response and an aberrant production of pro-oxidant molecules, 
which together may impair vascular endothelial function(105,262,263). Endothelial 
dysfunction is associated with an impaired bioavailability of nitric oxide (NO) and an up-
regulation of various other molecules involved in the adverse vascular function(6,264).  
This is particularly evident in older adults, as several studies support a new immune-
metabolic viewpoint for age-related diseases, termed “inflammaging” which is characterized 
by a chronic, low-grade inflammatory response in the absence of a pathogen(7). Additionally, 
excessive adiposity at all ages is associated with an up-regulation of a pro-inflammatory state, 
as the accumulation of adipose tissue mass promotes the secretion and release of inflammatory 
mediators, including high sensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6), 
interleukin 1 beta (IL-1β) and tumour necrosis factor alpha (TNF-α)(63,64). This process also 
leads to chronic low-grade inflammation that is driven by a nutrient excess and/or overnutrition 
and has the same mechanisms as those underpinning “inflammaging”(7). A HFHE challenge 
is a method to investigate such imbalances that regularly occur in response to typical ‘Western’ 
dietary patterns(264,265). A review of 57 studies investigating the postprandial state has shown 
that a HFHE meal induces acute postprandial inflammation; however, heterogeneity was 
observed for cytokines and soluble adhesion molecules, while leukocyte surface markers, 
mRNA and proteins were elevated in almost all studies(266). Strategies that aim to attenuate 
these potential detrimental postprandial effects will be of clinical relevance. 
Dietary factors play a major role in regulating the inflammatory state and mobilizing 
the endogenous antioxidant defences(9). Protective dietary components that are consumed 
124 
 
together with a HFHE meal may be beneficial in attenuating the potentially harmful 
postprandial responses(226). Anthocyanins, a subclass of flavonoids, are emerging as one such 
potential agent for ameliorating adverse CVD risk factors(21,222,267). Anthocyanins have 
been shown to elicit immunomodulatory(21,23) and antioxidant effects(23,268), thereby 
blunting the cooperative and synergistic deleterious effects of oxidative stress and 
inflammation(190) and may, therefore, provide protection against CVD risk factors. A number 
of in vitro and in vivo studies have shown that anthocyanins upregulate endothelial nitric oxide 
synthase (eNOS) mRNA and NO synthesis(126,144,269,270) via several signalling pathways, 
and prevent peroxynitrite-mediated ED(125,271). Anthocyanins can also prevent the 
expression of adhesion molecules and the adhesion of monocytes to endothelial cells 
challenged by pro-inflammatory agents, and have the ability to elicit cell adaptive responses 
involving the transcription factor Nrf2(272). However, there is still limited data regarding the 
effect of anthocyanins on vascular function(273). To our knowledge, no study to date has 
investigated such effects on the microvasculature and predictive values for CVD are not yet 
defined, as they are for vascular function measured by flow mediated dilatation(11), which is 
considered to be a well-recognized early biomarker of atherosclerosis and a key contributor to 
the onset and progression of CVD(243,274,275). Measurement of the systemic 
microcirculatory function may help to identify ED pathological processes, and better elucidate 
the mechanisms underlying structural changes among these two vascular beds(96,102,276). 
The aim of this study was to investigate the postprandial effects of food anthocyanins 
on vascular and microvascular functions, inflammatory biomarkers and oxidative stress 
following a HFHE meal challenge in overweight older adults. A secondary aim was to evaluate 
the acute effects of the 4 day run-in period of food anthocyanins on such markers. Outcomes 
combined both vascular and microvascular function analyses, along with the evaluation of 
classic CVD risk factors and associated biomarkers(277,278), including blood pressure, serum 
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concentration of triacylglycerols (TG) and total cholesterol (TC), inflammatory markers 
including hs-CRP, IL-6, IL-1β, TNF-α, and serum derivatives of reactive oxidative metabolites 
(DROM).   
 
4.2 Methods 
This study was conducted according to the guidelines of the Declaration of Helsinki, 
and approved by the University of Wollongong Human Research Ethics Committee, New 
South Wales, Australia (HREC 2019/043). It was also registered with the Australian New 
Zealand Clinical Trials Registry (ACTRN12620000437965). Written informed consent was 
obtained from all subjects. 
 
Study Subjects 
Sixteen subjects (13 female and 3 male) were recruited from Wollongong, NSW, 
Australia through advertisements within the local community, and through the University of 
Wollongong and Illawarra Health and Medical Research Institute social media networks 
between June and August 2019. Inclusion criteria included males and females aged 55+ years 
with a body mass index (BMI) ≥25kg/m2. Exclusion criteria were: current treatment or 
diagnosis of hypertension or diabetes; chronic liver or renal diseases; history of cardiovascular 
events; current administration of either anti-inflammatory medication, aspirin or warfarin; 
smoking; diagnosis or self-reported gastrointestinal disorders; allergy to stone fruits or food 
colorants, unwillingness to consume a full English style breakfast that included meat products 
(e.g. vegetarians) at the research facility. 
 
Study Design and Treatments 
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The study was a crossover, randomized, controlled, double-blind design with a 4 day 
run-in period. The study design and procedures are outlined in Figure 4-1. Briefly, four days 
prior to the test days, participants were asked to consume either 250 mL of Queen Garnet plum 
juice (intervention) or apricot juice (control) per day. Participants underwent consultation with 
a dietitian that included education on avoiding foods that are rich in anthocyanins during the 4 
day run-in period prior to testing. On the night prior to the testing day, a standardised low 
flavonoid frozen meal was consumed for dinner by all participants. Participants fasted (12h) 
prior to the testing day.  
On the testing day, participants were required to consume a HFHE meal in conjunction 
with a 250mL dose of either the intervention or the control juice. Blood samples and blood 
pressure measures were collected at baseline (fasted state), and 2h and 4h following the 
consumption of the HFHE meal. Vascular function and microvascular blood flow was 
evaluated at baseline and 2h after the meal. Urine was collected for 24h following the HFHE 
meal. 
After a wash-out period of 14 days, participants were allocated to the opposite treatment arm, 
starting with the 4 day run-in period. Randomization was conducted by a researcher 
independent to the data collection using a computer generated randomization sequence and, 
in order to minimize order effects, an across subjects counter-balancing process was used. 
Several blinding strategies were undertaken, including advertising the study to participants as 
a “fruit juice study” without providing information on which fruit was being investigated, as 
well as colouring of the control juice to match the intervention juice colour. The usual dietary 
intake of participants was collected before the beginning of the study using a 3-day food 
record, consisting of 2 weekdays and 1 weekend day, and analysed using Foodworks 10 
(Xyris Software, Australia), which includes the Australian Food Composition Database 
2019(279). (Table 4-1) 
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Table 4-1. Dietary intake of participants 
Energy (kcal) 1724 (375.6) 
Protein (g) 80.7 (26.0) 
Fat – total (g) 71.4 (18.9) 
Saturated fat (g) 29.2 (5.0) 
Carbohydrates (g) 171.2 (42.3) 
Dietary fibre (g) 20.7 (7.4) 
Sodium (mg) 1870.5 (563.8) 
Vitamin C (mg) 30.4 (22.9) 
Vitamin E (mg) 3.7 (2.6) 
Vitamin A* (µg) 362.6 (170.7) 
Anthocyanins (mg) 19.1 (31.8) 
Values are mean and SD. *Total Vitamin A equivalents.  
Values were obtained from the Australian Food Composition  
Database 201926.  
 
 
 Figure 4-1.  Study design and procedures repeated on each treatment arm
 
Test meals, and intervention and control juices 
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 The test meal consisted of 1 hash brown (62g) 2 beef chipolatas (90g), 1 croissant 
(168g) served with unsalted butter (5g) and apricot jam (10g) and 2 scrambled eggs (2 x52g  
eggs, 30mL pure cream, 10g unsalted butter, 0.5g salt) (Table 4-2). One serving of Queen 
Garnet plum juice (intervention) was provided as 220g of plum puree with 30mL of water 
added. The anthocyanin content was analysed by the Queensland Department of Agriculture 
and Fisheries (DAF, Australia) by Performance Liquid Chromatography (HPLC) (91.3 mg of 
anthocyanins  per 100g of Queen Garnet plum juice) and a pH differential method (94 
mg/100g), following the standard AOAC 2005.02 protocol for total monomeric anthocyanin 
pigment(280). The 200 mg of anthocyanins provided per serve can be considered a high dose 
based on a systematic literature review of similar studies. In that review, only 2 of the included 
13 studies used a higher dose, and a number of studies achieved significant vascular  effects at 
doses lower than 100mg(273). Apricot juice was chosen as the control juice due to its similar 
consistency, nutritional content and total flavonoid concentration, but an overall lack of 
anthocyanins(281). Food dyes (red and blue) were added to the apricot juice to resemble the 
colour of the Queen Garnet plum juice.  
 
 
Table 4-2. Nutrition information of the test meal and fruit juices 





Energy (kcal) 856.9 98 96 
Protein (g) 25.9 0.6 0.7 
Fat – total (g) 65.3 < 0.1 < 0.1 
Saturated fat (g) 32.9 < 0.1 < 0.1 
Carbohydrates (g) 41.4 22.2 22.2 
Dietary fibre (g) 1.7 4.4 4.0 
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Sodium (mg) 941 6 2 
Vitamin C (mg) 0 0.3 1.2 
Anthocyanins (mg) 02 200.83 02 
Anthocyanins (mg) 02 206.84 02 
1Whole meal including one hash brown (62g), two scrambled eggs (104g) with pure cream 
(30g), butter (10g) and salt (0.5g), two beef chipolatas (90g), one croissant (168g) with butter 
and apricot jam; 2Phenol-explorer 3.0(282); 3High Performance Liquid Chromatography; 4pH 




BP was measured at baseline (fasted state), and 2h and 4h following the consumption 
of the HFHE meal using an using a Welch Allyn Connex 6700 Vital Signs Monitors (Welch 
Allyn, NSW, Australia). Participants were rested in supine position for 5 minutes, in a quiet 
room with a correctly fitting arm cuff. BP was measured on both arms, and a repeat measure 
taken on the arm with the higher reading, with the average of the two readings recorded(283). 
 
Flow mediated dilation (FMD) and microvascular perfusion 
 Participants were rested in a quiet, temperature-controlled room (23 °C ±1), in a supine 
position for 20 minutes. In brief, the first procedure was the microvascular PORH test 
conducted on the left arm, followed by the FMD conducted on the right arm, and lastly 
iontophoresis of acetylcholine, combined with LSCI, conducted in the left forearm (with 30 
minutes between tests in the left forearm). 
Vascular function was measured using FMD following standard guidelines(284), by a 
trained researcher. The same blinded researcher administered the test for each participant at 
two time points (baseline and 2hrs post-meal consumption, Figure 4-1) on both treatment arms, 
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and was responsible for the analysis of the resulting images to prevent inter-rater error. FMD 
of the brachial artery was measured using an uSmart3300 Ultrasound system (Terason, 
Massachusetts, USA) in combination with a semi-automated computerized analysis system 
(FMD Studio, QUIPO, Pisa, Italy). The brachial artery was imaged longitudinally at 2-10cm 
proximal to the antecubital fossa. Video recording collected beat to beat measures of the 
diameter and velocity for 1 minute, and the average was used as the baseline. Then the blood 
pressure cuff placed around the forearm was inflated to 60mmHg above resting systolic blood 
pressure. Blood flow was restricted for 5 minutes, then the cuff was rapidly released, resulting 
in reactive hyperaemia. Video was recorded for the 5 minutes period following the cuff release. 
The FMD response was calculated as the relative diastolic diameter change from baseline 
compared to the peak diastolic diameter following hyperaemia and expressed as a percentage. 
This flow-mediated dilatation protocol is routinely performed in our laboratory using the 
methods outlined by Francois et al. (2016)(285); with intra-subject coefficients of variation of 
7.1% for %FMD. 
Microvascular cutaneous vascular reactivity was measured using an LSCI system with 
a laser wavelength of 785 nm (Pericam PSI System, Perimed AB, Järfälla, Sweden). The image 
acquisition rate was 21 images/s, and the distance between the laser head and the skin surface 
was fixed at 25 ±0.5 cm. The skin of the volar side of the left arm was gently cleaned with 70% 
isopropyl alcohol swabs. Three equidistant skin areas (region of interest) of approximately 80 
mm2 were selected in the central volar part for the left arm(286), avoiding any skin mark or 
bulge areas(95). Participants were instructed to avoid any movement, and not to speak or 
breathe deeply during the record(95). During the PORH test, the baseline perfusion was 
measured in the volar side of the left forearm for 2 minutes, followed by an arterial occlusion 
maintained for 3 minutes using a blood pressure cuff around the upper arm inflated to a pressure 
of 50-60 mmHg above systolic pressure reading(96,276). After the blood pressure cuff was 
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released, the PORH response was recorded for 3 minutes. The following parameters were 
extracted: baseline flow (BF), biological zero (BZ) and peak value (PV)(95). The PV was 
obtained with a 5 second “time of interest” starting from the highest value after deflation of the 
cuff(286). RF was calculated as BF – BZ. The maximum PORH perfusion (PORHmax) was 
calculated as PV – RF (Supplementary material, Figure S1 and Table S1). This PORH 
protocol is routinely performed in our laboratory; with intra-subject coefficients of variation of 
7.7% for PV and 11.4% for PORHmax.  
Additionally, a pharmacological reactivity test was conducted using iontophoresis of 
acetylcholine (2%, dissolved in deionized water) using a micropharmacology system (PF 751 
PeriIont USB Power Supply; Perimed) with a single electrical current of 0.1mA for 30s(101). 
Microvascular blood flow was recorded for 2 minutes prior to the current and 8 minutes after 
the pharmacological stimulus. The maximum perfusion following the iontophoresis of 
acetylcholine (IONTmax) was calculated by using subtracting the RF from the PV using the 
same procedures used in the PORH test (Supplementary material, Table S1). 
 
Blood and urine samples 
Plasma and serum samples were stored at -80 °C, prior to analysis. IL-1β, IL-6 and 
TNF-α, were analysed in a Luminex 200 using a Human High sensitivity T cell magnetic bead 
panel kits (Merck Millipore, Billerica, MA, USA). hs-CRP, TC and TG were analysed on a 
BK400 automated chemistry analyser using a commercial immunoturbidometric assay 
(Biobase, Shandong, China). Derivatives of reactive oxidative metabolites were analysed in a 
Cobas Mira Plus (Roche, Washington, USA) using a commercially available colorimetric kit 
(Diacron, Grosseto, Italy).  
Urine samples were collected between 0-4h, 4-12h and 12-24h and stored at -80 °C, 
prior to analysis. Aliquots of 3 mL from each timepoint were pooled and 1 mL of the pooled 
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sample was analysed using ultra-performance liquid chromatography–tandem mass 
spectrometry (UPLC-MS/MS) to determine differences in excretion of total anthocyanins 
(expressed as cyanidin-3-O-glucoside equivalents equivalents), and phenolic acid metabolites 
related to anthocyanins (protocatechuic acid, hippuric acid and ferulic acid). Briefly, 1 ml urine 
was extracted by solid phase extraction using Discovery® DSC-18 (6 mL, 1 g) cartridges(287). 
The eluate was evaporated under nitrogen, reconstituted in 1 % formic acid in water and 
analysed by UPLC-MS/MS (Waters Acquity H-Class UPLC instrument coupled to a Waters 
Xevo TQ tandem mass spectrometer), operating in multiple reaction monitoring and positive 




Data are presented as mean and standard deviation or median and interquartile range. 
Natural log transformation was used when non-normal data better fit the normal distribution 
(triacylglycerol, total cholesteterol, hs-CRP, PV and PORHmax). Two-way repeated measures 
ANOVAs were used to investigate the outcomes. Significant interaction effects were analysed 
by post-hoc comparisons with Bonferroni correction. Dependent t- and Wilcoxon signed-tank 
tests evaluated the difference in baseline measures to investigate the effects of the 4 day run-in 
period, as well as to investigate the differences in other time points among the treatments. 
Pearson and Spearman coefficients were calculated to evaluate potential baseline correlations 
between vascular parameters and inflammatory biomarkers. All LSCI parameters were 
transformed from arbitrary perfusion units (PU) to cutaneous vascular conductance (cvc) by 
dividing the obtained values by the mean arterial pressure to yield cvc in PU/mmHg. SPSS 
(version 25, IBM, Chicago, IL, USA 2019) was used for all statistical analyses. Significance 
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was accepted at alpha p<0.05, and non-significant p values between p=0.05-0.099 were 
considered a trend in the data. 
The primary endpoint of change in FMD from baseline to 2 h was used for the power 
calculation. Based on a previous study that found a significant effect of anthocyanins on post-
prandial changes in FMD(229), and aiming for a significant improvement of 1% in FMD, 13 
participants were required to achieve a study power of 80% with an α of 0.05.  
 
4.3 Results 
All sixteen recruited subjects completed the study (n=16). The mean age and BMI for 
the study group were 65.9 years (SD 6.0) and 30.6 kg/m2 (SD 3.9), respectively. Mean baseline 
body anthropometry and clinical measures (weight, height; total cholesterol, triacylglycerol, 
systolic and diastolic blood pressure) are presented in Table 4-3. No harms or unintended 
effects were observed through the study. The sample size of some vascular parameters was 
reduced due to experimental error (participant movement during the tests), resulting in n=15 
for PORH and FMD, and n=13 for iontophoresis with acetylcholine. No significant correlations 
were observed between baseline vascular parameters and inflammatory biomarkers (P>0.05) 
(Supplementary material, Table S2). 
 




Age (years) 65.9 (SD 6.0) 
Body weight (kg) 81.5 (SD 10.5) 
Height (cm) 163 (SD 8.7) 
BMI (kg/m2) 30.6 (SD 3.9) 
Total cholesterol (mmol/L) 6.28 (IQR 1.33) 
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Triacylglycerol (mmol/L) 0.94 (IQR 0.84) 
SPB (mm Hg) 120.2 (SD 12.3) 
DPB (mm Hg) 69.3 (SD 7.4) 
Values are means and standard deviation or median and  
interquartile range. SD, standard deviation; IQR,  
interquartile range; DBP, diastolic blood pressure;  
SBP, systolic blood pressure. 
 
Blood pressure, triacylgycerol and cholesterol  
There were significant post-prandial changes on diastolic blood pressure, 
triacylglycerol and total cholesterol across the time points (P<0.05 for time effect), but no 
significant interaction or simple effect of treatment between the intervention and the control 




Table 4-4. Blood pressure, triacylglycerol, total cholesterol and triacylglycerol before and after a high fat high energy meal challenge in 
control and intervention groups. 
Measures Group Baseline 2h 4h Timea Treatmenta Time x treatmenta 
SPB (mm hg) 
Control 118.9 (SD 11.1) 116.3 (SD 12.6) 123.2 (SD 12.8) 
0.001* 0.692 
F(2,30)=0.278, 
P=0.759,  ηp2=0.018 Anthocyanins 118.8 (SD 12.9) 117.7 (SD 10.6) 123.4 (SD 12.4) 
DBP (mm hg) 
Control 70.1 (SD 6.9) 67.4 (SD 7.3) 70.5 (SD 7.6) 
0.002* 0.148 
F(2,30)=1.684, 
P=0.203,  ηp2=1.01 Anthocyanins 68.0 (SD 6.7) 66.6 (SD 5.5) 70.8 (SD 6.6) 
Triacylglycerol 
(mmol/L) 
Control 0.95 (IQR 0.79) 1.30 (IQR 0.96) 2.12 (IQR 1.45) 
>0.001* 0.357 
F(2,30)=0.083, 




Control 6.16 (IQR 1.39) 6.02 (IQR 1.65) 6.09 (IQR 1.26) 
>0.001* 0.756 
F(2,30)=0.648, 
P=0.530,  ηp2=0.041 b Anthocyanins 6.28 (IQR 1.27) 6.40 (IQR 1.16) 6.27 (IQR 1.14) 
Values are mean and standard deviation or median and interquartile range (n=16). SD, standard deviation; IQR, interquartile range; ηp2, partial 
eta-squared, DBP, diastolic blood pressure; SBP, systolic blood pressure. a P-values for two-factors repeated measures ANOVA; b results from 




Postprandial changes (i.e. the difference between baseline and 2h after the HFHE meal) 
in mean FMD were +0.16% in the anthocyanins group and -0.47% in the control group (Table 
4-5). There was a significant treatment effect (P=0.028); however, there was no main effect of 
time (P=0.474) or interaction between treatment and time (P=0.219) (Table 4-5). Dependent 
t-tests showed no significant difference between baseline in FMD results (P=0.212, +4.09% 
SD 1.12 intervention vs 3.58% SD 1.14 control arm) indicating no effect of the 4 day run-in 
period, and a significant difference (P=0.019) of 1.14% in post-prandial FMD among 
treatments (+4.25% SD 1.34 intervention vs 3.11% SD 1.00 control arm), (Figure 4-2a). There 
was no significant interaction between time and treatment nor a significant treatment effect for 




Table 4-5. Vascular and microvascular reactivity parameters before and after a high fat high energy meal challenge in control and intervention 
groups. 
Parameter Group Baseline 2h Timea Treatmenta Time x treatmenta 
FMD (%) 
Control 3.58 (SD 1.14) 3.11 (SD 1.00) 
0.474 0.028 
F(1,14)=1.653, P=0.219, 
ηp2=0.106 Anthocyanins 4.09 (SD 1.12) 4.25 (SD 1.34) 
Peak shear 
rate (sec -1) 
Control 954.7 (SD 344.1) 881.9 (SD 219.6) 
0.091 0.583 
F(1,14)=1.293, P=0.275, 
ηp2=0.085 Anthocyanins 955.5 (SD 324.7) 811.5 (SD 300.5) 
PV (cvc) 
Control 1.20 (IQR 0.37) 1.08 (IQR 0.28) 
<0.001 0.125 
F(1,14)=0.121 P=0.465,  
ηp2=0.036 b  Anthocyanins 1.21 (IQR 0.28) 1.16 (IQR 0.23) 
PORHmax 
(cvc) 
Control 0.85 (IQR 0.28) 0.73 (IQR 0.23) 
<0.001 0.062 
F(1,14)=2.247 P=0.155,  
ηp2=0.130 b Anthocyanins 0.88 (IQR 0.27) 0.83 (IQR 0.21 ) 
IONTmax 
(cvc) 
Control 0.45(SD 0.20) 0.45 (SD 0.25) 
0.748 0.620 
F(1,12)=0.020, P=0.889,  
ηp2=0.002 Anthocyanins 0.43 (SD 0.22) 0.41 (SD 0.22) 
Values are mean and standard deviation or median and interquartile range. FMD,  flow-mediated dilatation; SD, standard deviation; IQR, 
interquartile range; cvc, cutaneous vascular conductance in PU/mmHg; ηp2, partial eta-squared; PV, peak value; PORHmax, post-occlusive 





Figure 4-2. Flow mediated dilatation and microvascular reactivity parameters before and after 
a high fat high energy meal challenge in control and intervention groups (n=15 for panels A, B 
and C, and n=13 for panel D). Values are mean and error bars are standard deviation (A and 
D) or median and error bars are 1st and 3rd quartile (B and C). FMD, flow mediated dilatation; 
PORHmax, post occlusive reactive hyperaemia maximum perfusion; cvc, cutaneous vascular 
conductance in PU/mmHg *P<0.05 (dependent t-test at A and Wilcoxon signed-tank test at C); 






No significant interactions between time and treatment were evident for any parameter 
of the PORH test (Table 4-5). A significant time effect for PV and PORHmax (p<0.001 for 
both parameters) was found, indicating a post-prandial effect of the HFHE meal challenge 
independent of treatment. The treatment effect for PV was not significant (P=0.125) and 
dependent t-tests showed no significant difference resulting from the 4 day run-in period on 
fasting measures (P=0.334, Wilcoxon signed-tank test). There was a trend for a higher post-
prandial PV in the anthocyanins group (p=0.088, Wilcoxon signed-tank test) (Figure 4-2b). 
The parameter PORHmax presented a trend towards a treatment effect (P=0.062) and no 
significant difference carried by the 4 day run-in period in fasting measures (P=0.594, 
Wilcoxon signed-tank test) (Figure 4-2). A significantly higher postprandial PORHmax of 
0.10 PU/mmHg (P=0.049, Wilcoxon signed-tank test) was evident in the anthocyanins group 
compared to the control group (Figure 4-2c). The microvascular reactivity test induced by the 
iontophoresis of acetylcholine showed no significant effects for IONTmax (Table 4-5). There 
was no significant difference between the fasting (P=0.582, dependent t-test) and post-prandial 
(P=0.684, dependent t-test) IONTmax between the treatments (Figure 4-2d). The data used to 
calculate the microvascular parameters are presented in the supplementary material (Table S3). 
 
Inflammatory markers and serum derivatives of reactive oxidative metabolites 
 A significant interaction effect was found for serum hs-CRP (P=0.036) (Table 4-6). 
Corrected pairwise comparisons showed no significant differences between the baseline 
(fasted), 2h and 4h postprandial values for both treatments (P>0.05) (Figure 4-3). However, 
there was a significantly lower hs-CRP concentration 4h postprandially in the anthocyanins 
group when compared to the control arm (P=0.026, Wilcoxon signed-tank test), as well as 
trends in the baseline and in the 2h postprandial time point (P=0.098 and P=0.083, respectively, 
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Wilcoxon signed-tank test) (P=0.095 at baseline P=0.099 at 2h, and P=0.008 at 4h, Wilcoxon 
signed-tank tests) (Figure 4-3).  
There were no significant effects for serum concentration of IL-6, TNF- α and IL-1β 
(Table 4-6). A trend in the treatment effect was evident for IL-6 concentrations (P=0.075). 
There was a significantly lower concentration of IL-6 at the 4h post-prandial time point in the 
anthocyanins group when compared to the control group (P=0.009, Wilcoxon signed-tank test) 
(Figure 3). There was no significant difference evident following the 4 day run-in period in 
fasting concentrations for any of the inflammatory biomarkers between groups (P>0.05, 
dependent t tests) (Figure 4-3).  
There was a significant effect of time (P=0.002) in serum concentrations of DROM, 
however, no significant treatment or interaction effect was evident (P>0.05) (Table 4-6).  
 
Urinary excretion of total anthocyanins and phenolic acids 
The 24h concentration of total anthocyanins in the urine was higher in the intervention 
arm 1.86 ng/mL (IQR 3.23) than the control arm 0.015 ng/mL (IQR 0.12) following the HFHE 
meal challenge (P<0.001 ) (Table S4, Supplementary material). Concerning anthocyanins 
metabolites, there were significantly higher concentration of hippuric acid in the urine for 
participants within intervention arm versus the control (P=0.027), while no significant 
differences were observed for protocatechuic acid and ferulic acid. 
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Table 4-6. Serum concentration of inflammatory biomarkers and derivatives of reactive oxidative metabolites before and after a high fat 
high energy meal challenge in control and intervention groups. 
Parameter Group Baseline 2h 4h Timea Treatmenta Time x treatmenta 
hs-CRP 
(mg/L) 
Control 2.30 (IQR 1.95) 2.40 (IQR 2.05) 2.30 (IQR 1.95) 
0.299 0.094 
F(2,30)=3.763, 
P=0.036,  ηp2=0.212b Anthocyanins 1.70 (IQR 1.00) 1.70 (IQR 0.95) 1.80 (IQR 0.90) 
IL-6 
(pg/mL) 
Control 5.95 (IQR 4.20) 5.40 (IQR 3.70) 5.98 (IQR 4.73) 
0.436c 0.075 
F(2,30)=0.635, 
P=0.537,  ηp2=0.041 Anthocyanins 6.00 (IQR 8.83) 5.85 (IQR 6.45) 5.55 (IQR 5.48) 
TNF-α 
(pg/mL) 
Control 13.65 (IQR 10.65) 12.45 (IQR 9.25) 12.53 (IQR 9.89) 
0.277 0.987 
F(2,30)=0.868, 
P=0.430,  ηp2=0.055 Anthocyanins 13.65 (IQR 8.88) 14.30 (IQR 7.95) 13.10 (IQR 7.33) 
IL-1β 
(pg/mL) 
Control 1.60 (IQR 1.39) 1.55 (IQR 1.65) 1.55 (IQR 1.26) 
0.896 0.868 
F(2,30)=1.436, 
P=0.254,  ηp2=0.087 Anthocyanins 1.20 (IQR 1.15) 1.40 (IQR 1.10) 1.45 (IQR 1.28) 
DROM 
(cu) 
Control 487.3 (SD 77.6) 497.1 (SD 81.1) 502.6 (SD 68.3) 
0.002 0.298 
F(2,30)=0.752, 
P=0.480,  ηp2=0.048 Anthocyanins 473.1 (SD 75.5) 496.4 (SD 77.0) 496.5 (SD 78.6) 
Values are mean and standard deviation or median and interquartile range. hs-CRP, high-sensitivity c-reactive protein; IQR, interquartile range; 
ηp2, partial eta-squared, IL-6, interleukin-6; TNF-α. Tumour necrosis factor alpha; IL-1β, interleukin-1 beta; DROM, derivatives of reactive 
oxidative metabolites; cu, Carratelli units SD, standard deviation. a P-values for two-factors repeated measures ANOVA; b results from log 




Figure 4-3. Serum concentration of inflammatory biomarkers before and after a HFHE meal 
challenge in control and intervention groups (n=16). Values are median and error bars are 1st 
and 3rd quartile. hs-CRP, high-sensitivity c-reactive protein, IL, interleukin, TNF, tumour 
necrosis factor. *P<0.05 (Wilcoxon signed-tank test); † P=0.095 at 0h and P=0.099 at 2h 
(Wilcoxon signed-tank tests). 
 
4.4 Discussion 
The intake of food anthocyanins with a HFHE meal challenge was able to attenuate the 
potential detrimental effects on both vascular and microvascular function, and on the 
inflammatory response. Compared to the control arm, participants had a significant higher 
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postprandial FMD and some of the parameters of microvascular function, and significant lower 
concentration of postprandial hs-CRP, with a trend for lower IL-6 levels when allocated in the 
anthocyanins intervention arm. Several outcomes presented a significant time effect from the 
fasted state to the post-prandial measures, confirming that a single HFHE meal is a sufficient 
challenge to induce some negative vascular and inflammatory responses that are not apparent 
in the fasted state. Importantly, our findings indicate that food-based anthocyanins may confer 
protection against cardiovascular and inflammatory insults caused by a typical HFHE 
‘Western’ diet in older overweight, though otherwise healthy, adults.  
The endothelium plays a major role in vascular homeostasis and its implications in the 
development of atherosclerosis and CVD are well established(288,289). Flow-mediated 
dilatation is a non-invasive measurement of endothelium function that has been associated with 
CVD risk prediction(243,274). A meta-analysis of 23 studies, including 14,753 subjects, found 
an overall 8 % reduction in CVD risk (RR= 0.92; 95%CI: 0.88; 0.95) for each percentage 
increase in FMD(274). In the present study, food anthocyanins induced a slightly increase in 
the postprandial FMD, while a decline was observed in the control arm. Participants had a 
1.14% higher post-prandial FMD when allocated in the anthocyanins intervention. The ability 
of anthocyanins to prevent the reduction in FMD caused by a HFHE meal challenge suggests 
that there are benefits for cardiovascular health in older adults that consume a high fat diet; 
however, the extrapolation of such results has to be cautious, considering the difference 
between FMD assessed in the fasted and in the postprandial state are still not elucidated. 
Although a 1.14% change may be considered small in healthy, normal weight young adults, 
this magnitude of effect is of higher clinical significance for individuals in the present study, 
who had a BMI >30kg/m2 and were aged >65 years, two factors related to impaired brachial 
artery FMD(42,284,290). In the current study, the postprandial difference of 1.14% represents 
a 36.7% higher FMD in the anthocyanin compared to the control arm. Similar findings were 
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observed in a double-blind, randomized, crossover study (conducted in 23 male participants, 
aged 46y SD 1.9, BMI of 27.6 kg/m2 SD 0.4) that investigated postprandial effects of an açaí 
smoothie following a HFHE meal challenge compared to a control smoothie matched by 
macronutrients and vitamin C(229). In that study, the intervention arm was provided more than 
a twofold (493mg) quantity of anthocyanins than that provided in the current trial but a similar 
improvement was observed in postprandial FMD after 2h (1.4% vs 0.4% for intervention vs 
control smoothie; P = 0.001)(229). The immunomodulatory(21,23) and antioxidant 
effects(23,125,268,271) of anthocyanins, as well as their capacity to upregulate eNOS mRNA 
and NO synthesis(126,144,269,270), are the proposed mechanisms to exert this vascular 
protective effect against the potential pro-inflammatory and oxidative stress state caused by the 
HFHE meal. However, NO is a highly reactive molecule with a short half-life, which 
complicates its direct measurement(291), and the  evaluation and implication of its metabolites 
remains challenging in vascular biology research(292). Concerning the peak shear rate, there 
were no significant changes between treatment arms before and after the HFHE meal challenge. 
Participants had an identical peak shear rate before the HFHE meal, followed by a slightly 
postprandial decrease in both conditions. 
 In additional to effects on macrovascular function, we observed significant changes for 
microvascular reactivity tests. Flow-mediated dilatation and PORH both rely on measuring the 
transient increase in blood flow following the release of a brief occlusion; however, while FMD 
assesses changes in diameter of the brachial artery induced by shear stress in the artery 
wall(293), PORH assesses the cutaneous perfusion in the microvasculature, in this case in areas 
of the skin of the forearm(96). In the present trial, both the PV and PORHmax parameters were 
reduced after the high-fat meal challenge in both groups, but there was a significantly lower 
reduction when anthocyanins were consumed with the meal, indicating a preventative effect of 
anthocyanins in HFHE meal-induced changes in these parameters. Unlike FMD, the effects of 
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anthocyanin consumption on LSCI microvascular parameters and CVD outcomes have not yet 
been explored in larger studies. To our knowledge, this is the first study to report the results of 
LSCI microvascular parameters along with FMD following a dietary intervention. Our findings 
suggest that underlying mechanisms associated with the observed effects might be due to 
common mechanisms between different vascular beds. The mechanisms underlying the 
vascular reactivity in the PORH test are still being elucidated, but many mediators seems to 
contribute to vasodilation and although most of these responses are endothelial-dependent, NO 
and COX pathways do not appear to exert significant influences(102,103). The major 
contributors for peak and time course of this microvascular reactivity are the sensory nerves 
through an axon reflex response(95). The endothelium-derived hyperpolarizing factors 
(EDHF) are also involved, including large-conductance calcium-activated potassium channels 
(BKCa) stimulated by epoxyeicosatrienoic acids(93,104). Therefore, we also utilised LSCI 
technology with iontophoresis of acetylcholine to assess a more specific endothelial 
microvascular reactivity response related to NO availability(96). However, the cutaneous 
perfusion following iontophoresis of acetylcholine was not altered in either of the study arms. 
This may be in keeping with the finding that the NO response associated with endothelial 
function decreases with age, while other pathways are preserved(294–296).  
The inflammatory response is a fundamental component of atherosclerosis and is 
related to the development of CVD,(190,277) with low grade continuous inflammation 
occurring in association with adiposity(297) and aging (“inflammaging”)(298).  Higher pro-
inflammatory cytokine concentrations are also associated with decreased health-related quality 
of life in older adults(299). For these reasons, the target population for the current study was 
older adults who were overweight or obese. The ability to suppress a persistent inflammatory 
state is important to attenuate the progress of  atherosclerotic disease(277,278). A large number 
of in vitro and animal studies(21,121,127,139) provide insight into these mechanisms related 
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to the anti-inflammatory actions of anthocyanins. These include: (1) modulation of arachidonic 
acid metabolism, in which lipid mediators that regulate inflammation (e.g.  prostaglandins and 
leukotrienes) are modulated by anthocyanins through inhibition of the key enzymes 
cyclooxygenases and lipoxygenases; (2) decreased activity of the NF-κB pathway, which is a 
transcription factor responsible for triggering and regulating inflammatory processes that lead 
to the expression of pro-inflammatory cytokines and enzymes; (3) suppression of acute pro-
inflammatory genes that regulate inducible nitric oxide synthase (iNOS), an enzyme 
responsible for moderating some of the production of nitric oxide (NO). hs-CRP has emerged 
as a major marker of vascular inflammation playing a direct role in promoting endothelial 
dysfunction(65,66) and clinical CVD events(67,68,297). In the present trial, we found a 
significant interaction effect between time and treatment for serum hs-CRP. Breaking down 
this simple effect, we showed no significant influence of time and a significantly lower hs-CRP 
concentration at the 4h post-prandial time point in the anthocyanin arm, as well as a trend for 
lower concentrations at the fasted state and at the 2h post-prandial time point. An ability of 
food-based anthocyanins to reduce hs-CRP concentrations in a population with risk factors 
such as advanced age and high BMI, could be of major clinical benefit regarding attenuation 
of the “inflammaging” process and chronic low-grade inflammation.  
A systematic review of the literature examining the postprandial inflammatory response 
to a HFHE meal challenge reported consistent robust increases in IL-6 across studies, while 
IL-1β and TNF-α did not appear to transiently and/or robustly change in the postprandial 
period(244). Among the six studies(37,231,233–236) that evaluated the effect of food 
anthocyanins on post-prandial IL-6  concentrations, three studies(37,231,236) reported 
significant reductions in postprandial concentrations when compared to the control group. In 
the present trial, no significant main or simple effects were evident for serum concentration of 
IL-6; however, a trend was observed in the main effect of treatment, as well as significantly 
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lower IL-6 concentration at the 4h post-prandial time point (P=0.009). IL-6 has a high 
expression on vascular endothelium(64)  and although IL-6 possess both pro- and anti-
inflammatory properties(300), it is an independent contributor to variations in endothelium-
dependent vasodilatation(301). Our results demonstrate changes associated with food-based 
anthocyanins on hs-CRP and IL-6 concentrations, which combined could indicate reduced 
vascular inflammation. Such findings may have positive implications in the progression of 
atherosclerosis and CVD events in this high risk group. Further studies are required to better 
elucidate the different clinical implications between fasted and post-prandial serum 
concentration of such biomarkers. Similar to other studies(244), serum concentrations of IL-
1β and TNF-were not altered after the HFHE meal challenge by any treatment. Only a small 
number of studies (one(231) out of four(37,231,233,234)) that investigated TNF-α response to 
a meal challenge found that the anthocyanins prevented a postprandial rise of concentrations, 
while no significant effects were found for IL-1β in these studies(37,231,233,234).  
Serum DROM was evaluated in the present trial as a marker of oxidative stress. DROM 
is increased in patients with coronary artery disease and is also associated with cardiovascular 
events, thus could provide clinical benefits for risk stratification of coronary artery disease 
where higher DROM place a person at greater risk(302). We found a significant time effect in 
serum concentrations of DROM, indicating postprandial oxidative stress induced by the HFHE 
meal; however, no significant difference between treatment arms was found. This same 
response was observed for systolic and diastolic blood pressure, as well for total cholesterol 
and triacylglycerol. Similar to our findings, no significant changes in postprandial systolic 
blood pressure were reported in 3 studies(229,238,239) following a food anthocyanin 
intervention, except for one study that found a reduction in diastolic blood pressure(239). A 
large number of studies(231–240) that evaluated postprandial total cholesterol and 
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triacylglycerol also reported no changes, while only two studies found a reduction in 
triacylglycerol(233,239) concentrations and total cholesterol(231,239). 
The urinary analyses demonstrated higher concentrations of total anthocyanins and 
hippuric acid biomarkers in 24h urine following consumption of the intervention and control 
juices, confirming the uptake and metabolism of these compounds from the anthocyanin-rich 
plum juice. The absence of anthocyanins in the urine corresponding to the control arm confirms 
the anthocyanins dietary restriction during the 4-day run-in period, the lack of anthocyanins in 
the control juice, as well as a sufficient wash-out period. A large variation in the excretion of 
both anthocyanin and phenolic acid biomarkers reflects the large intra-individual variation in 
the metabolism of anthocyanins and flavonoids46,85. The lack of significant difference between 
the arms for protocatechuic acid and ferulic acid may reflect the potential presence of other 
flavonoids in the background diet and in the control (apricot) juice. 
Limitations in the present study include the different numbers of females and males 
enrolled, thus precluding sub-analysis by gender; however, the small number of males included 
in the study had similar scores to females and the exclusion of them for sensitivity analyses did 
not alter the significance of any of the results. A further limitation was the impossibility to 
repeat the FMD and microvascular reactivity tests in case of experimental errors (participant 
movement during the tests) due to the protocol of measures being collected at specific time 
points. This resulted in a small sample size reduction for the FMD and PORH test (n=1) and 
the iontophoresis of acetylcholine (n=3). Concerning the evaluation of endothelium and non-
endothelium mechanisms in vascular and microvascular reactivity, we were not able to conduct 
nitrate-mediated dilation nor iontophoresis of sodium nitroprusside due to temporal reasons, 
considering it would be not viable, if not impossible, in a postprandial study to conduct a 
protocol with all of these measures. Discussion of the results is therefore based on the tests that 
were conducted and the elucidated underlying mechanisms described in the literature. Another 
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limitation is that there were no measures before the start of the 4 day run-in period, and despite 
that there was no significant difference in baseline, the 4 day run in period might have 
modulated a few parameters in the anthocyanins group, and therefore facilitating the significant 
post-prandial difference between the treatment arms. On the other hand, this design simulates 
a daily diet routine, in which individuals could be constantly eating random sources of 
anthocyanins, or still consuming supplements or food items on a daily basis that continuously 
exposes them to many bioactive compounds. This allowed us to investigate the postprandial 
effect of a continuous anthocyanins stimulus, while at the same time, avoid an overestimated 
effect in a ‘super controlled’ setting. 
An important strength and key feature in the design of this study should be considered 
for interpretation of the results, as well as for comparison with other post-prandial studies. It is 
challenging to investigate a specific bioactive compound, such as a specific flavonoid, in a 
clinical trial using foods as vehicles for delivery. A food item that is a rich source of a particular 
flavonoid may also contain other classes of flavonoids or still other bioactive compounds, such 
as other polyphenols, and/or inorganic compounds (such as nitrate) that might have similar or 
synergistic effects on the outcomes to those being assessed. In order to address this issue, the 
choice of the placebo food item for the control arm is an important consideration. A placebo 
that is only matched in macro, or even micronutrient content, can underestimate the effects of 
other bioactive compounds. In this study, we aimed to evaluate the acute effect of a high dose 
of anthocyanins using Queen Garnet plum juice as the food source. In order to isolate the effect 
of the anthocyanins, we chose apricot juice as the control due to its lack of anthocyanins, but 
its similarly matched macro- and micronutrient content, as well as its polyphenol profile(281), 
that includes flavanols (such as quercetin), catechins and epicatechins, all of which are potential 
mediators of cardiovascular health(200,303–305). The choice of this control juice is novel in 
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The postprandial effects of food anthocyanins improved several CVD biomarkers in 
overweight older adults following a HFHE meal challenge. Potentially beneficial effects were 
observed in parameters of both macrovascular and microvascular function, as well as some 
inflammatory biomarkers. The HFHE meal challenge induced increases in postprandial blood 
pressure, DROM, triacylglycerol and total cholesterol; however, anthocyanin consumption did 
not attenuate these responses. Our findings may have a relevant role in the cardiovascular 
health of this high-risk group considering the major role of the vascular endothelium and the 
inflammatory response in the atherosclerosis disease and CVD events. Further studies are 
required to better elucidate the clinical implications of post-prandial biomarkers of CVD. 
 








Figure 4-S1. Cutaneous perfusion recorded with laser speckle contrast imaging during post-
occlusive reactive hyperaemia. 























Table 4-S1. Description of Post-Occlusive Reactive Hyperaemia Microvascular Parameters  
MICROVASCULAR PARAMETER DESCRIPTION 
Baseline flow (BF) 
The most stable 15 seconds within the first 2 
minutes of reading. 
Biologic zero (BZ) 
The most stable 3 seconds displaying the lower 
values before the deflation of the cuff. 
Resting flow (RF) BF-BZ 
Peak perfusion value (PV) 
Five seconds period starting from the highest 
value in the first rise (slope) after deflation of 
the cuff 
PORHmax PV – RF 
Area under the curve (AUC) 
Area under the curve comprising of 60 seconds 
after deflation of the cuff 
PORHmax, post-occlusive reactive hyperaemia maximum perfusion. 
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Table 4-S2. Correlations between baseline vascular parameters and inflammatory biomarkers 
 










Correlation Coefficient 1.000 .505 .594 -.265 -.052 -.032 -.480 .272 .324 
Sig. (2-tailed) . .046 .015 .341 .849 .905 .114 .326 .238 
N 16 16 16 15 16 16 12 15 15 
IL-6 
Correlation Coefficient .505 1.000 .469 .039 -.043 .018 .161 .220 -.334 
Sig. (2-tailed) .046 . .067 .889 .875 .948 .618 .431 .223 
N 16 16 16 15 16 16 12 15 15 
TNF-α 
Correlation Coefficient .594 .469 1.000 -.136 -.026 .021 -.469 .121 .007 
Sig. (2-tailed) .015 .067 . .629 .922 .940 .124 .666 .980 
N 16 16 16 15 16 16 12 15 15 
hs-CRP 
Correlation Coefficient -.265 .039 -.136 1.000 .434 .209 .123 .064 -.007 
Sig. (2-tailed) .341 .889 .629 . .106 .454 .719 .829 .982 
N 15 15 15 15 15 15 11 14 14 
Peak 
value 
Correlation Coefficient -.052 -.043 -.026 .434 1.000 .944 .336 .461 .346 
Sig. (2-tailed) .849 .875 .922 .106 . .000 .286 .084 .206 
N 16 16 16 15 16 16 12 15 15 
PORH
max 
Correlation Coefficient -.032 .018 .021 .209 .944 1.000 .413 .421 .211 
Sig. (2-tailed) .905 .948 .940 .454 .000 . .183 .118 .451 
N 16 16 16 15 16 16 12 15 15 
IONT
max 
Correlation Coefficient -.480 .161 -.469 .123 .336 .413 1.000 -.247 a -.443 a 
Sig. (2-tailed) .114 .618 .124 .719 .286 .183 . .464 .172 
N 12 12 12 11 12 12 12 11 11 
FMD 
Correlation Coefficient .272 .220 .121 .064 .461 .421 -.247 a 1.000 .286 a 
Sig. (2-tailed) .326 .431 .666 .829 .084 .118 .464 . .301 
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Correlation Coefficient .324 -.334 .007 -.007 .346 .211 -.443 a .286 a 1.000 
Sig. (2-tailed) .238 .223 .980 .982 .206 .451 .172 .301 . 
N 15 15 15 14 15 15 11 15 15 
IL-1β, interleukin-1 beta; IL-6, interleukin-6; TNF-α. Tumour necrosis factor alpha; hs-CRP, high-sensitivity c-reactive protein; PORHmax, 
post-occlusive reactive hyperaemia maximum perfusion; IONTmax, maximum perfusion following iontophoresis of acetylcholine; FMD,  flow-
mediated dilatation. 
All correlations derived from Spearman's rank correlation coefficient, unless described elsewhere.  
a Correlations derived from Pearson correlation coefficient. 
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Table 4-S3. Additional data from microvascular parameters 
Parameter Group Baseline 2h 
PORH PV 
(PU) n=15 
Control 103.7 (SD 14.1) 88.5 (SD 14.5) 
Anthocyanins 105.3 (SD 17.1) 91.3 (SD 12.6) 
PORH BF 
(PU) n=15 
Control 42.5 (SD 5.6) 42.5 (SD 6.7) 
Anthocyanins 42.6 (SD 7.5) 42.2 (SD 9.7) 
PORH BZ 
(PU) n=15 
Control 16.2 (SD 6.0) 15.9 (SD 5.3) 
Anthocyanins 15.0 (SD 4.6) 16.8 (SD 6.2) 
PORH RF 
(cvc) n=15 
Control 0.31(SD 0.07) 0.32 (SD 0.07) 
Anthocyanins 0.32 (SD 0.05) 0.31 (SD 0.08) 
IONT BF 
(cvc) n=13 
Control 0.35 (SD 0.08) 0.36(SD 0.11) 
Anthocyanins 0.33 (SD 0.07) 0.33 (SD 0.08) 
IONT PV 
(cvc) n=13 
Control 0.80(SD 0.23) 0.80(SD 0.28) 
Anthocyanins 0.75 (SD 0.26) 0.74 (SD 0.24) 
AUC (PU) 
n=14 
Control 3968.7 (SD 437.4) 3731.3 (SD 493.3) 
Anthocyanins 3941.5 (SD 591.9) 3783.9 (SD 542.5) 
AUC (cvc) 
n=14 
Control 0.0216 (SD 0.004) 0.0222 (SD 0.003) 
Anthocyanins 0.0218 (SD 0.003) 0.228  0.003) 
Data are mean and standard deviation or median and interquartile range. PORH, post-
occlusive reactive hyperaemia; PU, perfusion units, BF, baseline flow; RF, resting flow; IQR, 
interquartile range; cvc, cutaneous vascular conductance in PU/mmHG; BZ, biologic zero; 








Table 4-S4. Urinary concentrations of total anthocyanins and phenolic acid biomarkers from 
a 24-hour pooled urine sample from the control and intervention arms. 



































P=0.733,  ηp2=0.008 
Values are mean and standard deviation (SD) or median and interquartile range (IQR) 
a P-values from repeated measures ANOVA; ηp2, partial eta-squared;   












CHAPTER 5: Food anthocyanins decrease serum concentrations 
of TNF-α in older adults with mild cognitive impairment: a 
randomized, controlled, double blind clinical trial. 
 
There are still several gaps to be addressed regarding the effects of anthocyanins on the 
vascular-inflammatory axis in older adults, especially among those with neurodegenerative 
diseases, such as mild cognitive impairment (MCI), a condition that shares pathological 
mechanisms with CVD. This is particularly evident in older adults, as several studies support 
a gradual loss of the vascular function, and a new immune-metabolic viewpoint for age-related 
diseases, termed ‘inflammaging’ which is characterized by a chronic low-grade inflammation. 
Therefore, the present trial aimed to evaluate the chronic effects of food anthocyanins (8 weeks) 
on the microvascular function, inflammatory biomarkers and 24 h ambulatory blood pressure 
(ABP) in older adults with diagnosis of MCI. 
A daily high dose of fruit-based anthocyanins (201 mg) for 8 weeks reduced concentrations 
of TNF-α in older adults with MCI. Anthocyanins did not alter other inflammatory biomarkers, 
microvascular function or blood pressure parameters, while an overall lack of effects were 
observed in the low dose (47 mg) group. 
Considering the major role of the inflammatory response and vascular function in CVD and 
cognitive decline, this novel data may present relevant clinical implications in this high-risk 
group; however, further studies with a larger sample size and longer period of follow-up are 
required to better elucidate whether these changes in inflammatory biomarkers will alter CVD 
risk and progression of cognitive decline. 





Vascular function, blood pressure and inflammation are a triad of factors relevant to the 
pathogenesis of several major chronic diseases, including cardiovascular disease 
(CVD)(306,307), and neurodegenerative conditions, such as mild cognitive impairment 
(MCI)3,4. The endothelium can be considered an organ that regulates vascular homeostasis by 
maintaining an appropriate vascular tone, platelet activity, leukocyte adhesion, and 
angiogenesis. When one or more of these components is compromised due to impaired 
endothelial vascular signalling, endothelial dysfunction (ED) may occur(306). In addition to 
hypertension and ED, the inflammatory response mediates several CVD related underlying 
mechanisms5,6. The association between concentrations of pro-inflammatory cytokines, such 
as CRP, IL-6 and TNF-α, and the development of atherosclerosis and CVD is well 
established5,7. There is evidence to suggest that directly targeting inflammation may be 
beneficial for the secondary prevention of CVD, and that such benefits may be independent of 
traditional CVD risk factors, such as cholesterol8,9. The role of inflammatory cytokines 
provides a mechanism through which risk factors for atherosclerosis may alter arterial biology, 
and thereby result in a systemic pro-atherothrombotic milieu8. This is particularly evident in 
older adults; several studies support a new immune-metabolic viewpoint for age-related 
diseases termed ‘inflammaging’, characterized by a chronic, low-grade inflammatory 
response10,11. Furthermore, there is evidence that diseases of the cardiovascular system, such 
as stroke, atrial fibrillation, coronary heart disease (CHD), and heart failure are linked to 
cognitive decline12. A meta-analysis of 10 prospective cohort studies showed that CHD was 
associated with increased risk of cognitive impairment or dementia (OR = 1.45, 95%CI = 1.21–
1.74, p<0.001)13. Several mechanisms underlying the association between CVD and cognitive 
decline have been proposed: [1] shared risk factors, which might alter clearance of brain toxins 
or otherwise increase neurodegeneration; [2] CVD might lead to clinical or subclinical strokes, 
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leading to cognitive impairment; and [3] CVD might directly alter cerebral perfusion14. In this 
context, interventions aiming to regulate the CVD risk factors are also relevant therapeutic 
targets to attenuate cognitive decline. 
Potential nutritional therapeutic options are emerging, with anthocyanins, a subclass of 
flavonoids, showing promising benefits related mainly to immunomodulatory, vascular 
signalling and antioxidant effects(21), thereby blunting the cooperative and synergistic 
deleterious effects of oxidative stress and inflammation5,16.  Anthocyanins are the largest class 
of water-soluble plant  pigments that are responsible for the blue, purple and red colour of many 
fruits and vegetables, such as blueberries,  blackberries, red grapes, plums and eggplants17. A 
large number of in vitro and animal studies(21,317–319) provide insight into these mechanisms 
related to the anti-inflammatory actions of anthocyanins.  These studies also observed a 
potential positive effect on vascular function through the suppression of acute pro-
inflammatory genes that regulate inducible nitric oxide synthase (iNOS), an enzyme 
responsible for moderating some of the production of nitric oxide (NO)21, as well as attenuating 
endothelium‐dependent dysfunction by anthocyanins metabolites20.A meta-analyses of 
randomized clinical trials (RCT) observed an improvement in vascular reactivity measured by 
flow-mediated dilation (FMD) among 6 studies ranging from one week to six months of 
intervention, with anthocyanin daily doses of 12 to 320mg22. Concerning lipid profiles and 
blood pressure, a systematic review of 12 RCT (3-24 weeks of duration and dose range of 7.35–
640 mg/day of anthocyanins) identified a significant effect only on lowering LDL-c among 
diseased individuals or those with elevated biomarkers23.  Both reviews22,23 did not find a dose-
response relationship in the cited RCTs, nor evidence of  adverse effects of anthocyanins within 
those concentrations. Therefore, the relevant concentration of anthocyanins required to produce 
physiologically relevant is still to be elucidated. 
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Among non-invasive techniques to measure endothelial function, Laser Speckle 
Contrast Imaging (LSCI) is a relatively new technique that provides a non-invasive index of 
blood flow in the microcirculation24. This technique, combined with dynamic tests such as 
post-occlusive reactive hyperaemia (PORH), is able to provide information on several different 
aspects of microvascular physiology25. Measuring 24-hour ambulatory blood pressure (ABP) 
has several benefits over traditional single assessment, such as minimising white-coat 
phenomena and masked hypertension, and demonstrating nocturnal hypertension and loss of 
normal dipping patterns26. ABP monitoring is a stronger predictor of cardiovascular morbidity 
and mortality than most traditional BP measuring techniques26–28. 
This paper provides secondary analysis of a clinical trial that investigated the effect of 
combining a cognitive training rehabilitation program with a dietary intervention focusing on 
increasing anthocyanin intake in older persons with MCI.  The aim of the current analysis is to 
investigate the effects of a nutritional intervention consisting of 8 weeks of food-anthocyanins 
on inflammatory markers associated with CVD risk factors(277,278), along with analysis of 
microvascular function and 24-hour ABP in older adults with MCI.  
 
5.2 Methods 
The clinical trial was conducted according to the guidelines of the Declaration of 
Helsinki, and approved by the joint University of Wollongong and Local Health District 
Human Research Ethics Committee, New South Wales, Australia (HREC 2017/581). The study 
was registered with the Australian New Zealand Clinical Trials Registry 
(ACTRN12618001184268). This manuscript is reporting results from the secondary outcomes, 
while the primary outcome related to cognitive function will be reported elsewhere. Written 





A total of 34 subjects enrolled in the study between April 2018 and November 2019. 
The inclusion criteria were: 55+ years; diagnosis of MCI-amnesic type with memory 
complaints, Mini Mental State Examination (MMSE) score of 24 or above, and estimated 
premorbid IQ of more than 80, confirmed by clinical psychologists (ZF, SB, AP). A diagnosis 
of MCI was given when an individual experienced cognitive change (typically 1 to 1.5 standard 
deviation below age and education matched peers on culturally appropriate normative data) in 
one of more cognitive areas that are insufficient to interfere with activities of daily living and 
without progressive deterioration. All subjects were participating in a 6 week ‘Making the most 
of your Memory’ rehabilitation group.  Exclusion criteria were: a diagnosis of dementia; 
significant neurological history, untreated hypertension or diabetes; chronic liver or renal 
disease; smoking; diagnosis or self-reported gastrointestinal disorders; acute upper respiratory 
tract infection; allergy to stone fruits or food colorants.  
 
Study Design and Treatments 
The study was a randomized, controlled, double-blind clinical trial conducted at the 
Illawarra Health and Medical Research Institute and at the Port Kembla Hospital, NSW 
Australia. On test days, participants attended the research facility for the study procedures after 
a 12 hour overnight fast (Figure 5-1). Briefly, the PORH test (microvascular reactivity) and 
blood collection were completed before provision of a standardized breakfast (minimal 
anthocyanin-containing cereals, milk, bread, butter and anthocyanin-free fruit jam), followed 
by collection of data including socio-economic status, anthropometry, medication use and 
dietary intake.  
The  usual diet was assessed using a 3-day food record that participants were instructed by a 
dietitian to complete at home (Table 5-1) and analysed using Foodworks 10 (Xyris Software, 
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Australia), which includes the Australian Food Composition Database 2019(325). The 
anthocyanins content was calculated using the ‘PhenolExplorer’ polyphenol food composition 
database(206). Participants were instructed to maintain their usual diet throughout the course 
of the study. 
Participants were fitted with a 24-hour ambulatory blood pressure monitor which was 
collected from their home the following day. Participants were randomly allocated to one of 
three dietary interventions (250 ml/day): a) low-anthocyanins Queen Garnet Plum (QGP) juice; 
b) high-anthocyanins QGP juice; c) apricot juice (control). Juice was supplied weekly to 
participants when they attended the memory clinic. The duration of the dietary intervention 
was 8 weeks, after which time participants returned to the research facility for the final data 
collection. Compliance was measured by requesting the empty bottles from participants. 
Block randomization (3x3) was conducted by a researcher independent to the data 
collection or enrolment of participants using a computer generated randomization sequence. 
Blinding strategies included colouring of control juice, as well as advertising and consenting 





Figure 5-1. Study design and procedures. PORH, post-occlusive reactive hyperaemia; ABP, 
ambulatory blood pressure; QGP queen garnet plum. 
 




















Protein (g) 103.2 SD 38.6 95.0 SD 28.6 88.9 SD 10.5 97.7 SD 31.3 0.634 
Fat – total (g) 86.7 SD 35.9 72.1 SD 26.4 72.8 SD 17.5 79.3 SD 30.1 0.453 
Saturated fat (g) 35.9 SD 18.1 29.8 SD 13.0 31.0 SD 8.6 33.0 SD 14.9 0.608 
Carbohydrates (g) 227.3 SD 79.9 239.4 SD 52.0 236.4 SD 32.3 233.0 SD 62.9 0.900 











Vitamin C (mg) 90.4 IQR 99.9 76.1 IQR 59.7 
101.7 IQR 
122.5 
86.7 IQR 85.6 0.546 
Vitamin E (mg) 9.6 IQR 5.4 8.2 IQR 6.3 8.3 IQR 1.5 9.0 IQR 4.8 0.441 










2.7 IQR 22.5; 
13.9 SD 22.9 
3.6 IQR 17.8; 
68.1 SD 188.3 
1.4 IQR 5.4; 
73.3 SD 101.5 
43.1 IQR 82.8; 
43.1 SD 114.2 
0.426 
Values are mean and standard deviation or median and interquartile range. aP-value for one-way 
ANOVA among the three treatments; * Total Vitamin A equivalents. Values obtained from the 
Australian Food Composition Database 2019(325). Anthocyanins content values obtained from the 
‘PhenolExplorer’ polyphenol food composition database(206). 
 
Intervention and control juices 
 The low-anthocyanins QGP juice consisted of 99% fruit and 1% water that went 
through a high pressure-low temperature treatment. The high-anthocyanins QGP juice was a 
blend of 220g of frozen QGP with 30mL of water added. The anthocyanin content of both 
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juices were analysed by the Queensland Department of Agriculture and Fisheries (DAF, 
Australia) by Performance Liquid Chromatography (HPLC) and the pH differential method, 
following the AOAC 2005.02 protocol. An apricot juice was chosen as the control arm due to 
similar consistency, nutritional content and flavonoid content(282) to the QGP juice, but 
without anthocyanins. Food dyes (red and blue) were added to the apricot juice to closely 
approximate the colour of the QGP juice. The total anthocyanins content for the 250 mL bottle 
of low-anthocyanins QGP juice was 48 mg based on the HPLC method and 44 mg based on 
the pH differential method, while the total anthocyanins content for the 250 mL bottle of 
untreated QGP juice was 201 mg based on the HPLC method and 207 mg based on the pH 
differential method. Additional nutritional information of the fruit juices can be found in the 
supplementary material (Table 5-S1). 
 
Blood samples 
Pre and post (baseline and 8 weeks) fasted plasma and serum samples were collected 
in the morning, following the microvascular reactivity test, and then stored at -80 °C, prior to 
analysis. IL-1β, IL-6 and TNF-α were analysed in a Luminex 200 using a Human High 
sensitivity T cell magnetic bead panel kits (Merck Millipore, Billerica, MA, USA). High 
sensitivity CRP was analysed on a BK400 automated chemistry analyser using a 
immunoturbidometric assay (Biobase, Shandong, China).  
 
24-hour ambulatory blood pressure 
The 24-hour ambulatory blood pressure was measured using an automated Welch Allyn 
ABPM 7100 (Welch Allyn, NSW, Australia). Participants were fitted with the device and 
appropriate instructions were provided(322). Participants were asked to record any moderate 
or intense physical activity. Criteria for measurements errors include the exclusion of the 
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following measures: 70 mmHg ≤ SBP ≤ 250 mmHg and 30 mmHg ≤ DBP ≤ 130 mmHg. 
Daytime blood pressure was defined as 09-21h and night-time as 11-05h. The “dipping” pattern 
was calculated using a ratio of night-time/daytime blood pressure(322). 
 
Microvascular function 
 Participants were rested in a quiet, controlled temperature room 23 °C ±1, in a supine 
position for 15 minutes. Blood pressure was measured before the PORH test procedure using 
a Welch Allyn Connex 6700 Vital Signs Monitors (Welch Allyn, NSW, Australia), according 
to clinical guidelines(283). Microvascular cutaneous vascular reactivity was measured by using 
LSCI (Pericam PSI System, Perimed AB, Järfälla, Sweden), The baseline perfusion was 
measured in the volar side of the left forearm for 2 minutes, followed by the PORH test: an 
arterial occlusion was maintained for 3 minutes using a BP cuff around the upper arm inflated 
to a pressure of 50-60 mmHg above systolic BP reading; after the BP cuff was released, the 
PORH response was recorded for 3 minutes. The following parameters were extracted: baseline 
flow (BF), biological zero (BZ) and peak value (PV). The PV was obtained with a 5 second 
“time of interest” starting from the highest value after deflation of the cuff(326). RF was 
calculated as BF – BZ. The maximum PORH perfusion (PORHmax) was calculated as PV – 
RF (Supplementary Figure 5-S1 and Table 5-S2. By international convention all parameters 
are expressed in arbitrary Perfusion Units (PU). Microvascular flow parameters were then 
transformed to cutaneous vascular conductance (CVC) by dividing mean arterial pressure to 
yield CVC in PU/mmHg. This PORH protocol is routinely performed in our laboratory; with 
intra-subject coefficients of variation of 7.7% for PV and 11.4% for PORHmax. Additional 
LSCI data combined with the PORH test are listed in the supplementary material 





Data are presented in mean and standard deviation (SD) or median and interquartile 
range according to data distribution. Natural log transformation was used to normalize the data, 
where appropriate. Differences in the baseline demographics among the treatment groups were 
investigated by one-way ANOVA and chi-squared tests. Outliers were graphically inspected 
and exclusions were conducted with Z-scores >2.5 or modified Z-scores >3.5. A two-way 
mixed [1 between-subject factor with 3 levels (treatment) and 1 within-subject with 2 levels 
(time)] ANOVA was used to investigate the outcomes and significant effects were followed by 
corrected post-hoc pairwise comparisons(327,328). Parameters with significant baseline 
between-group imbalances (IL-6 and IL-1β) were further inspected using ANCOVA(329,330). 
The Kruskal-Wallis test was used to inspect results from ANOVA tests conducted with data 
with normality concerns. SPSS (version 25 SPSS Statistic Subscription, IBM, Chicago, IL, 
USA 2019) was used for all statistical analyses. Significance was accepted at alpha p<0.05, 
and non-significant p values between p=0.05-0.099 were considered a trend in the data. Post-
hoc power analysis were conducted for each parameter that had a significant result or trend. 
 
5.3 Results 
A total of 47 participants were assessed for eligibility and 31 participants (19 female 
and 12 male) out of 34 enrolled participants completed the trial (Figure 5-S2). Two withdrawals 
were related to the participants reporting that the study was too onerous and one withdrawal 
was related to an underlying gastrointestinal condition that made the juice consumption 
unviable. Baseline mean age and BMI of participants were 75.3 (SD 6.9) years and 26.1 (SD 












n 14 10 7 31  
Gender (M/F) 5/9 6/4 1/6 12/19 0.043 
Age (years) 74.9 (SD 7.8) 76.1 (SD 6.7 ) 75.1 (SD 6.1) 75.3 (SD 6.9) 0.875 
BMI (kg/m2) 25.2 (SD 3.1) 27.1 (SD 2.3) 26.6 (SD 4.7) 26.1 (SD 3.3) 0.377 
Hypertensionb 5 (35.7%) 4 (40%) 4 (57%) 13 (41.9%) 0.637 
Day SPB (mm 
Hg) 
127.9 (SD 17.9) 128.1 (SD 13.9) 128.5 (SD 16.9) 128.1 (SD 15.9) 0.997 
Day DPB (mm 
Hg) 
78.4 (SD 10.0) 78.6 (SD 8.7) 80.2 (SD 12.5) 78.9 (SD 9.9) 0.928 
SPB night/day 
ratio 
0.89 (SD 0.04) 0.90 (SD 0.09) 0.98 (SD 0.08) 0.92 (SD 0.08) 0.112 
DPB night/day 
ratio 
0.89 (SD 0.09) 0.88 (SD 0.09) 0.95 (SD 0.12) 0.91 (SD 0.10) 0.362 
BMI, body mass index; SPB, systolic blood pressure; DPB, diastolic blood pressure. aP-value for one-
way ANOVA or chi-square test among the three treatments; b Participants with controlled hypertension 
taking anti-hypertensive drugs. 
 
Inflammatory biomarkers  
A significant time and treatment interaction effect was found for serum concentrations 
of TNF-α [F(2,27)=7.739, P=0.002, ηp2=0.364] with post-hoc analysis indicating a power of 
99.2% The breakdown of this interaction showed a lower TNF-α in the high anthocyanins 
group (7.60 pg/mL SD 3.18) vs controls (11.00 pg/mL SD 3.51) after 8 weeks of intervention 
(P=0.047, independent t-test) (Figure 5-2a). Regarding serum concentrations of IL-6, there was 
a significant treatment effect (P=0.013), a trend towards an effect of time (P=0.096) and a trend 
for an interaction effect [F(2,21)=2.933, P=0.075, ηp2=0.218]; however, post-hoc analysis 
indicated a power of 44.6%. Baseline IL-6 was higher in the high anthocyanins group when 
compared to the low anthocyanins group or controls (P<0.001 and P=0.009, respectively, 
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independent t tests), but between-group differences were not significant after 8 weeks of 
intervention (P>0.05) with a 36.6% decrease in IL-6 levels in the high anthocyanins group from 
baseline to 8 weeks (Figure 5-2b). An ANCOVA adjusting for baseline imbalances identified 
no significant treatment effect (P>0.05). The values of IL-1β were natural log transformed to 
approximate a normal distribution. There were significant time and treatment effects (P=0.022 
and 0.038), and a trend for an interaction effect [F(2,27)=2.972, P=0.068, ηp2=0.180], however, 
post-hoc analysis indicated a power of 42.3%. Similar to IL-6, baseline serum concentration of 
IL-1β was higher in the high anthocyanins group, compared to the low anthocyanins group or 
controls (P=0.025 and P=0.019, respectively, Mann-Whitney test), but not significant between 
groups after treatment (P>0.05), with a 23.3% decrease in IL-1β observed in the high 
anthocyanins group over time (Figure 5-2c). A Kruskal-Wallis test confirmed that differences 
between treatment groups at baseline (P=0.028) were no longer significant after 8 weeks of 
treatment (P=0.153). An ANCOVA adjusting for baseline imbalances identified no significant 
treatment effect (P>0.05).  There was no interaction effect [F(2,25)=1.146, P=0.334, 
ηp2=0.084], nor time or treatment effects (P>0.05) for serum concentration of CRP (Figure 5-
2d). Analyses conducted with natural log transformed data or with the Kruskal-Wallis test for 
non-parametric raw data confirmed no effects on CRP serum concentrations (P>0.05). There 
were no gender differences in baseline concentrations of TNF-α (P=0.931), IL-6 (P=0.061), 






Figure 5-2. Serum concentration of inflammatory biomarkers before and after 8 weeks intervention. 
Values are mean and error bars are standard deviation (A and B) or median and 1st and 3rd quartile (C 
and D). TNF, tumor necrosis factor; IL, interleukin; CRP, c-reactive protein. A) time*treatment effect 
(P=0.002); *HighAntho vs Control (P=0.047, independent t-test). B) No significant treatment effect 
between groups (P>0.05); *HighAntho vs LowAntho (P<0.001, independent t-test); C) No significant 
treatment effect between groups (P>0.05); *HighAntho > Control (P=0.019, Mann-Whitney test) 
*HighAntho > LowAntho (P<0.025, Mann-Whitney test) D) No significant changes or differences 




24-hour ambulatory blood pressure 
There was no significant interaction, treatment or time effects on any of the 24-hour 
ambulatory systolic and diastolic BP parameters (daytime, nocturnal and 24-hour, and dipping 
patterns) (Table 5-3). Based on the classification of dipping ratios(322) of <0.9 and >0.8 for 
‘normal dipping’, <1.0 and >0.9 for ‘reduced dipping’, and >1.00 for ‘no dipping and rising’, 
there were several changes between treatments. The mean systolic and diastolic BP dipping 
pattern of controls changed from ‘normal dipping’ at baseline to ‘reduced dipping’ after the 
intervention, and the systolic BP dipping pattern of the high anthocyanins group changed from 
‘reduced dipping’ at baseline to ‘no dipping and rising’ after the intervention. There were no 





Table 5-3. 24-hour ambulatory blood pressure measures before and after treatment in control and intervention groups 
Parameter Group n PRE POST Timea Treatmenta Time x treatmenta 
Day SPB 




LowAntho 8 127.7 (SD 14.8) 129.3 (SD 16.9) 
HighAntho 7 127.4 (SD 14.7) 123.7 (SD 17.2) 
Day DPB 




LowAntho 8 78.5 (SD 9.3) 81.3 (SD 9.5) 
HighAntho 7 80.2 (SD 12.5) 77.6 (SD 8.1) 
24h SPB 




LowAntho 8 123.2 (SD 11.0) 126.0 (SD 14.3) 
HighAntho 7 129.3 (SD 19.9) 125.8 (SD 16.4) 
24h DPB 




LowAntho 8 74.6 (SD 8.4) 78.8 (SD 10.4) 
HighAntho 7 80.0 (SD 13.8) 76.9 (SD 10.0) 
Nocturnal SBP 




LowAntho 8 114.9 (SD 11.9) 115.0 (SD 14.2) 
HighAntho 7 126.4 (SD 27.1) 126.9 (SD 22.4) 
Nocturnal DBP Control 9 71.0 (SD 8.4) 73.4 (SD 9.8) 0.623 0.651 
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LowAntho 8 68.6 (SD 9.9) 72.3 (SD 14.1) 
F(2,21)=0.470, P=0.632, 
ηp2=0.043 
HighAntho 7 71.9 (SD 19.1) 74.5 (SD 13.4) 
SPB night/day 
ratio 




LowAntho 8 0.90 (SD 0.09) 0.89 (SD 0.08) 
HighAntho 7 0.98 (SD 0.08) 1.03 (SD 0.17) 
DPB night/day 
ratio 




LowAntho 8 0.88 (SD 0.09) 0.88 (SD 0.09) 
HighAntho 7 0.95 (SD 0.12) 0.96 (SD 0.12) 





No significant time or treatment effects were observed in the microvascular parameter ‘peak 
value’ in CVC. A trend towards an interaction effect was found [F(2,24)=2.678, P=0.089, ηp2=0.182]; 
however, post-hoc comparisons showed no significant effect of time nor treatment. There was no 
significant interaction effect [F(2,24)=0.309, P=0.737, ηp2=0.025], nor time or treatment effects 
(P>0.05) in the maximum perfusion following the PORH test (PORHmax). There were no gender 
differences in baseline BF (P=0.549), BZ (P=0.858), RF (P=0.451), PV (P=0.675) and PORHmax 
(P=0.884) in CVC. A full description of all microvascular parameters in PU and CVC (PU/mmHg) are 
presented in the supplementary material (Table 5-S3). 
 
 
Figure 5-3. Microvascular reactivity parameters before and after 8 weeks intervention. Values are mean 
and error bars are standard deviation. CVC, cutaneous vascular conductance in PU/mmHg; PORHmax, 






Consumption of anthocyanins provided in the QGP juice for 8 weeks decreased the 
serum concentrations of TNF-α in older adults diagnosed with MCI. This effect was only 
observed in the intervention group that received the higher dose (201 mg/day) of anthocyanins. 
Other outcomes, including other inflammatory biomarkers, parameters of microvascular 
function and 24-hour ABP measures, remained unchanged in both treatment groups compared 
to controls.   
The major finding in the present trial was the significant decrease in serum 
concentration of TNF-α in the high-anthocyanins intervention group. TNF-α is a cytokine with 
a wide range of pro-inflammatory activities that is primarily produced by macrophages, 
endothelial cells, and smooth muscle cells of atherosclerotic arteries(64). TNF-α may influence 
the atherosclerotic process by causing metabolic perturbations and by increasing the expression 
of surface leukocyte adhesion molecules, chemokines and enhancing the production of other 
cytokines and growth factors. High concentrations of TNF-α have been associated with 
premature coronary artery disease, acute myocardial infarction, peripheral arterial disease, and 
congestive heart failure(277). The magnitude of reduction of TNF-α observed with the high 
dose of anthocyanins in this trial [2.86 pg/mL, from 10.46 (SD 2.84) to 7.60 (SD 3.18) pg/mL] 
may have important clinical implications considering the predictive role of TNF-α in CVD 
events supported by previous studies. For example, in a case-cohort study comprising 105 CAD 
cases and 638 individuals randomly selected from a cohort of 5,404 participants aged 35–74 
years (mean follow-up of 6.1 years), TNF-α was significantly and independently associated 
with CAD (adjusted HRs=1.87;1.31–2.66)(331). Furthermore, there is evidence from large-
scale prospective studies, such as a cohort of 2225 participants (70-79 years old) without 
baseline CVD that were assessed for incident coronary heart disease, stroke and congestive 
heart failure events during an average follow-up of 3.6 years. In that cohort, TNF-α was 
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significantly associated with coronary heart disease (per TNF-α SD increase: RR, 1.22; 95% 
CI, 1.04 to 1.43) and congestive heart failure (per TNF-α SD increase: RR, 1.59; 95% CI, 1.30 
to 1.95) events(76). The beneficial outcomes reported in such studies were found for 
differences in TNF-α, which supports the clinical significance of the reductions observed in 
our study in older adults.  
 Despite a reduction in concentrations of IL-6 (36.6%) and Il-1β (23.3%) in the group 
receiving the high-anthocyanins treatment, these changes were no longer significant after 
adjusting for baseline imbalances between groups. These two interleukins are fundamental 
components of atherosclerosis, related to CVD(190,277). IL-6 is highly expressed by the 
vascular endothelium and the pharmacological inhibition of IL-6 can improve endothelial 
function(332). Concerning the clinical significance of the magnitude of effect found in the high 
anthocyanins intervention in the present trial, a significant reduction of 2.08 pg/mL represents 
a change from baseline of approximately 2 SD [5.68 (SD 1.24) pg/mL at baseline to 3.60 (SD 
0.97) pg/mL after the treatment]. Other studies have reported hazard ratios of 1.80 according 
to each 1-SD increase in IL-6 for risk of first-ever cerebrovascular events in individuals with 
vascular risk factors, but without any pre-existing CVD(333). Furthermore, in a meta-analysis 
of 17 prospective studies investigating clinical coronary outcomes (i.e., myocardial infarction 
or coronary death), an odds ratio of 1.61 (95% CI 1.42–1.83) was found per 2 SD increase in 
baseline IL-6(334). 
IL-1β synthesis is significantly upregulated after cardiovascular events such as 
myocardium infarction, as well as in advanced plaque formations in atherosclerosis disease; 
thus, it has been investigated as a therapeutic option in secondary and tertiary prevention of 
CVD(335). Local stimuli in the plaque induces the generation of active IL-1β through the 
action of a molecular assembly known as the inflammasome(336). The convincing links 
between IL-1β to pro-inflammatory diseases, such as atherosclerosis indicates this cytokine as 
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a potential therapeutic target to improve cardiovascular outcomes(336). In support of this, an 
anti-IL-1β therapy was investigated in a large randomized, double-blind, placebo-controlled 
trial of 10,061 patients (median follow-up of 3.7y) with a history of myocardial infarction and 
CRP ≥ 2 mg/L. Treatment with canakinumab (anti-IL-1β monoclonal antibody) led to 15% 
reduction in major adverse CVD events (p=0.007)(313). Furthermore, a meta-analysis 
including 6 cohort studies with 1,855 CVD cases and 18,745 non-cases with follow-up times 
between 5-16y investigated the role of Interleukin-1 receptor antagonist (IL-1RA), which 
counter-regulates IL-1β as an endogenous inhibitor in vivo by blocking the binding site for IL-
1β, and incident CVD(337). A pooled standardized hazard ratio (95% CI) for incident CVD of 
1.11 (1.06–1.17) was found after adjustment for age, sex, anthropometric, metabolic, and 
lifestyle factors (P<0.0001)(337). A lack of studies regarding the magnitude of change in IL-
1β concentration and CVD prediction makes it complex to extrapolate the clinical significance 
of our findings. The significant treatment effect showed a reduction of 0.140 pg/mL [0.600 
(IQR 1.065) pg/mL at baseline and 0.460 (IQR 0.215) pg/mL after treatment] in the high 
anthocyanins group, representing a 23.3% reduction from baseline. Overall, our results, 
combined with the strong evidence pinpointing a relationship between inflammatory markers 
and CVD suggest that food-derived anthocyanins may be an important potential therapeutic 
treatment for reducing inflammation and promoting subsequent health benefits. Another 
feature of the present trial is that all participants were diagnosed with MCI; therefore, such 
health benefits may have potential implications in attenuating the advance of cognitive decline, 
considering that a number of studies support the association between neuroinflammation and a 
decline in cognitive function(338–340). Several studies support that CVD are associated with 
increased risk of cognitive impairment and dementia(314–316,341,342). 
The changes observed in concentrations of TNF-α were not accompanied by changes 
in vascular outcomes, either in parameters derived from the 24h ABP measurements or 
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microvascular assessment. The observed changes in mean systolic and diastolic BP dipping 
pattern are not clinically relevant considering that the ratios were borderline compared to the 
classification thresholds and had relatively high standard deviations. It has been suggested that 
the cutaneous microcirculation may mirror generalized systemic vascular dysfunction(343), 
and continuous high frame assessment of skin perfusion over wide areas measured through 
LSCI provides strong reproducibility for vascular challenges(344,345). Based on the ability of 
anthocyanins to exert beneficial physiological effects as antioxidant and anti-inflammatory 
compounds, we proposed that treatment might improve the vascular reactivity measured using 
the PORH test. Mechanisms underlying the vascular reactivity response in the PORH test are 
still being elucidated; however, the findings of the present study suggest that reduction in serum 
TNF-αmay not affect microvascular reactivity in older adults. The use of the LSCI in 
nutritional intervention studies is relatively new, and there are no published reference values 
for predicting any condition, nor values that have an established clinical significance in 
vascular biology literature. A recent study from our group found a positive acute effect 
(postprandial) of anthocyanins in attenuating vascular and inflammatory responses to a high 
fat high energy meal challenge in overweight older adults(346). An improvement for both 
microvascular and macrovascular function was observed in that study, as assessed by PORH 
test combined with LSCI and FMD, respectively.  
Limitations of our study include the variation in sample size and gender between 
treatment groups. Forty two percent of participants were hypertensive; however, this is 
reflective of the overall prevalence of 45.2% in Australians aged 75 years and older(347) and 
values did not significantly differ between the treatment groups. The limited sample size 
hindered the ability to conduct sub-analysis by sex or prevalence of hypertension, and may 
have influenced the baseline between-group imbalances in IL-6 and IL-1β concentration 
despite randomization. It should be noted that RCTs conducted in participants with MCI have 
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a complex recruitment process, and that the sample size of the present study was larger than 
that in 44% of included studies in a systematic review of treatments for MCI(348). A key 
feature in the design of this study was the placebo chosen for the control group. Investigation 
of a specific bioactive compound, such as anthocyanins, in a clinical trial using foodstuffs as 
the vehicle of delivery is challenging. Foods that are rich in a particular flavonoid sub-class 
may also contain other classes of flavonoids or other bioactive compounds, such as other 
polyphenols, and/or inorganic compounds (such as nitrate) that might have similar or 
synergistic effects on the outcomes assessed. We aimed to evaluate the effect of two different 
doses of anthocyanins using differently processed juice as the food source. A potential 
limitation that may have led to the absence of effects in the low dose group is that the average 
mean intake of anthocyanins in the usual diet of participants was similar to the intervention per 
se (68mg compared to 48mg). In order to isolate the effect of anthocyanins from other 
bioactives, apricot juice was provided as the control due to its lack of anthocyanins, but its 
similarly matched macro- and micronutrient content, as well as its polyphenol profile(206), 
including flavanols (such as quercetin), catechins and epicatechins, all of which are potential 
mediators of cardiovascular health(200,303–305).  
 
5.5 Conclusion 
A daily high dose of fruit-derived anthocyanins for 8 weeks decreased serum 
concentrations of TNF-α in older adults diagnosed with MCI. This change was not 
accompanied by effects on other inflammatory biomarkers, 24h ABP or microcirculation 
function, and no effects were observed in the low anthocyanin dose treatment group. 
Considering the major role of the inflammatory response in CVD and cognitive decline, our 
finding suggest that a regular high intake of anthocyanins may have clinical implications in 
this high-risk group; however, further studies with a longer follow-up and larger sample size 
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are required to better elucidate if these changes in concentrations of TNF-α will alter CVD risk 
and progression of cognitive decline. 
 
5.6 Supplementary Material 
Table 5-S1. Description of Post-Occlusive Reactive Hyperaemia Microvascular Parameters  
MICROVASCULAR PARAMETER DESCRIPTION 
Baseline flow (BF) 
The most stable 30 seconds within the first 2 minutes 
of reading. 
Biologic zero (BZ) 
The most stable 3 seconds displaying the lower 
values before the deflation of the cuff. 
Resting flow (RF) BF-BZ 
Peak perfusion value (PV) 
Five seconds period starting from the highest value 
in the first rise (slope) after deflation of the cuff 
PORHmax PV - RF 



























Energy (kcal) 113 98 96 
Protein (g) 0.7 0.6 0.7 
Fat – total (g) < 0.1 < 0.1 < 0.1 
Saturated fat (g) < 0.1 < 0.1 < 0.1 
Carbohydrates (g) 23.1 22.2 22.2 
Dietary fibre (g) 2.9 4.4 4.0 
Sodium (mg) 7 6 2 
Vitamin C (mg) 0.3 0.3 1.2 
Anthocyanins1 (mg) 46.7  200.8 03 
Anthocyanins2 (mg) 43.7 206.8 03 
1High Performance Liquid Chromatography; 2pH differential method; 3Phenol-explorer23. Remaining 





Table 5-S3. Post-occlusive reactive hyperaemia parameters 
Parameter Group n PRE POST Timea Treatmenta Time x treatmenta 
PV (pu) 




LowAntho 9 85.9 (SD 10.2) 82.2 (SD 12.6) 
HighAntho 7 99.4 (SD 16.9) 101.4(SD 19.6) 
PV (cvc) 




LowAntho 9 1.00 (SD 0.13) 0.90 (SD 0.15) 
HighAntho 7 1.00 (SD 0.26) 1.07 (SD 0.25) 
PORH (cvc) 




LowAntho 9 0.42 (SD 0.15) 0.36 (SD 0.09) 
HighAntho 7 0.56 (SD 0.24) 0.50 (SD 0.18) 
RF (cvc) 




LowAntho 9 0.39 (SD 0.09) 0.38 (SD 0.07) 
HighAntho 7 0.28 (SD 0.08) 0.37 (SD 0.18) 
BZ (pu) 




LowAntho 9 16.2 (SD 6.6) 14.4 (SD 3.9) 
HighAntho 6 15.2 (SD 2.9) 18.9 (SD 4.9) 
BF (pu) Control 11 44.8 (SD 12.3) 44.9 (SD 14.2) 0.134 0.564 
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LowAntho 9 49.9 (SD 6.7) 49.0 (SD 7.4) 
F(2,24)=2.751, P=0.084, 
ηp2=0.187 
HighAntho 6 44.0 (SD 8.3) 53.9 (SD 16.1) 
Data are mean and standard deviation. PV, peak value; ηp2, partial eta-squared ;PORH, post-occlusive reactive hyperaemia; RF, resting flow; BZ, biologic 





Figure 5-S1. Cutaneous perfusion recorded with laser speckle contrast imaging during post-
















CHAPTER 6: Conclusions and recommendations 
 
6.1 Overview of core findings 
 
The studies presented in this thesis utilised different study design methodologies to 
address the central research questions concerning the role of dietary intake of flavonoids and 
anthocyanins on vascular function, inflammation and other cardiovascular disease risk factors. 
Following an extensive exploration of the literature, gaps were identified that guided the design 
and conduct of all studies. The availability of resources, expertise of the research team 
collaborators and access to healthcare services in the local area were also considered in order 
to maximize efficiency of the body of work. This approach covered domains of: a) 
Epidemiological evidence: analytical work conducted in national representative cohort of 
Australian women: b) Knowledge syntheses: systematic literature review of randomized 
clinical trials; and c) Experimental evidence: conduct of two clinical trials to assess the acute 
and chronic effect of anthocyanin nutritional interventions in older adults. 
The first gap identified was a lack of data from the Australian population regarding the 
association between the dietary intake of flavonoids and incidence of hypertension. 
Epidemiological evidence suggests that a higher dietary flavonoid intake is associated with a 
reduced risk of several chronic diseases, including hypertension. However, different dietary 
patterns and cuisines between populations affects the amounts and types of flavonoid-rich 
foods consumed, while differing lifestyle factors and life expectancy also influence the 
contribution of flavonoids to the incidence of hypertension and other chronic diseases. 
Moreover, the flavonoid content of foods is likely to be influenced by seasonality and differ 
between geographic areas. Therefore, a study was developed to investigate the association 
between intake of flavonoids and their subclasses, and incidence of hypertension among 
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Australian women in two age cohorts. Findings from this population-based prospective study 
showed an association between a higher dietary intake of flavonoids and lower incidence of 
hypertension. In the middle-aged cohort, higher intakes of the flavonoid subclasses, flavones, 
isoflavones and flavanones, found mainly in orange and orange juice, apples and soy milk, 
were associated with a reduced risk of hypertension among middle-aged women followed-up 
over 15 years. In the younger, reproductive-aged cohort, a higher intake of total flavonoids and 
flavanols, attributed mainly to orange juice, red wine, apples and onions, were associated with 
a reduced risk of hypertension over a 12 year follow-up period. These findings contribute to 
the current knowledge in his field, which may be used in nutritional messages and policies 
aiming to improve the cardiovascular health of women at these two different life stages. 
Interestingly, in two other similar studies (119,185) that found a reduction in incident 
hypertension in other countries, the benefits were attributed to other groups of flavonoids, such 
as flavonols and anthocyanins. This confirms a need to conduct studies in different regions 
because of variations in cultural and socio-economic characteristics that influence dietary 
patterns. Taken together, such findings suggest that nutritional messages and policies aiming 
to improve the cardiovascular health through increased consumption of dietary flavonoids may 
vary from population to population, as well as between different ages ranges.  
 The epidemiological study had a general approach regarding the classes of flavonoids, 
while the other studies that composed this Thesis had a scope focused in clinical nutrition, and 
advanced into a more specific investigation of one class of flavonoids, the anthocyanins. 
Additionally, although blood pressure and hypertension were addressed in all of these studies, 
a variety of parameters related to CVD were further investigated. Among studies that evaluate 
the effects of anthocyanins on CVD risk factors and associated biomarkers, a number of studies 
addressed the potential acute effects of anthocyanins in studies using a HFM challenge; 
however, such finding were not yet collated and synthetized. This gap led to the second study 
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of this Thesis, a systematic literature research  that was conducted focusing in knowledge 
synthesis of the postprandial effects of anthocyanins on CVD risk factors in HFM studies. A 
total of 13 eligible studies were included and beneficial effects of anthocyanins were reported, 
with most promising results indicating attenuation of deleterious postprandial effects on 
oxidative stress and antioxidant status, triacylglycerol and total cholesterol concentrations, 
vascular endothelial function and inflammatory biomarkers. Post-prandial changes in blood 
pressure and lipoproteins were least affected by anthocyanins. The systematic literature review 
identified beneficial effects of acute dietary anthocyanin interventions on CVD risk factors 
following a HFM challenge; however, due to the heterogeneity in changes of some parameters 
identified between the studies, further studies are required in order to advance the current 
knowledge of the underlying mechanisms between post-prandial imbalances and CVD 
incidence and progression, and to investigate how these imbalances are attenuated by bioactive 
compounds such anthocyanins. 
Based on the findings from the systematic literature review, another gap that was 
identified was a need for a more robust investigation of vascular function in the postprandial 
state, which along with the immune response, is an important predictor for CVD risk. This is 
particularly evident in older adults, as several studies support a gradual loss of the vascular 
function, and a new immune-metabolic viewpoint for age-related diseases, termed 
‘inflammaging’ which is characterized by a chronic low-grade inflammation. Additionally, 
excessive adiposity at all ages is associated with an up-regulation of a pro-inflammatory state, 
as the accumulation of adipose tissue mass promotes the secretion and release of inflammatory 
mediators. This process also leads to chronic low-grade inflammation that is driven by a 
nutrient excess and/or overnutrition and has the same mechanisms as those underpinning 
“inflammaging”. Therefore, a clinical trial was designed in the same setting of investigating 
the postprandial effects of anthocyanins following a HFHE meal challenge; however the 
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novelty was related to evaluation of both macro and microvascular parameters by combining 
classical and novel techniques with the latest imaging technologies, such as the flow-mediated 
dilatation (FMD) and the Laser Speckle Contrast Imaging (LSCI). In addition to vascular 
function assessments, classical CVD biomarkers such as lipid profile and blood pressure, and 
inflammatory biomarkers were also evaluated. To our knowledge, this is the first study to 
conduct this type of protocol in studies with nutritional interventions. The findings supported  
the postprandial effects of food anthocyanins in improving several CVD biomarkers in 
overweight older adults following a HFHE meal challenge. Potentially beneficial effects were 
observed in parameters of both macrovascular and microvascular function, as well as some 
inflammatory biomarkers. The HFHE meal challenge induced increases in postprandial blood 
pressure, diacron reactive oxygen metabolites, triacylglycerol and total cholesterol; however, 
anthocyanin consumption did not attenuate these responses. Such results corroborated with 
findings from the systematic literature review, and also advanced knowledge concerning the 
postprandial vascular regulation and how the effects exerted by anthocyanins can be observed 
in different vascular beds. Our findings contribute new evidence regarding the potential 
protective effect of dietary anthocyanins on vascular function and inflammatory responses, 
parameters that have a major role on atherosclerotic disease and CVD events.  
Considering there were still several gaps to be addressed regarding the longer term 
effect of anthocyanins in this vascular-inflammatory axis in older adults, another clinical trial 
was conducted to investigate the chronic effects (8 weeks) of two different doses of food-
anthocyanins on inflammatory markers associated with CVD risk factors, along with analysis 
of microvascular function and 24-hour ABP. This study was also conducted in older adults, but 
the aim was to investigate such parameters in individuals that had a diagnosis of Mild Cognitive 
Impairment, a neurodegenerative condition that shares pathological mechanisms with CVD. A 
daily high dose of fruit-derived anthocyanins for 8 weeks decreased serum concentrations of 
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TNF-α. These changes were not accompanied by effects on other inflammatory biomarkers 
(IL-6, hs-CRP and IL-1β), 24h ABP or microcirculation function, and no effects were observed 
in the low anthocyanin dose treatment group. Considering the major role of the inflammatory 
response in CVD and cognitive decline, our findings suggest that a regular high intake of 
anthocyanins may have clinical implications in this high-risk group; however, further studies 
with a longer follow-up are required to better elucidate whether this change on the i will alter 
overall CVD risk and/or progression of cognitive decline. 
Overall, the findings from all four studies suggest that flavonoids and anthocyanins 
have an important role as a potential non-pharmacological treatment option to improve vascular 
health and reduce cardiovascular risk.  
 
6.2 Strengths and limitations  
 The specific methodological strengths and limitations of each study have been 
addressed in-depth in each of the research chapters. However, more general aspects of the 
thesis will be addressed in this section. 
 Firstly, for the epidemiological aspect, the main strength of this study was the 
representative sample of Australian women across two age cohorts, the prospective design, and 
repeated measures over time. The statistical approach of using generalized estimated equations 
allowed for adjustments of key confounding factors. Potential confounders were extensively 
explored in our models, as there was access to a wide range of demographic, hypertension risk 
factor and dietary intake variables. The large sample size allowed for a stepwise regression 
with bidirectional elimination in order to create the models for such adjustments, therefore 
avoiding multicollinearity and overfitting of the model. Recruitment of participants was 
proportional to the population size in all Australian states, thereby enabling generalizability of 
the study findings to Australian women generally. However, a few limitations were present 
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such as the absence of men in this cohort and the use of self-reported data for hypertension. 
Moreover, the FFQ used may lack detail about some flavonoid-rich food sources due to it being 
developed over two decades ago, and it may not have included relevant high-flavonoid food 
items that have increased in popularity over this period, such as blackberries, cherries, 
blueberries and raspberries. This could have led to an underestimation of anthocyanin intake, 
as the mean intake in the present study was 4.7 mg/day in the middle-aged and 5.0 mg/day in 
the reproductive-aged cohort, compared to 24.2 mg/day reported in 2019 in the overall 
Australian population from a nationally representative sample that used two 24-hr recalls as 
the method of dietary assessment (222). This may have hindered a more robust overall message 
from the Thesis, considering that all other three studies focused in this specific flavonoid 
subclass.  
The most notable challenge and limitation of conducting the systematic literature 
review was to address a wide range of CVD-related biomarkers assessed in this type of acute 
clinical trial. We had originally considered conducting a meta-analyses for the various 
outcomes included in the review, particularly for those outcomes that were most frequently 
reported. However, the major variation in reporting of the included meal challenge studies, 
presentation of data according to varying postprandial time points, and the use of different 
methodologies to measure outcome variables rendered the possibility of meta-analysis or other 
pooled analyses as unfeasible. However, the narrative analysis remains valuable. Another 
source of heterogeneity in the included studies may have resulted from the variability in the 
macronutrient and energy content of the HMF challenges, particularly regarding the types of 
fat, as well as the format in which the meals were delivered.  
Despite these limitations, all included studies were conducted in young and middle-
aged adults (mean age ranging from 20.2 to 46.9y), but there were differences in mean BMI 
between studies (two studies included participants with BMI<25kg/m2 [34,40], while six 
191 
 
targeted those with BMI between 25 and 30kg/m2 [26,29–31,36,39] and three included 
participants with BMI>30kg/m2 [33,35,38]). Another feature in the design of this type of study 
is that tests are conducted over multiple time periods following the HFM challenge, thereby 
raising a concern that the number of false positive findings may be inflated. For this reason, 
the interpretation of results found for only one or a few time points, and that were not sustained, 
had to be interpreted with caution. Still, parameters that have been used in included studies to 
investigate oxidative stress and antioxidant status represented a wide range of analytical 
methods, and there is no formal mechanism to establish consensus regarding the optimal 
biomarkers to use in such nutritional interventions (259,261). The main strength of the 
systematic literature review was to present the body of evidence to date in a clear and concise 
way, as well as discussing and suggesting which results need to be further investigated and 
identifying gaps that require further elucidation. The latter was what guided the design of the 
clinical trial included in Chapter 4.  
 A key feature of the two studies that comprised the experimental evidence part of this 
thesis was the ability to evaluate microcirculatory functioning using a cutting edge technology, 
the Laser Speckle Contrast Imaging (LSCI) method. Assessment of the microcirculation has 
been performed for decades, but the LSCI method is the first one to provide excellent 
reproducibility to assess skin microvascular reactivity (97). The main methodological strength 
of the acute study that evaluated postprandial effects of anthocyanins in older adults following 
a HFM challenge was the inclusion of a more robust evaluation of the vascular function, by 
exploring both macro and microvascular parameters by combining classical (FMD) and novel 
techniques (LSCI). To our knowledge, this is the first study to conduct this type of protocol in 
a nutritional intervention study. Although this innovative design allowed us to explore 
macrovascular and microvascular function, a few limitations need to be highlighted. It was not 
possible to repeat the FMD and microvascular reactivity tests in case of experimental errors, 
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such as a participant movement during testing, due to the protocol of measures being collected 
at specific time points. Concerning the evaluation of endothelial and non-endothelial 
mechanisms in vascular and microvascular reactivity, we were not able to conduct nitrate-
mediated dilation nor iontophoresis of sodium nitroprusside due to the time limit between 
measures, considering it would be not viable, if not impossible, in a postprandial study to 
conduct a protocol with all of these measures. Another strength that can be attributed to both 
the acute and longer clinical trials was the choice of the control intervention. It is challenging 
to investigate a specific bioactive compound, such as a specific flavonoid, in a clinical trial 
using foods as vehicles for delivery. A food item that is a rich source of a particular flavonoid 
may also contain other classes of flavonoids, or still other bioactive compounds such as other 
polyphenols and/or inorganic compounds (such as nitrate), that might have similar or 
synergistic effects on the outcomes to those being assessed. In order to address this issue, the 
choice of the placebo food item for the control arm is an important consideration. A placebo 
that is only matched in macro, or even micronutrient content, can underestimate the effects of 
other bioactive compounds. In both studies, we aimed to evaluate the acute effect of 
anthocyanins using Queen Garnet plum juice as the intervention food source. In order to isolate 
the effect of anthocyanins, we chose apricot juice as the control due to its lack of anthocyanins, 
but its similarly matched macro- and micronutrient content, as well as its polyphenol profile 
(281), that includes flavanols (such as quercetin), catechins and epicatechins, all of which are 
potential mediators of cardiovascular health (20,303,305,349). The choice of this control juice 
allowed the effects of only anthocyanins to be isolated from other bioactive compounds. 
Concerning the second clinical trial that was conducted in older adults with a diagnosis of MCI, 
the small sample size was its main limitation. In addition to recruitment being slower than 
expected due to difficulties recruiting this patient group, and difficulties in ensuring a definite 
clinical diagnosis of MCI, the trial had to be cut short due to COVID-19 restrictions that 
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prevented face-to-face data collection. The smaller sample size of the final clinical trial has 
probably introduced issues of insufficient power and possibility of Type II error. 
 Overall, the main strength of this thesis is that all studies were highly connected to each 
other. The epidemiological study, answered a more general research question using data from 
a nationally representative cohort study, while the research questions were more narrowly 
focused in the experimental clinical trials. The systematic literature review and the first clinical 
trial addressed similar research outcomes. Both clinical trials shared several important features 
such as: food-based intervention of anthocyanins; microcirculation assessment using LSCI 
technology; evaluation of inflammatory biomarkers; and were conducted in older adults. The 
combination of studies presented in this thesis together helps address the main research 
questions in a complementary manner.  
 
6.3 Future research and recommendations 
  Findings from this thesis have contributed novel findings to advance knowledge of this 
topic, but have also highlighted new areas for further research. 
 In the epidemiological approach of investigating the association of dietary intake of 
flavonoids in the Australian population, further studies with a similar methodology, but in  
different populations with varying outcomes are recommended. For example, a national 
representative study investigating the incidence of hypertension among Australian men is still 
lacking. Likewise, data on the incidence of other CVD and related conditions and their 
associations with the dietary intake of flavonoids are also needed. Considering that the dietary 
intake, in terms of sources of flavonoids, vary according to many factors over time, it is 
recommended that such analyses need to be conducted from time-to-time in different 
populations, using an appropriate and updated dietary intake assessment method for accurate 
estimation of dietary intake. Still, the possibility of evaluating blood, urine and faecal samples, 
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and measures of vascular function along with an epidemiological analyses, provide an 
important link between experimental and epidemiological evidence and would help elucidate 
the mechanisms underlying the dietary intake of flavonoids and incidence of various disease 
states.  
 At the clinical level, a number of key points and recommendations for future research 
are highlighted below: 
• The choice of the intervention and placebo is an important consideration in order to 
compare and generalise conclusions across studies. As the evidence of the effects of 
anthocyanins to prevent and treat certain conditions is increasing, future studies will 
need to investigate specifically which types of anthocyanins exert these effects, as well 
as identify the synergistic effects of nutrients and food matrices that may be 
contributing to observed effects. There is also a need to focus on methodologies to 
stabilise or reduce degradation of these bioactive compounds in foods during 
processing and handling. In cases where the research question aims to explore the 
effects of a specific bioactive compound, a placebo choice that isolates this compound 
is recommended, in order to avoid non-specific effects of other polyphenols or nutrients 
such as dietary fibre and nitrate concentration. 
• The assessment of postprandial parameters as CVD risk factors is still relatively new 
and less explored when compared to fasting measures. Although the findings from the 
systematic literature review and the clinical trial presented in Chapter 4 showed 
improvements in a variety of biomarkers associated with CVD, future studies should 
explore whether such changes will impact on CVD incidence and progression, and how 
these measures may differ from fasting measures. In other words, determine how the 
fasting and postprandial flow-mediated dilatation scores differ in prediction values for 
later CVD events.  
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• The use of the LSCI technology to assess microvascular function has increased in recent  
years; however, this remains an exploratory field, and further studies that include this 
outcome measure are required in the context of CVD research. There is a need to 
standardize the vascular reactivity tests protocols, in order to allow better comparison 
between studies and improve reproducibility of such tests within and between studies. 
Moreover, studies with larger sample sizes are required to investigate the association 
between these new microvascular parameters and other already established measures 
of vascular function, such as the gold-standard FMD, as well to investigate the 
association with other traditional and related CVD biomarkers. 
• In studies that evaluate risk factors that are shared between CVD and neurodegenerative 
conditions such as in the clinical trial presented in Chapter 5, a longer nutritional 
intervention and follow-up period would be recommended in order to investigate if the 
improvements of such risk factors will reduce the overall incidence of CVD events and 
attenuate further cognitive decline over time.  
 
6.4 Conclusion 
 The studies included in this thesis have addressed several gaps related to the role of 
dietary intake of flavonoids and anthocyanins on vascular function, inflammation and other 
cardiovascular disease risk factors. This body of research was conducted across three levels of 
evidence: Epidemiological evidence; Knowledge syntheses; and Experimental evidence. This 
was achieved by utilising a wide range of scientific methods in the medical sciences field, 
especially in nutritional epidemiology and clinical nutrition. From secondary data analysis, to 
the identification, selection and critical appraisal of relevant primary research, and the design 
and execution of original clinical trials, a vast array of interpersonal and laboratory skills, 
statistical methods and forms of presenting results were utilized.  
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 Collectively, the four studies included in this thesis have resulted in novel findings that 
contributed to the advance of the knowledge in this field, as well as highlighting what is still 
have to be addressed, and identified new gaps to be explored in future studies. In a broader 
context, this research strengthen the concept that bioactive compounds, as part of diet or as a 
nutritional intervention, may have positive impact in health outcomes and help to attenuate the 
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